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ABSTRACT OF DISSERTATION

DISCOVERY OF NOVEL MURAYMYCIN ANTIBIOTICS AND
INSIGHT INTO THE BIOSYNTHETIC PATHWAY

New antibiotics with novel targets or mechanisms of action are needed to counter the
steady emergence of bacterial pathogens that are resistant to antibiotics used in the clinic. MraY,
a promising novel target for antibiotic development, initiates the lipid cycle for the biosynthesis
of peptidoglycan cell wall, which is essential for the survival of most, if-not-all, bacteria. MraY
is an enzyme that catalyzes the transfer and attachment of phospho-MurNAc-pentapeptide to a
lipid carrier, undecaprenylphosphate. Muraymycins are recently discovered lipopeptidyl
nucleoside antibiotics that exhibit remarkable antibiotic activity against Gram-positive as well
as Gram-negative bacteria by inhibiting MraY. We conducted a thorough examination of the
metabolic profile of Streptomyces sp. strain NRRL 30473, a known producer of muraymycins.
Eight muraymycins were isolated and characterized by a suite of spectroscopic methods,
including three new members of muraymycin family named B8, B9 and C5. Muraymycins B8
and B9, which differ from other muraymycins by having an elongated fatty acid side chain,
showed potent antibacterial activity against Escherichia coli ∆tolC mutant and pM IC50 against
Staphylococcus aureus MraY. Muraymycin C5, which is characterized by an N-acetyl
modification of the disaccharide’s primary amine, greatly reduced its antibacterial activity,
which possibly indicates this modification is used for self-resistance.
In addition to the discovery of new muraymycins, eleven enzymes from the
biosynthetic pathway were functionally assigned and characterized in vitro. Six enzymes
involved in the biosynthesis of amino ribofuranosylated uronic acid moiety of muraymycin
were characterized: Mur16, a non-heme, Fe(II)-dependent α-ketoglutarate: UMP dioxygenase;
Mur17, an L-threonine: uridine-5′-aldehyde transaldolase; Mur20, an L-methionine:1aminotransferase; Mur26, a low specificity pyrimidine nucleoside phosphorylase; Mur18, a
primary
amine-requiring
nucleotidylyltransferase;
Mur19,
a
5-amino-5deoxyribosyltransferase. A one-pot enzyme reaction was utilized to produce this disaccharide
moiety and its 2′′-deoxy analogue. Two muraymycin-modifying enzymes that confer selfresistance were functionally assigned and characterized: Mur28, a TmrB-like ATP-dependent
muraymycin phosphotransferase, and Mur29, a muraymycin nucleotidyltransferase. Notably,
Mur28 preferentially phosphorylates the intermediate, aminoribofuranosylated uronic acid, in

the muraymycin biosynthetic pathway to produce a cryptic phosphorylated-dissacharide
intermediate. Mur23 and Mur24 were assigned as two enzymes that modify the cryptic
phosphorylated intermediate by attachment of an aminopropyl group. Mur24 catalyzes the
incorporation of butyric acid into the phosphorylated-disaccharide. Following the incorporation,
Mur23 catalyzes a PLP-dependent decarboxylation. Finally, Mur15, which belongs to the cupin
family, is functionally assigned as a non-heme, Fe(II)-dependent α-ketoglutarate dioxygenase
that catalyzes the β-hydroxylation of a leucine moiety in muraymycin D1 to form muraymycin
C1. Mur15 can also hydroxylate the γ-position of leucine moiety to muraymycins with fatty
acid chain in β-position.
KEYWORDS: nucleoside antibiotics, muraymycin, translocase I (MraY), antibiotic resistance,
biosynthesis

Zheng Cui
Student’s Signature
12/14/2017
Date

DISCOVERY OF NOVEL MURAYMYCIN ANTIBIOTICS AND
INSIGHT INTO THE BIOSYNTHETIC PATHWAY

By
Zheng Cui

Steven G. Van Lanen
Director of Dissertation
David Feola
Director of Graduate Studies
12/14/2017
Date

献给我的奶奶姥姥爸爸妈妈, 我爱你们
Dedicated to my grandmas and parents for their unconditional love

ACKNOWLEDGEMENTS

I am indebted to the following people for their help and support:

To my mentor, Dr. Steven Van Lanen, thank you for leading me into the realm of biochemistry,
showing me its tremendous beauty and logic, and helping me overcome every obstacle we met
in the journey.

To my husband, Xiaofei Zhang, thank you for tolerating my obsession, sharing my happiness
and sadness, and doing the first format editing.

To my amazing committee members (Dr. Jurgen Rohr, Dr. Sylvie Garneau-Tsodikova and Dr.
Luke Moe), thank you for the guidance, patience, encouragement and the prompt reply for
every email. I believe you guys will keep doing that after my graduation. I would also like to
thank you all especially Dr. Garneau-Tsodikova for helping with my thesis modification.
To our awesome collaborators in Christian Ducho’s lab and my super cooperative friends, Dr.
Yinan Zhang, Dr. Xiaodong Liu and Dr. Wenlong Cai, thank you for helping me dealing with
synthetic problems and activity assays. I would also like to thank Dr. Xiachang Wang here for
analyzing all the NMR data showed in this thesis.

To all wonderful members in Van Lanen lab and natural product super group, thank you for
your priceless friendship and helpful discussion.

And finally, a huge thank-you to everyone at UKY. Go cats!

iii

TABLE OF CONTENTS

ACKNOWLEDGEMENTS ......................................................................................................iii
LIST OF TABLES .................................................................................................................... ix
LIST OF FIGURES ................................................................................................................... x
LIST OF FIGURES IN SUPPORTING INFORMATION .....................................................xiii
LIST OF ABBREVIATIONS................................................................................................xviii
Chapter 1 : Introduction and Background .................................................................................. 1
1.1 Muraymycins Discovery .................................................................................................. 1
1.2 Targets of Muraymycin .................................................................................................... 3
1.3 SAR of Muraymycins ...................................................................................................... 5
1.4 Muraymycin Related Nucleoside Antibiotics .................................................................. 7
1.5 Biosynthetic Gene Cluster of Muraymycin ...................................................................... 8
1.6 Contents of the Dissertation ............................................................................................. 9
Chapter 2 : Antibacterial Muraymycins from Streptomyces sp. NRRL 30473 ........................ 10
2.1 Introduction .................................................................................................................... 10
2.2 Materials and Methods ................................................................................................... 12
2.2.1 General Experimental Procedures ........................................................................... 12
2.2.2 Fermentation, Extraction, Isolation and Purification .............................................. 13
2.2.3 DNA Extraction, Genome Sequencing, and Analysis ............................................. 14
2.2.4 Antimicrobial Bioactivities...................................................................................... 15
2.2.5 MraY Inhibition Assay ............................................................................................ 16
2.3 Results ............................................................................................................................ 19
2.3.1 Structure Elucidation ............................................................................................... 21
2.3.2 Antimicrobial Bioactivity ........................................................................................ 26
2.4 Discussion ...................................................................................................................... 29
2.4.1 Synthesized Muraymycin B9 Analogue with Good Antibacterial Activity ............. 29
iv

2.4.2 Resistant Modifications of Muraymycin ................................................................. 30
2.5 Conclusion ..................................................................................................................... 30
2.6 Supporting Information .................................................................................................. 32
Chapter 3 : Enzymatic Formation of Ribofuranosylated Glycyl-uridine Scaffold of Antibiotic
Muraymycin ............................................................................................................................. 46
3.1 Introduction .................................................................................................................... 46
3.2 Materials and Methods ................................................................................................... 48
3.2.1 Cloning, Overexpression and Purification of Proteins ............................................ 48
3.2.2 Synthesis of 2'-Methoxy-UMP, 1c........................................................................... 49
3.2.3 Activity Assay of Mur16 ......................................................................................... 50
3.2.4 Kinetics of Mur16 ................................................................................................... 51
3.2.5 Activity Assay of Mur17 ......................................................................................... 51
3.2.6 Activity Assay of Mur20 ......................................................................................... 52
3.2.7 Activity Assay of Mur26 ......................................................................................... 52
3.2.8 Activity Assay of Mur18 ......................................................................................... 52
3.2.9 Activity Assay of Mur19 ......................................................................................... 53
3.2.10 MIC assay of AQC modified 8b............................................................................ 53
3.2.11 One-Pot Enzymatic Reaction for the Biosynthesis of 8a ...................................... 54
3.2.12 One-Pot Enzymatic Reaction for the Biosynthesis of 8b ...................................... 54
3.3 Results and Discussion ................................................................................................... 54
3.3.1 Functional Assignment of Mur16 as a Non-heme, Fe(II)-dependent α-Ketoglutarate:
UMP Dioxygenase ........................................................................................................... 54
3.3.2 Functional Assignment of Mur17 as an L-Threonine: Uridine-5′-aldehyde
Transaldolase .................................................................................................................... 58
3.3.3 Functional Assignment of Mur20 as an L-Methionine: 2-Aminotransferase. ......... 60
3.3.4 Functional Assignment of Mur26 as a Low Specificity Uridine Nucleoside
Phosphorylase................................................................................................................... 62
3.3.5

Functional

Assignment

of

Mur18
v

as

a

Primary

Amine-requiring

Nucleotidylyltransferase. .................................................................................................. 63
3.3.6 Functional Assignment of Mur19 as a GlyU: 5-Amino-5-Deoxyribosyltransferase
.......................................................................................................................................... 65
3.3.7 One-Pot Six-enzyme Synthesis of Ribofuranosylated Uronic Acid Moiety of
Muraymycin ..................................................................................................................... 70
3.4 Conclusion ..................................................................................................................... 73
3.5 Supporting Information .................................................................................................. 74
Chapter 4 : Self-Resistance During Muraymcyin Biosynthesis: A Complementary
Nucleotidyltransferase and Phosphotransferase with Identical Modification Sites and Distinct
Temporal Order ........................................................................................................................ 90
4.1 Introduction .................................................................................................................... 90
4.2 Materials and Methods ................................................................................................... 94
4.2.1 Chemicals, reagents, and instrumentation ............................................................... 94
4.2.2 Cloning Genes of mur28, mur29 and tmrB ............................................................. 95
4.2.3 Production of muraymycin D congeners ................................................................. 97
4.2.4 Enzyme reactions .................................................................................................... 98
4.2.5 Single-substrate kinetics .......................................................................................... 98
4.2.6 Antimicrobial Bioactivity ........................................................................................ 99
4.2.7 MraY Inhibition ..................................................................................................... 100
4.3 Results .......................................................................................................................... 101
4.3.1 Functional insight through bioinformatic analysis ................................................ 101
4.3.2 In vitro functional assignment and characterization of recombinant Mur29 ......... 102
4.3.3 In vitro functional assignment and characterization of Mur28 .............................. 106
4.3.4 Insight into the Function of Mur28-homologs BsTmrB ........................................ 112
4.3.5 Potential role of Mur29 and Mur28 in self-resistance ........................................... 112
4.4 Discussion .................................................................................................................... 114
4.4.1 Why We Choose Muraymycin D Series to Test the Activity................................. 114
4.4.2 Distinct Temporal Order for Mur29 and Mur28 Catalysis .................................... 115
vi

4.4.3 Predicted Phosphorylation Position of Tunicamycin by TmrB ............................. 116
4.5 Conclusion ................................................................................................................... 117
4.6 Supporting Information ................................................................................................ 118
Chapter 5 : A PLP and AdoMet Dependent Strategy for Aminopropyl Group Incorporation in
Nuceloside Antibiotics Biosynthesis...................................................................................... 147
5.1 Introduction .................................................................................................................. 147
5.2 Materials and Methods ................................................................................................. 149
5.2.1 Synthesis................................................................................................................ 149
5.2.2 Isotopic Enrichment .............................................................................................. 150
5.2.3 Heterologous Protein Expression .......................................................................... 151
5.2.4 Enzyme Assays ...................................................................................................... 154
5.3 Results and Discussion ................................................................................................. 158
5.3.1 Bioinformatic Analysis of Mur23 and Mur24 ....................................................... 158
5.3.2 Feeding Experiments: the Source of the Aminopropyl Group .............................. 159
5.3.3 Six-enzyme Biosynthesis of Amino Disaccharide, compound 7: the Aminopropyl
Group Acceptor .............................................................................................................. 161
5.3.4 Function Assignment of Mur23 and Mur24 .......................................................... 161
5.3.5 Kinetic and Mutational Analysis of Mur24 and Mur23 ........................................ 166
5.3.6 Mechanism Study of Mur24 .................................................................................. 167
5.4 Discussion .................................................................................................................... 170
5.4.1 Similarity between ACC Synthase and Mur24 ...................................................... 170
5.4.2 Relationship of Mur24 and MocR Transcription Regulator .................................. 170
5.4.3 Phosphorylation Modification is Also Required in Caprazamycin Biosynthetic
Pathway .......................................................................................................................... 171
5.5 Conclusion ................................................................................................................... 171
5.6 Supporting Information ................................................................................................ 173
Chapter 6 : Characterization of Mur15 as a Non-heme Fe(II), α-Ketoglutarate: Muraymycin
Dioxygenase........................................................................................................................... 190
vii

6.1 Introduction .................................................................................................................. 190
6.2 Materials and Methods ................................................................................................. 191
6.2.1 Cloning, Overexpression and Purification of Proteins .......................................... 191
6.2.2 Fermentation, Extraction, Isolation, and Purification of Muraymycins ................ 191
6.2.3 Activity Assay of Mur15 ....................................................................................... 191
6.2.4 Activity Optimization ............................................................................................ 192
6.2.5 Kinetics of Mur15 ................................................................................................. 192
6.2.6 Antimicrobial Bioactivities.................................................................................... 193
6.2.7 MraY Inhibition ..................................................................................................... 193
6.3 Results and Discussion ................................................................................................. 193
6.3.1 Bioinformatic Analysis of Mur15.......................................................................... 193
6.3.2 Functional Assignment and Activity Test .............................................................. 193
6.3.3 Activity Optimization and Kinetics Analysis ........................................................ 199
6.3.4 Bioactivity of the Mur15 Products ........................................................................ 201
6.4 Discussion .................................................................................................................... 202
6.4.1 Timing of Hydroxylation in Muraymycin Biosynthetic Pathway ......................... 202
6.4.2 Repeated Hydroxylation by Multifunctional Enzyme ........................................... 202
6.5 Conclusion ................................................................................................................... 203
6.6 Supporting Information ................................................................................................ 204
Chapter 7 : Ongoing Studies and Future Directions .............................................................. 216
7.1 Biosynthetic Mechanism of the NRPS Assembly Line ................................................ 216
7.2 Biosynthetic Mechanism of the Formation of the N-methyldiazepanone Moiety of
Caparazamycin Like A-90289............................................................................................ 216
7.3 Acyltransferase for the Fatty Acid Chain Appendage of Muraymycin ........................ 217
References .............................................................................................................................. 219
Vita ......................................................................................................................................... 226

viii

LIST OF TABLES
Table 1.1 Summary of synthesized muraymycin analogues with good activity. ....................... 5
Table 2.1 13C NMR data (100 MHz) of compounds 1−4. ........................................................ 24
Table 2.2 1H NMR data (400 MHz, J in Hz) of compounds 1−3 and muraymycin C1. .......... 25
Table 2.3 In vitro MraY assays and antimicrobial activities .................................................... 28
Table 4.1 Kinetic parameters for Mur29 and Mur28 ............................................................. 111
Table 4.2 Bacterial MraY assays and antimicrobial activities ............................................... 114
Table 6.1 Bacterial MraY assays and antimicrobial activities of the substrate and product of
Mur15..................................................................................................................................... 201

ix

LIST OF FIGURES
Figure 1.1 Structure of muraymycin. ......................................................................................... 2
Figure 1.2 Translocase I (MraY) catalyzed reaction. ................................................................. 4
Figure 1.3 SAR results for structural variations of muraymycin scaffold. ................................ 6
Figure 1.4 Structure of representative members from different classes of nucleoside antibiotics
that target MraY. Similarities are highlighted in blue. ............................................................... 7
Figure 1.5 The gene cluster identified for muraymycin biosynthesis. ....................................... 8
Figure 2.1 Structures of representative muraymycins.............................................................. 20
Figure 2.2 1H-1H COSY (▬) and selected HMBC (→) correlations of 1−3. .......................... 23
Figure 2.3 Structures of synthesized muraymycin analogues. ................................................. 29
Figure 3.1 Structure of muraymycin A1 and A-90289A containing similar ribofuranosylated
glycyl-uridine moiety. .............................................................................................................. 47
Figure 3.2 Proposed biosynthetic pathway towards ribofuranosylated glycyl-uridine moiety.
Enzymes that were previously functionally characterized were labeled in black. ................... 47
Figure 3.3 13C NMR spectrum (D2O, 100 MHz) and 1H NMR spectrum (D2O, 400 MHz) of 2′methoxy-UMP. ......................................................................................................................... 50
Figure 3.4 Characterization of Mur16...................................................................................... 56
Figure 3.5 Activity optimization and kinetic analysis of Mur16. ............................................ 57
Figure 3.6 Characterization of Mur17...................................................................................... 59
Figure 3.7 Characterization of Mur20...................................................................................... 61
Figure 3.8 Characterization of Mur26...................................................................................... 63
Figure 3.9 Characterization of Mur18...................................................................................... 64
x

Figure 3.10 Characterization of Mur19.................................................................................... 66
Figure 3.11 Characterization of Mur19 with 2'-fluoro-2'-deoxyuridine-5'-triphosphate. ........ 68
Figure 3.12 Comparison of substrate promiscuity of Mur19 and LipN with 4a and 4b. ......... 69
Figure 3.13 Characterization of one-pot enzymatic reaction with UMP and UTP as start
substrates. ................................................................................................................................. 71
Figure 3.14 Characterization of one-pot enzymatic reaction with GlyU, 2′-deoxy-UMP, UTP as
start substrates. ......................................................................................................................... 72
Figure 3.15 Biosynthetic pathway and substrate promiscuity towards ribofuranosylated glycyluridne moiety of muraymycins. ............................................................................................... 73
Figure 4.1 Structure of representative peptidyl nucleoside antibiotics consisting of an ADRGlyU disaccharide core. ........................................................................................................... 92
Figure 4.2 Functional assignment of Mur29 .......................................................................... 104
Figure 4.3 Biochemical characterization of Mur29. .............................................................. 106
Figure 4.4 Functional assignment of Mur28. ......................................................................... 108
Figure 4.5 Biochemical characterization of Mur28. .............................................................. 110
Figure 5.1 Structure of representative nucleoside antibiotics containing an aminopropyl moiety
(highlighted in red). ............................................................................................................... 148
Figure 5.2 13C NMR spectrum of isotope labelled muraymycin D1. ..................................... 160
Figure 5.3 Biosynthesis of the amino disaccharide moiety of muraymycins......................... 161
Figure 5.4 Two proposed biosynthetic pathway of the incorporation of aminopropyl moiety of
muraymycins. ......................................................................................................................... 163
Figure 5.5 HPLC analysis of tandem enzymatic reaction with Mur23, Mur24 and Mur28. . 164
xi

Figure 5.6 Characterization of Mur24 and Mur23. ................................................................ 165
Figure 5.7 Chemical shift assignment for compound 7, 8, 9 and 10...................................... 166
Figure 5.8 Kinetic analysis of Mur24 and Mur23. ................................................................. 167
Figure 5.9 Mechanistic proposal for Mur24 catalyzed aminopropyl incorporation reaction. 168
Figure 5.10 LC-MS analysis of MBTH modified Mur24 catalyzed reactions. ...................... 169
Figure 5.11 The biosynthesis of ethylene............................................................................... 170
Figure 5.12 Structures of caprazol-3’’-phosphate. ................................................................. 171
Figure 6.1 Characterization of Mur15 with muraymycin D1 (1). .......................................... 195
Figure 6.2 Characterization of Mur15 with muraymycin B2 (5), B6 (7) and A1 (9). ............ 196
Figure 6.3 Comparison of 1H NMR (DMSO-d6, 400 MHz) between muraymycin B2, 5 and
Mur15 product hydroxyl muraymycin B2, 6. ........................................................................ 197
Figure 6.4 Characterization of Mur15 with L-Arg-Leu dipeptide, 11. .................................. 198
Figure 6.5 Activity optimization and kinetic analysis of Mur15. .......................................... 200
Figure 6.6 Repeated hydroxylation catalyzed by Mur15. ...................................................... 203
Figure 7.1 Biosynthetic pathway towards alkyl aminoribosyl-glycyluridine moiety of
muraymycin. .......................................................................................................................... 216
Figure 7.2 Proposed biosynthetic pathway towards N-methyldiazepanone moiety of A-90289.
............................................................................................................................................... 217

xii

LIST OF FIGURES IN SUPPORTING INFORMATION
Figure S2.1 (+)-HR-ESI-MS (positive mode) of muraymycin B8 (1). .................................... 32
Figure S2.2 1H NMR spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). ..................... 32
Figure S2.3 13C NMR spectrum (DMSO-d6, 100 MHz) of muraymycin B8 (1). .................... 33
Figure S2.4 HSQC spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). ......................... 33
Figure S2.5 HMBC spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). ........................ 34
Figure S2.6 1H-1H COSY spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). .............. 34
Figure S2.7 TOCSY spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). ....................... 35
Figure S2.8 NOESY spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1). ...................... 35
Figure S2.9 (+)-HR-ESI-MS (positive mode) of muraymycin B9 (2). .................................... 36
Figure S2.10 1H NMR spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2). ................... 36
Figure S2.11 13C NMR spectrum (DMSO-d6, 150 MHz) of muraymycin B9 (2). .................. 37
Figure S2.12 HSQC spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2). ....................... 37
Figure S2.13 HMBC spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2). ...................... 38
Figure S2.14 1H-1H COSY spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2). ............ 38
Figure S2.15 NOESY spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2). .................... 39
Figure S2.16 (+)-HR-ESI-MS (positive mode) of muraymycin C6 (3). .................................. 39
Figure S2.17 1H NMR spectrum (D2O, 400 MHz) of muraymycin C6 (3). ............................ 40
Figure S2.18 13C NMR spectrum (D2O, 100 MHz) of muraymycin C6 (3). ........................... 40
Figure S2.19 HSQC spectrum (D2O, 400 MHz) of muraymycin C6 (3). ................................ 41
Figure S2.20 HMBC spectrum (D2O, 400 MHz) of muraymycin C6 (3). ............................... 41
Figure S2.21 1H-1H COSY spectrum (D2O, 400 MHz) of muraymycin C6 (3)....................... 42
Figure S2.22 NOESY spectrum (D2O, 400 MHz) of muraymycin C6 (3). ............................. 42
Figure S2.23 (+)-HR-ESI-MS (positive mode) of muraymycin C1 (4). .................................. 43
Figure S2.24 1H NMR spectrum (D2O, 400 MHz) of muraymycin C1 (4). ............................ 43
Figure S2.25 13C NMR spectrum (D2O, 100 MHz) of muraymycin C1 (4). ........................... 44
xiii

Figure S2.26 HSQC spectrum (D2O, 400 MHz) of muraymycin C1 (4). ................................ 44
Figure S2.27 HMBC spectrum (D2O, 400 MHz) of muraymycin C1 (4). ............................... 45
Figure S2.28 1H-1H COSY spectrum (D2O, 400 MHz) of muraymycin C1 (4)....................... 45
Figure S3.1 SDS-PAGE analysis of protein Mur16, Mur17, Mur18, Mur19, Mur20 and Mur26.
................................................................................................................................................. 77
Figure S3.2 LC-MS analysis of Mur16 catalyzed reactions. ................................................... 78
Figure S3.3 Detection of succinate production using LC-MS and an enzyme coupled reaction.
................................................................................................................................................. 79
Figure S3.4 LC-MS analysis of Mur17 catalyzed reactions. ................................................... 80
Figure S3.5 Comparative analysis of enzymatic and synthetic 3 diastereomers. .................... 81
Figure S3.6 LC-MS analysis of AQC modified GlyU epimers and Mur17 catalyzed reactions.
................................................................................................................................................. 82
Figure S3.7 (+)-HR-ESI-MS (positive mode) of purified Mur20 product amino uridine, 4a . 83
Figure S3.8 LC-MS analysis of MBTH modified Mur20 catalyzed reactions. ....................... 84
Figure S3.9 LC-MS analysis of Mur20 catalyzed reactions. ................................................... 85
Figure S3.10 LC-MS analysis of Mur26 catalyzed reactions. ................................................. 86
Figure S3.11 LC-MS analysis of Mur26 and Mur18 catalyzed reactions with HILIC column.
................................................................................................................................................. 87
Figure S3.12 (+)-HR-ESI-MS (positive mode) of purified AQC modified 8b ........................ 88
Figure S3.13 1H NMR spectrum (D2O, 400 MHz) of AQC modified 8b. ............................... 89
Figure S3.14 1H-1H COSY spectrum (D2O, 400 MHz) of AQC modified 8b. ........................ 89
Figure S4.1 SDS-PAGE analysis of purified Mur28, Mur29, TmrB, LipI and LipX. ........... 122
Figure S4.2 (+)-HR-ESI-MS (positive mode) of muraymycin D1 ........................................ 123
Figure S4.3 1H NMR spectrum (D2O, 400 MHz) of muraymycin D1. ................................. 123
Figure S4.4 13C NMR spectrum (D2O, 100 MHz) of muraymycin D1. ................................. 124
Figure S4.5 HSQC spectrum (D2O, 400 MHz) of muraymycin D1. ..................................... 124
Figure S4.6 1H−1H COSY spectrum (D2O, 400 MHz) of muraymycin D1. .......................... 125
Figure S4.7 HMBC spectrum (D2O, 400 MHz) of muraymycin D1. .................................... 125
xiv

Figure S4.8 (+)-HR-ESI-MS (positive mode) of muraymycin D2 ........................................ 126
Figure S4.9 1H NMR spectrum (D2O, 400 MHz) of muraymycin D2. .................................. 126
Figure S4.10 13C NMR spectrum (D2O, 100 MHz) of muraymycin D2. ............................... 127
Figure S4.11 HSQC spectrum (D2O, 400 MHz) of muraymycin D2..................................... 127
Figure S4.12 1H-1H COSY spectrum (D2O, 400 MHz) of muraymycin D2. ......................... 128
Figure S4.13 (+)-HR-ESI-MS (positive mode) of muraymycin D3. (calcd for C37H61N11O15,
expected (M+H)+ ion at m/z = 900.4421, found 900.4307; expected (M+2H)2+ ion at m/z =
450.7247, found 450.7202). ................................................................................................... 128
Figure S4.14 1H NMR spectrum (D2O, 400 MHz) of muraymycin D3. ................................ 129
Figure S4.15 (+)-HR-ESI-MS (positive mode) of compound ADR-GlyU ............................ 129
Figure S4.16 1H NMR spectrum (D2O, 100 MHz) of compound ADR-GlyU. ...................... 130
Figure S4.17 13C NMR spectrum (D2O, 100 MHz) of compound ADR-GlyU...................... 130
Figure S4.18 HSQC spectrum (D2O, 400 MHz) of compound ADR-GlyU. ......................... 131
Figure S4.19 1H-1H COSY spectrum (D2O, 400 MHz) of compound ADR-GlyU. ............... 131
Figure S 4.20 (+)-HR-ESI-MS (positive mode) of compound D1-AMP. .............................. 132
Figure S4.21 1H NMR spectrum (D2O, 400 MHz) of muramycin D1-AMP. ........................ 132
Figure S4.22 1H-1H COSY spectrum (D2O, 400 MHz) of muramycin D1-AMP. ................. 133
Figure S4.23 Reaction catalyzed by Mur29 with muraymycin D2 and ATP. ........................ 134
Figure S4.24 Reaction catalyzed by Mur29 with muraymycin D3 and ATP. ........................ 135
Figure S4.25 Reaction catalyzed by Mur29 with muraymycin D1 and GTP. ........................ 136
Figure S4.26 Reaction catalyzed by Mur29 with muraymycin D1 and CTP. ........................ 137
Figure S4.27 Reaction catalyzed by Mur29 with muraymycin D1 and dATP. ...................... 138
Figure S4.28 Reaction catalyzed by Mur29 with muraymycin D1 and dTTP. ...................... 139
Figure S4.29 Reaction catalyzed by Mur29 with muraymycin D1 and UTP. ........................ 140
Figure S 4.30 (+)-HR-ESI-MS (positive mode) of compound D2-PHOS ............................. 141
Figure S4.31 1H NMR spectrum (D2O, 400 MHz) of muramycin D2-PHOS. ...................... 141
Figure S4.32 1H-1H COSY spectrum (D2O, 400 MHz) of muramycin D2 -PHOS. .............. 142
Figure S4.33 Reaction catalyzed by Mur28 with D2 and [γ-P18O4]ATP. ............................... 142
xv

Figure S4.34 Reaction catalyzed by Mur28 with muraymycin D3 and ATP. ........................ 143
Figure S4.35 Reaction catalyzed by Mur28 with ADR-GlyU and ATP ................................. 144
Figure S4.36 Reaction catalyzed by Mur28 with muraymycin D2 and different phosphate
donors..................................................................................................................................... 145
Figure S4.37 Reaction catalyzed by TmrB. ........................................................................... 146
Figure S5.1 SDS-PAGE analysis of purified protein and UV/Vis spectrum of Mur23. ........ 177
Figure S5.2 (+)-HR-ESI-MS (positive mode) of L-[13C5,15N] Met enriched muraymycin D1.
............................................................................................................................................... 178
Figure S5.3 1H NMR spectrum (D2O, 100 MHz) of isotope enriched (L-[13C5, 15N] Met or L13

C4, 15N] Asp) muraymycin D1. ........................................................................................... 178

Figure S5.4 Analysis of tandem enzymatic reaction with Mur23, Mur24 and Mur28 .......... 179
Figure S5.5 ESI-MS spectrum of 7’ eluted at 23.325 min ..................................................... 180
Figure S5.6 ESI-MS of 10’ eluted at 24.157min .................................................................... 180
Figure S5.7 (+)-HR-ESI-MS (positive mode) of compound 8 .............................................. 181
Figure S5.8 1H NMR spectrum (D2O, 100 MHz) of compound 8. ........................................ 181
Figure S5.9 HSQC spectrum (D2O, 400 MHz) of compound 8............................................. 182
Figure S5.10 1H-1H COSY spectrum (D2O, 400 MHz) of compound 8. ............................... 182
Figure S5.11 (+)-HR-ESI-MS (positive mode) of compound 9............................................. 183
Figure S5.12 1H NMR spectrum (D2O, 400 MHz) of compound 9. ...................................... 183
Figure S5.13 HSQC spectrum (D2O, 400 MHz) of compound 9........................................... 184
Figure S5.14 1H-1H COSY spectrum (D2O, 400 MHz) of compound 9. ............................... 184
Figure S5.15 HMBC spectrum (D2O, 400 MHz) of compound 9.......................................... 185
Figure S5.16 (+)-HR-ESI-MS (positive mode) of compound 10 .......................................... 186
Figure S5.17 1H NMR spectrum (D2O, 400 MHz) of compound 10. .................................... 186
Figure S5.18 1H-1H COSY spectrum (D2O, 400 MHz) of compound 10. ............................. 187
Figure S5.19 (+)-HR-ESI-MS (positive mode) of 5’-deoxy-5’-(methylthio) adenosine ....... 187
Figure S5.20 1H NMR spectrum (D2O, 400 MHz) of L-VG. ................................................ 188
Figure S5.21 HPLC analysis of Mur24 reaction with or without PLP using 8 as substrates. 188
xvi

Figure S5.22 LC-MS analysis of MBTH modified Mur24 catalyzed reactions. ................... 189
Figure S6.1 SDS-PAGE analysis of purified His6-Mur15 ..................................................... 204
Figure S6.2 Identification of the Mur15 product with 1. ....................................................... 204
Figure S6.3 Identification of the Mur15 product with 3. ....................................................... 205
Figure S6.4 Identification of the Mur15 product with 1. ....................................................... 206
Figure S6.5 Identification of the Mur15 product with 5. ....................................................... 207
Figure S6.6 1H NMR spectrum (DMSO-d6, 400 MHz) of muraymycin B2 (5). ................... 208
Figure S6.7 13C NMR spectrum (DMSO-d6, 100 MHz) of muraymycin B2 (5). .................. 208
Figure S6.8 HSQC spectrum (DMSO-d6, 400 MHz) of muraymycin B2 (5). ....................... 209
Figure S6.9 HMBC spectrum (DMSO-d6, 400 MHz) of muraymycin B2 (5). ...................... 209
Figure S6.10 1H-1H COSY spectrum ((DMSO-d6, 400 MHz) of muraymycin B2 (5). ......... 210
Figure S6.11 Identification of the Mur15 product with 7. ..................................................... 211
Figure S6.12 1H NMR spectrum (DMSO-d6, 400 MHz) of muraymycin B6 (7). ................. 212
Figure S6.13 13C NMR spectrum (DMSO-d6, 100 MHz) of muraymycin B6 (7). ................ 212
Figure S6.14 HSQC spectrum (DMSO-d6, 400 MHz) of muraymycin B6 (7). ..................... 213
Figure S6.15 HMBC spectrum (DMSO-d6, 400 MHz) of muraymycin B6 (7). .................... 213
Figure S6.16 1H-1H COSY spectrum ((DMSO-d6, 400 MHz) of muraymycin B6 (7). ......... 214
Figure S6.17 Identification of the Mur15 product with 9. ..................................................... 215
Figure S6.18 Identification of the Mur15 product with 11. ................................................... 215

xvii

LIST OF ABBREVIATIONS
DMSO

dimethyl sulfoxide

2D

two dimensional

ACC

1-aminocyclopropanecarboxylic acid

AdoMet

S-adenosyl-L-methionine

ADR

5″-amino-5″-deoxyribose

AMP

adenosine monophosphate

AQC

6-aminoquinolyl-N-hydroxysuccinimidyl carbamate

Arg

arginine

Asp

aspartic acid

ATP

adenosine triphosphate

COSY

correlation spectroscopy

CTP

cytidine triphosphate

dATP

2′-deoxy-adenosine triphosphate

dTTP

2′-deoxy-thymidine triphosphate

E. coli

Escherichia coli

GlyU

(5′S,6′S)-5′-C-glycyluridine

GTP

guanosine triphosphate

h

hour

His6

hexa-histidine

HMBC

heteronuclear multiple-bond correlation spectroscopy

HPLC

high performance liquid chromatography

HR-ESI-MS

high resolution-electrospray ionization-mass spectrometry

HSQC

heteronuclear single-quantum correlation spectroscopy

IPTG

β-D-1-thiogalactopyranoside

kD

kilodalton

LC-MS

liquid chromatography-mass spectrometry

Leu

leucine

L-VG

L-vinylglycine
xviii

MBP

maltose binding protein

MBTH

3-methyl-2-benzothiazolinone hydrazone hydrochloride

MeOH

methanol

Met

methionine

MIC

minimum inhibitory concentration

min

minute

MTA

methylthioadenosine

MW

molecular weight

NDP

nucleotidyl diphosphate

NMR

nuclear magnetic resonance

NOESY

nuclear overhauser effect spectroscopy

NRPS

nonribosomal peptide synthetase

NTP

nucleotidyl triphosphate

OD

optical density

PCR

polymerase chain reaction

PHOS

phosphate

PLP

pyridoxal phosphate

rt

room temperature

S. aureus

Staphylococcus aureus

SAR

structural-activity relationship

SDS

sodium dodecyl sulfate

SMM

[(3S)-3-Amino-3-carboxypropyl] (dimethyl)-sulfonium iodide

TEA

triethylamine

TFA

trifluoroacetic acid

TOCSY

total correlation spectroscopy

UDP

uridine diphosphate

UMP

uridine monophosphate

UTP

uridine triphosphate

UV/Vis

ultraviolet/visible
xix

α-KB

α-ketobutyrate

α-KG

α-ketoglutarate

xx

Chapter 1 : Introduction and Background
1.1 Muraymycins Discovery

Muraymcyins were discovered from a Streptomyces sp. organism guided by cell-wall
specific biological assays by Wyeth-Research in 2001.1 Structural elucidation revealed that the
muraymycin family belongs to the lipopeptidyl nucleoside antibiotic family. The 22
muraymycins that were discovered have a common peptide-appended, ribofuranoside uronic
acid core structure (Figure 1.1). Discovered members of this family differ in one or more of
three components: the fatty acyl chain, the aminoribose and the terminal amino acid in the
peptide chain. Muraymycin A1 with a guanidino fatty acyl side chain is the most potent member
of the family and showed good activity against Staphylococcal (MIC 2 to 16 μg/mL),
Escherichia coli imp mutant (MIC <0.03 μg/mL) and Staphylococcus aureus in infected mice
(ED50 1.1 mg/kg).2

1

Figure 1.1 Structure of muraymycin.

2

1.2 Targets of Muraymycin

Muraymycins inhibit peptidoglycan cell wall biosynthesis of Gram-positive as well as
Gram-negative bacteria by inhibiting the activity of bacteria translocase I (MraY). MraY
catalyzes the transfer and attachment of phospho-MurNAc-pentapeptide to a lipid carrier,
undecaprenylphosphate, to form undecaprenyl-diphodpho-MurNAc-pentapeptide, also called
Lipid I (Figure 1.2).3 Recently, the crystal structure of MraY from the Gram-negative bacteria
Aquifex aeolicus (MraYAA) in complex with muraymycin D2 was solved.4 Surprisingly,
muraymycin D2 didn’t interact with any of the conserved amino acid residues (Asp117, Asp118,
and Asp265) of MraYAA, which is essential for catalytic activity from previous studies.5 Instead,
muraymycin D2 bound with the nucleoside-binding pocket, which was formed by large
conformational rearrangement of loops C and D of MraYAA.4, 6

Recently, Kurosu’s group reported that besides MraY, muraymycin D1 also inhibited
a second, distinct bacterial transferase, polyprenyl phosphate-GlcNAc-1-phosphate transferase
(WecA), which is an essential enzyme in the biosynthesis of cell wall components of
Mycobacterium tuberculosis in both replicating and nonreplicating states.7

3

Figure 1.2 Translocase I (MraY) catalyzed reaction.

4

1.3 SAR of Muraymycins
Antibacterial activity of the 22 discovered muraymycins showed that better activity
was observed for acylated muraymycins, especially with longer and charged fatty acyl
chains.Various structurally diverse muraymycin analogues have been synthesized, and, many
of them showed comparable activity with natural muraymycins (Table 1.1). A graphical
summary of SAR of muraymycin is shown in Figure 1.3 based on the activity of naturally
occurring muraymycins and chemically synthesized or semisynthesized analogues.7-17 The SAR
is, to some extent, consistent with the crystal structure of the binding pattern of muraymycin
D2 with MraYAA.4
Table 1.1 Summary of synthesized muraymycin analogues with good activity.
Compound IC50 (μM)
MIC (μg/mL)
MurX 0.011
M. tuberculosis 1.567 (1.68 μM)
1
MurX 0.011
M. tuberculosis 1.567 (1.68 μM)
2
MurX 0.0096
M. tuberculosis 6.25 7 (6.74 μM)
3
MraY 0.0011
P. aeruginosa ATCC25619 >6418
4
MraY 0.0008
P. aeruginosa ATCC25619 >648
5
MraY 0.0007
P. aeruginosa ATCC25619 >648
6
MraY 0.00024
P. aeruginosa ATCC25619 648 (68.0 μM)
7
MraY 0.00022
P. aeruginosa ATCC25619 88 (8.5 μM)
8
MraY 0.00014
P. aeruginosa ATCC25619 88 (9.18 μM)
9
MraY 0.00060
P. aeruginosa ATCC25619 88 (9.18 μM)
10
MraY 1.7-2.7
E. coli ∆tolC 50 13 (65.1 μM)
11
12
MraY/ MurG ~5.9
NA
12

5

Figure 1.3 SAR results for structural variations of muraymycin scaffold.
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1.4 Muraymycin Related Nucleoside Antibiotics
Besides muraymycin, many other nucleoside antibiotics are known to inhibit
peptidoglycan biosynthesis by targeting MraY. Four review articles10, 19-21 provide a broad
overview of these nucleoside antibiotics. Figure 1.4 shows the structures of representative
members of the different classes of nucleoside antibiotics inhibiting MraY.

Figure 1.4 Structure of representative members from different classes of nucleoside antibiotics
that target MraY. Similarities are highlighted in blue.
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1.5 Biosynthetic Gene Cluster of Muraymycin
The muraymycin biosynthetic gene cluster was identified by the Deng group in 2010
from Streptomyces sp. NRRL30471.22 18F3 cosmid was introduced into S. lividans TK24 for
heterologous production of muraymycin. The minimal muraymycin biosynthetic gene cluster
(mur12-mur34) was determined by gene disruption (Figure 1.5). Mur34 was identified as a
negative regulator involved in muraymycin biosynthesis.23 The function of the other genes in
the cluster was preliminarily assigned by BLAST analysis.

Figure 1.5 The gene cluster identified for muraymycin biosynthesis.
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1.6 Contents of the Dissertation
Our over-arching goal is to delineate the biosynthetic pathway of muraymycin in order
to develop analogues through chemoenzymatic synthesis and mutasynthesis. Prior work has
identified the gene cluster involved in the biosynthesis of muraymycin.22 However, the
enzymatic mechanism of the muraymycin scaffold assembly has not been elucidated. This
dissertation consists of seven chapters. Chapter 1 is the introduction of murymycins while
chapter 7 discusses the future direction of the projects. In chapter 2, we report the isolation,
structural elucidation, and biological activity of muraymycins. Three new muraymycin
congeners were isolated and the antibacterial activity was evaluated. Chapters 3 to 6 focus on
studying biosynthetic mechanism of the alkyl-ribofuranosylated glycyl-uridine scaffold and
fatty acid side chain of muraymycin. In chapter 3, six enzymes that are responsible for the
biosynthesis of the ribofuranosylated glycyl-uridine moiety of muraymycin were functionally
assigned. In chapter 4, unique resistance pattern of muraymycin was defined. A complementary
nucleotidyltransferase and phosphotransferase modifies identical position of muraymycin, but
shows distinct temporal order. In chapter 5, two enzymes that are functionally assigned to
modify the cryptic phosphorylated intermediate by attachment of an aminopropyl group are
characterized. In chapter 6, one enzyme belonging to the cupin family is functionally assigned
as an Fe(II)- and α-KG-dependent dioxygenase to catalyze the hydroxylation of the peptide
moiety of muraymycins.

9

Chapter 2 : Antibacterial Muraymycins from Streptomyces sp. NRRL 30473
2.1 Introduction

Muraymycins, initially reported as a mixture of nineteen congeners from the
fermentation broth of Streptomyces sp. NRRL 30471,1 were discovered using biological assays
to identify inhibitors of Lipid II and peptidoglycan cell wall biosynthesis. 1-2, 24-25 Muraymycin
A1, one of the more potent of the congeners, was shown to have good activity against
Staphylococcal (MIC 2 to 16 μg/mL) and E. coli imp mutant (MIC <0.03 μg/mL), and was
further shown to be effective in a murine model of Staphylococcus aureus infection (ED50 1.1
mg/kg). Follow-up efforts have revealed that muraymycins likely exhibit antibacterial activity
by directly inhibiting translocase I (MraY). MraY initiates the lipid cycle of cell wall
biosynthesis by catalyzing the transfer and attachment of phospho-MurNAc-pentapeptide from
UDP-MurNAc-pentapeptide to a lipid carrier, undecaprenylphosphate, to form UMP and
undecaprenyl-diphospho-MurNAc-pentapeptide, also referred to as Lipid I.7, 9, 13-14, 26 Notably,
several muraymycin synthetic variants have been screened against MraYs from different
species, achieving IC50 values as low as 0.7 nM. However, only two naturally occurring
muraymycins have been directly tested against MraY to date: muraymycin D1 and D2, both
prepared by total synthesis and yielding IC50 values of 10 nM and 2.8 nM, respectively.7, 14 Our
understanding of muraymycin structure-activity relationship from these studies has recently
been reviewed.10

Muraymycins have several unique structural features when compared with clinically
used antibiotics. They are classified as lipopeptidyl nucleoside antibiotics, consisting of a
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(5′S,6′S)-glycyluridine (GlyU) core that is modified with two distinct components: an
aminoribose attached by a traditional O-glycosidic bond and an unusual peptide attached by a
propylamine linker.1, 27 The different congeners have been categorized into four types (series
A-D) based on structural variation of a Leu residue of the peptide moiety. The D series, which
includes the aforementioned muraymycins D1 and D2, contain an unmodified L-Leu and are
structurally the simplest. The C series of muraymycins contain a (3S)-3-hydroxy-L-Leu, and
the A and B series are O-acylated variants of the hydroxylated L-Leu. The B series are
characterized by a branched, saturated fatty acid ranging from seven to ten linear carbons
(represented by muraymycin B2 in Figure 1) and the A series characterized by a terminal
guanidinium-substituted fatty acid ranging from fourteen to sixteen linear atoms in length
(represented by muraymycin A1 in Figure 1).1

As part of our on-going efforts to characterize the inhibitory properties and establish
structure-activity relationships of naturally occurring muraymycins toward the target MraY, we
report the discovery, structural elucidation, and activity of three new muraymycins (1-3) from
Streptomyces sp. NRRL30473 and NRRL 30477, two strains previously derived from
Streptomyces sp. NRRL 30471 by random, chemical mutagenesis. Importantly, a complete
suite of 1D and 2D NMR spectroscopic analysis was performed, and the entirety of the NMR
spectral data is provided in the public domain for the first time for any muraymycin congener.
Compounds 1 and 2, named muraymycin B8 and B9, respectively, differ from other
muraymycins by having an elongated fatty acid side chain. Both are shown to be potent
inhibitors of Staphylococcus aureus and Aquifex aeolicus MraY in vitro. Compound 3, named
muraymycin C6, is characterized by an N-acetyl modification of the primary amine of the
11

aminoribose. The inhibitory activity of 3 against MraY is significantly reduced, which is
consistent with an important role of this amine in target binding and suggests acetylation as a
possible means of self-resistance by the producing strain.

2.2 Materials and Methods
2.2.1 General Experimental Procedures
UV spectra were recorded on an Ultraspec 8000 spectrometer (GE, Pittsburgh, PA,
USA). All NMR data was recorded at 400 MHz for 1H and 100 MHz for 13C with Varian Inova
NMR spectrometers (Agilent, Santa Clara, CA), and 600 MHz for 1H and 150 MHz for 13C
with an Agilent DD2 NMR spectrometer (Agilent, Santa Clara, CA). LC-MS was conducted
with an Agilent 6120 Quadrupole MSD mass spectrometer (Agilent Technologies, Santa Clara,
CA) equipped with an Agilent 1200 Series Quaternary LC system and an Eclipse XDB-C18
column (150 × 4.6 mm, 5 µm). HR-ESI-MS spectra were recorded on an AB SCIEX Triple
TOF 5600 System (AB Sciex, Framingham, MA, USA). Analytic HPLC was performed with
Waters Alliance 2695 separation module (Milford, MA) equipped with a Waters 2998 diode
array detector and an analytical Apollo C18 column (250 mm x 4.6 mm, 5 µm). Semipreparative
HPLC was performed with a Waters 600 controller and pump (Milford, MA) equipped with a
996 diode array detector, 717 plus autosampler, and an Apollo C18 column (250 × 10 mm, 5 µm)
purchased from Grace (Deerfield, IL). All solvents used were of ACS grade and purchased from
Pharmco-AAPER (Brookfield, CT). Sephadex LH-20 (25-100 μm) was purchased from GE
Healthcare (Little Chalfont, United Kingdom). A solution of resazurin sodium salt (Alfa aesar
B21187) was prepared to 1 mg/mL in sterile distilled water.
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2.2.2 Fermentation, Extraction, Isolation and Purification
Streptomyces sp. NRRL 30473 and NRRL 30477 were cultivated on MS agar plates at
28 °C for 7 days. Chunks of the corresponding agar with bacterial growth were added to five
250 mL Erlenmeyer flasks, each containing 50 mL TSBG (Tryptic soy broth (Difco)
supplemented with 20 g/L glucose), at 30 °C on a rotary shaker (250 rpm) for 72 h. The cultures
were used to inoculate 200 flasks (250 mL), each containing 50 mL PM-1 medium.28 PM-1 was
composed of glucose 2%, soluble starch 1%, pressed yeast 0.9%, peptone 0.5%, meat extract
0.5%, NaCl 0.5%, CaCO3 0.3% and CB-442 (NOF Co., Ltd.) 0.01% (pH 7.4, before
sterilization). The fermentation was continued for 7 days at 23 °C on a rotary shaker (210 rpm).

All culture flasks were combined and centrifuged at 6000 x g for 15 min to separate the
mycelium and water phase. The mycelial-cake portion was extracted with methanol (3 × 1 L)
by sonication, and the organic phase was evaporated to afford 15 g of brown crude extract.
Amberlite XAD-16 (4%, Sigma) resin was added to the water phase and stirred for 12 h. The
resin was washed with water until the effluent became colorless, and then eluted with 3 L of
methanol. The MeOH extract was concentrated under reduced pressure to obtain a crude extract
(12 g). Components of the mycelium crude extract and water phase crude extract were subjected
to Sephadex LH-20 column, and methanol was used to elute compounds at a flow rate at 2
mL/min to yield twelve fractions. Fraction I was further purified by using a semipreparative
HPLC (CH3CN−H2O, 0.01 % TFA; flow rate: 3.0 mL/min)to yield 1 (6 mg) and 2 (2 mg).
Compound 3 (4 mg) and muraymycin C1 (5 mg) were isolated from fraction II by
semipreparative HPLC (CH3CN−H2O, 0.01 % TFA; flow rate: 3.0 mL/min).
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muraymycin B8 (1): white amorphous powder; UV (MeOH) λmax (log ε) 260 (3.83) nm;
13

C and 1H NMR data, see Tables 1 and 2; (+)-HR-ESI-MS: m/z 1184.6757 [M + H]+ (calcd for

C64H94N11O18, 1184.6778).

muraymycin B9 (2): white amorphous powder; UV (MeOH) λmax (log ε) 258 (1.93) nm;
13

C and 1H NMR data, see Tables 1 and 2; (+)-HR-ESI-MS: m/z 1156.6458 [M + H]+ (calcd for

C62H90N11O18, 1156.6465).

muraymycin C6 (3): white amorphous powder; UV (MeOH) λmax (log ε) 261 (3.95) nm;
13

C and 1H NMR data, see Tables 1 and 2; (+)-HR-ESI-MS: m/z 988.4598 [M + H]+ (calcd for

C40H66N11O18, 988.4587).

2.2.3 DNA Extraction, Genome Sequencing, and Analysis
A single colony of Streptomyces sp. NRRL30473 from MS agar was used to inoculate
50 mL TSBG in a 250 mL baffled flask and cultured for 3 days at 30 °C. Cells were harvested
via centrifugation and washed once with TE buffer and resuspended with 5 mL of 2 mg/mL
lysozyme (dissolved in TE buffer). Cells were incubated at 30 °C for 30 min and then 1.2 mL
0.5 M EDTA was added and mixed. Proteinase K (6 ml of 0.2 mg/mL) was added to the solution
and incubated at 37 °C for 2 h.

DNA was extracted using phenol-chloroform with the protocol

shared by Pacific Biosciences with minor modifications. Phenol/chloroform/isoamyl alcohol
solution (7 mL of 25: 24: 1) was added, and the mixture rotated for 10 min. The top aqueous
solution was transferred after centrifugation and 7 mL chloroform/isoamyl alcohol solution
(24:1) was added. After rotating for 5 min, the top aqueous solution was transferred after
centrifugation. The solution was treated with RNase for 1 h at 37 °C. After mixing with 0.25
14

volume of 5 M NaCl, 30% PEG6000 was added to final concentration of 10%. Precipitated
DNA was transferred with glass tube to a new tube and rinsed with 70% ethanol and air dried.
DNA was re-dissolved in 2 mL TE buffer and stored at 4 °C.
2.2.4 Antimicrobial Bioactivities
The protocol used for the determination of the minimum inhibitory concentration (MIC)
was as described previously with minor modifications.29 The bacterial strains S. aureus subsp.
aureus (Newman strain), E. coli ∆tolC mutant JW5503 (E. coli genetic stock center), and E.
coli BL21(DE3) were used as model strains for antimicrobial susceptibility assays. All strains
were grown in appropriate liquid or on agar plates using LB media (BD244620) for S. aureus
and LB media supplemented with 50 μg/mL kanamycin for E. coli ∆tolC mutant. Individual
strains were grown in 5 mL of medium for 16 h at 37 °C with shaking (250 rpm), and then were
diluted X1000 into 4.5 mL of medium and incubated until OD600 reaching 0.4. An aliquot of the
suspensions was diluted X1000. Aliquots (90 μL) of each diluted culture and transferred into
the individual well of a 96-well plate supplied with 5 μL of the tested compound. Maximum
final concentration of 256 μg/mL or 32 μg/mL with serial dilutions was maintained to obtain
the antimicrobial activities and compared to the negative control 1% DMSO or water alone.
The culture plates were incubated at 37 °C for 16 h with shaking (160 rpm) for E. coli strains
and (50 rpm) for S. aureus. The OD600 of each well measured using BioTek™ Synergy™ 2
Multi-Mode Microplate Readers. The acquired OD600 values were normalized to the negative
control wells (100% viability). Resazurin solution (5 μL) was also added to each well, and the
plates were shaken for 10 s and incubated at 37 °C for another 3 h to allow resazurin to convert
to resorufin by viable bacteria. The minimal concentration of the tested compound that caused
15

growth inhibition was recorded as the MIC. The MIC assay with S. aureus was carried out by
Prof. Christian Ducho’s lab in Department of Pharmacy, Pharmaceutical and Medicinal
Chemistry, Saarland University.
2.2.5 MraY Inhibition Assay
MraY inhibition to determine IC50 was carried out by Prof. Christian Ducho’s lab in
Department of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University.
Overexpression of MraY from S. aureus. The overexpression of SaMraY in E. coli was
performed as described, and a crude membrane preparation was employed for in vitro MraY
assays.13
Overexpression of MraY from Aquifex aeolicus. For the overexpression of AaMraY
from in E. coli, the plasmid previously reported by Lee and co-workers4-5 was used. This
plasmid contained the codon-optimized mraY gene from Aquifex aeolicus encoding a fusion
protein with decahistidine maltose-binding protein (His-MBP) and a PreScission protease
cleavage site for removal of the tag. The plasmid was transformed into C41 (DE3) E. coli cells
and MraY was expressed in terrific broth (TB) medium containing 35 μg/mL kanamycin.
Protein expression was induced at OD600 ~1.0 at 37 °C for 3 h using 0.4 mM isopropyl-β-Dthiogalactopyranoside (IPTG). Cells were harvested by centrifugation at 5750 x g. All further
steps were carried out at 4 °C. The cells were resuspended in 10-20 mL resuspension buffer per
liter culture (resuspension buffer: 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM βmercaptoethanol (BME), lysozyme, DNAse I and one cOmplete™ EDTA-free Protease
Inhibitor Cocktail tablet), the cells were lysed by sonication (30% amplitude, 3/10 s pulse, 7/10
16

s pause for 15 min). n-Dodecyl-β-D-maltoside (DDM, 30 mM) was added and the resultant
lysate was stirred for 2 h. After centrifugation at 30000 x g for 45 min, the cleared lysate was
loaded onto pre-equilibrated TALON Superflow™ resin (~0.5 mL/L culture), imidazole was
added to a final concentration of 7 mM and the mixture was rotated at 4 °C overnight.
Subsequently, the resin was washed with 20 column volumes of washing buffer (50 mM TrisHCl (pH 8.0), 150 mM NaCl, 2 mM BME, 10 mM imidazole, 1 mM DDM) and eluted with
10-20 mL elution buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM BME, 250 mM
imidazole, 1 mM DDM). Dithiothreitol (DTT, final concentration of 1 mM),
ethylenediaminetetraacetic acid (EDTA, final concentration of 1 mM) and PreScission protease
(ratio to His-MBP-MraY 1:100) were added and the solution was incubated at 4 °C overnight.
The cleaved protein was separated on a HiLoad 16/600 Superdex 200 pg in a buffer containing
20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM DTT and 5 mM n-decyl-β-D-maltopyranoside
(DM). The resultant solution was employed as a source of solubilized and purified AaMraY for
in vitro MraY assays.
Fluorescence-based MraY assay. In vitro MraY assays were performed using our
previously reported adapted version30 of Bugg's fluorescence-based method.31-36 Fluorescence
intensity over time was measured at ex = 355 nm and em = 520 nm (BMG Labtech
POLARstar Omega, 384-well plate format). Each well contained a total volume of 20 L with
100 mM Tris-HCl buffer (pH 7.5), 200 mM KCl, 10 mM MgCl2, 0.1% Triton X-100, 0-5%
DMSO, 50 mm undecaprenyl phosphate, 7.5 mm dansylated Park’s nucleotide (synthetic or
semi-synthetic),30 a protein preparation (see below) and the potential inhibitor at various
concentrations.
17

For SaMraY, 1 L of a crude membrane preparation with a total protein concentration
of 1.0 mg/mL was used and the reaction was initiated by the addition of the protein preparation.
For AaMraY, 1 L of a solution of purified protein was used and preincubated with the assay
mixture (including the inhibitor but excluding the dansylated Park's nucleotide) at rt for 30 min.
The reaction was then initiated by the addition of Park's nucleotide. Concentrations of the
purified AaMraY was 0.1 mg/mL. The protein preparations of SaMraY and AaMray showed
comparable activity in the absence of inhibitors.
MraY activity at a certain inhibitor concentration was determined by a linear fit of the
fluorescence intensity curve from 0 to 2 min. This measure of enzymatic activity was plotted
against the logarithmic inhibitor concentration and fitted with a sigmoidal fit using the formula
shown below, thus furnishing the reported IC50 values.

𝑦 = 𝐴1 +

(𝐴2 − 𝐴1)
1 + 10log(𝑥0 −𝑥)∙𝑝
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2.3 Results
Initial attempts to produce muraymycins using the published fermentation conditions1,
24

were unsuccessful. Hence, a few different media were examined. Using analytical scale

fermentation with LC-MS analysis, production of muraymycins was observed using PM-1
media, which was previously employed for the production of capuramycin, a structurally
distinct nucleoside antibiotic from a different Streptomyces sp.28 As a consequence, a 100 mL
seed culture of Streptomyces sp. strain NRRL 30473 was grown for three days and used to
inoculate 10 L of PM-1 media. After fermentation for seven days, followed by extraction,
fractionation, and resolution of the components within the crude extract, five known
muraymycins were identified by LC-MS analysis (A1, B1, B2, B3, and B6). Two congeners,
muraymycins B8 (1, yield: 0.6 mg/L) and B9 (2, yield: 0.2 mg/L), with masses that did not
match prior reports, were purified by reverse-phase HPLC. Using identical fermentation
conditions with Streptomyces sp. strain NRRL 30477, one new congener, muraymycin C6 (3,
yield: 0.4 mg/L), and one known muraymycin C1 (yield: 0.5 mg/L) were obtained and likewise
isolated for structural elucidation and activity testing.
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Figure 2.1 Structures of representative muraymycins.
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2.3.1 Structure Elucidation

The molecular formula of 1 (C64H93N11O18) was determined by HR-ESI-MS (Figure
S2.1). An initial analysis of the 13C and 1H NMR data (Tables 2.1 and 2.2) in conjunction with
the HSQC spectra in DMSO-d6 showed the presence of 54 carbon resonances, which were
ascribed to 7 methyls (including 1 methoxyl), 18 methylenes, 18 methines, 1 double bond and
9 amide/acid carbonyls (Figures S2.2-S2.3). The NMR and UV data for 1 displayed typical
features of a muraymycin compound, including the GlyU nucleoside, ribofuranoside,
aminopropane, epicapreomycidine, urea, valine and hydroxy-leucine. Further interpretation of
the 1D and 2D NMR data (including 1H- 1H COSY, HSQC, HMBC and TOCSY; Figures S2.4S2.7) revealed the structure of 1, which was quite similar with muraymycin B11, except for the
fatty acid chain, which was identified as 14-methyl-pentadecanoic acid through 2D NMR
(Figure 2.2). A strong HMBC correlation from H-22 (δH 4.92) to C-1′ (δC 172.0) unambiguously
determined the position of pentadecanoic acyl group on hydroxy-leucine. Based on the NOESY
spectrum (Figure S2.8), the relative configuration of 1 was assigned to be identical with that
reported for muraymycin B1.1 Thus, the structure of compound 1 was established as a new
member of the muraymycin B family and subsequently named muraymycin B8.

Compound 2 was assigned the molecular formula C62H89N11O18 on the basis of HRESI-MS (Figure S2.9). A difference of C2H4 with 1 and their similar NMR spectroscopic data
was suggestive of 2 as a muraymycin B congener (Figures S2.10-S2.11). The fatty acid chain
for 2 was identified as 12-methyl-tridecanoic acid from a thorough analysis of the 2D NMR
data (Figures 2.12-S2.14). The relative configuration of 2 was also established by NOESY
(Figure S2.15). Compound 2 was designated as muraymycin B9.
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The UV and NMR spectroscopic data for 3 (C40H65N11O18) revealed characteristic
features of muraymycin (Tables 2.1 and 2.2, and Figures S2.16-2.22) and were similar to that
reported for muraymycin C1,1 which was likewise isolated from this strain (Figures S2.23S2.28).2 Specifically, 3 displayed an extra acetyl substitution of a methyl (δC 21.9 and δH 1.85)
and a carbonyl (δC 174.1). The key HMBC correlations from H2-16 (δH 3.05 and 3.41) to δC
174.1 established the N-acetyl at C-16. Based upon this analysis, the structure of 3 was
established as 16-N-acetyl-muraymycin C1, a new muraymycin C congener and subsequently
named muraymycin C6. Of note, 16-N-acetyl-muraymycin C1 was previously prepared from
muraymycin C1 via chemical semisynthesis,24 and the 1H NMR spectrum of the naturally
occurring congener matched the semisynthetic variant.
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Figure 2.2 1H-1H COSY (▬) and selected HMBC (→) correlations of 1−3.
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Table 2.1 13C NMR data (100 MHz) of compounds 1−4.
no. 1a

2a, b

3c

C1c

no.

1a

2a, b

3c

C1c

1

141.6,

141.5, CH

141.9, CH

142.3, CH

21

53.4,

53.4, CH

56.1, CH

56.0, CH

2

101.7,
CH

101.7, CH

101.9, CH

102.2, CH

22

75.0,
CH

75.0, CH

74.4, CH

74.6, CH

3

163.1, C
CH

163.1, C

165.9, C

165.9, C

23

27.8,
CH

27.8, CH

29.1, CH

29.2, CH

4

150.3, C

150.3, C

151.2, C

151.2, C

24

15.7,
CH

15.7, CH

3

14.6, CH
3

14.7, CH
3

5

90.6,

90.6, CH

91.1, CH

91.8, CH

25

19.6, CH

3

18.7, CH
3

18.7, CH
3

6

72.6,
CH

72.5, CH

72.8, CH

72.5, CH

26

169.5, C

171.2, C

171.1, C

7

70.0,
CH

69.9, CH

69.0, CH

69.1, CH

27

19.6,
CH
3
169.5, C
CH
3
54.8,

54.8, CH

55.3, CH

55.4, CH

8

82.8,
CH

82.8, CH

83.4, CH

83.7, CH

28

50.0,
CH

50.0, CH

49.1, CH

49.1, CH

9

76.3,
CH

76.3, CH

76.4, CH

76.3, CH

29

20.4,
CH

20.4, CH

2

20.3, CH
2

20.3, CH
2

10

62.5,
CH

62.5, CH

63.6, CH

62.8, CH

30

35.6, CH

2

35.6, CH
2

35.7, CH
2

11

168.8, C
CH

168.7, C

169.9, C

170.3, C

31

153.7, C

153.6, C

153.6, C

12

105.2,

105.1, CH

106.5, CH

106.7, CH

32

35.6,
CH
2
153.7, C
CH
2
157.5, C

157.5, C

158.7, C

158.7, C

13

84.1,
CH

84.1, CH

83.9, CH

83.6, CH

33

173.7, C

173.6, C

177.3, C

176.4, C

14

71.8,
CH

71.7, CH

70.1, CH

70.5, CH

34

57.5,

57.5, CH

59.4, CH

58.6, CH

15

79.3,
CH

79.3, CH

82.9, CH

79.6, CH

35

30.3,
CH

30.3, CH

30.1, CH

29.9, CH

16

42.1,
CH

42.0, CH

41.7, CH

42.2, CH

36

19.1,
CH

19.1, CH

3

18.5, CH
3

18.3, CH
3

17

45.5,
CH

45.5, CH
2

45.4, CH

2

45.6, CH
2

37

17.4, CH

3

16.6, CH
3

16.6, CH
3

18

25.5,
CH
2
36.1,
CH
2
169.2, C
CH
2

25.4, CH
2

25.2, CH

2

25.0, CH
2

14-OCH
3

3

57.8, CH
3

57.9, CH
3

36.0, CH
2

35.8, CH

2

35.8, CH
2

16-

17.4,
CH
3
57.5,
CH
3

169.1, C

172.5, C

172.5, C

16NHCOCH
3

19
20

Fatty acid for 1

a

57.4, CH

CH
3

NHCOCH
Fatty acid 3for 2

measured in DMSO-d6; bmeasured at 150 MHz; cmeasured in D2O.
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174.1, C
21.9, CH
3

Table 2.2 1H NMR data (400 MHz, J in Hz) of compounds 1−3 and muraymycin C1.
no

1a

.
1

2a, b

3c

C1c

no.

1a

25

0.79e

7.75, d

7.75, d

7.62, d

7.54, d

(8.0)

(9.5)

(6.4)

(5.7)

2

5.70d

5.68d

5.73, d

5.72, d

(6.4)

(6.4)

5

5.66d

5.66d

5.65, d

5.62, d

(2.2)

(2.3)

27

4.39, m

2a, b
0.79e

4.38, m

3c

C1c

0.76, d

0.77, d

(5.3)

(5.4)

4.19, m

4.20, d
(6.2)

28

3.60, m

3.61, m

3.71, m

3.71, m

6

4.13, m

4.14, m

4.23, m

4.25, m

29

1.70, m

1.71, m

1.72, m

1.72, m

7

3.98, m

3.99, m

4.11, m

4.12, m

30

3.19,

3.19,

3.15, m

3.12,

3.29, m

3.29, m

3.19, m

8

4.10, m

4.11, m

4.09, m

4.18, m

34

4.03, m

4.03, m

3.86, m

3.93, m

9

4.42, m

4.42, m

4.30, m

4.43, dd

35

2.02, m

2.03, m

1.96, m

1.98, m

36

0.86e

0.86e

0.75, d

0.76, d

(5.2)

(5.4)

0.70, d

0.72, d

(5.8)

(5.4)

3.22, s

3.25, s

(0.8, 3.1)
10

12

3.58, m

5.11, br

3.57, m

5.11, br s

s

3.73, m

3.92, m

5.03, d

5.11, d

(2.5)

(1.9)

37

0.82e

0.82e

13

3.54, m

3.54, m

3.64, m

3.68, m

3-NH

11.42, s

11.39, s

14

4.03, m

4.05, m

4.04, m

4.08, m

13-OCH3

3.27, s

3.28, s

15

3.95, m

3.94, m

3.85, m

3.95, m

16-NH2

8.02, br

8.02, br

s

s

16

17

18

19

21

22

3.03, m

3.03, m

2.87,

2.88,

2.94, m

2.95, m

1.73, m

1.73, m

2.93,

2.92,

3.16, m

3.17, m

4.44, m

4.44, m

3.05,

2.95,

3.41, m

3.13, m

2.98, m

2.95,

16NHCOCH3
19-NH

3.03, m
1.77, m

3.16, m

1.74, m

21-NH

3.05,

27-NH

3.18, m
4.14, m

4.14, m

4.92, dd

4.92, dd

3.48, dd

3.47, dd

(2.7,

(1.1, 5.8)

(3.3, 6.7)

(3.5, 6.6)

1.58, m

1.57, m

1.85, s

30-NH

31-NH

8.23, br

8.21, br

s

s

8.50, d

8.47, d

(8.2)

(9.6)

6.65, d

6.66, d

(8.2)

(9.3)

8.02, br

8.02, br

s

s

7.84, br

7.83, br

s

s

6.50, d

6.50, d

(9.5)

(10.1)

6.4)
23

1.89, m

1.90, m

24

0.82e

0.82e

0.65, d

0.64, d

(5.3)

(5.4)

32-NH

Fatty acid for 1

ameasured

Fatty acid for 2

in DMSO-d6; bmeasured at 600 MHz; cmeasured in D2O; d,eoverlapped signals.
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2.3.2 Antimicrobial Bioactivity
The newly isolated muraymycins were evaluated for inhibition of MraY activity. An in
vitro fluorescence-based assay for MraY was previously developed,35-39 which we have adapted
and optimized for screening.30 In short, this assay required the synthesis of a dansylated
derivative of the MraY substrate UDP-MurNAc-pentapeptide to generate a fluorescent readout,
and overproduction of recombinant S. aureus and A. aeolicus MraY. The MraY homologue
from S. aureus (SaMraY) was used as a crude membrane preparation as attempts to solubilize
and purify the protein resulted in loss of activity. In contrast, the solubilization and purification
of the MraY homologue from Aquifex aeolicus (AaMraY) was feasible,4-5 and the protein was
used accordingly in the in vitro assays for MraY inhibition. The results for the inhibitory
activities (IC50 values) of the new muraymycins 1-3 along with the known compound
muraymycin C1 are listed in Table 2.3. To summarize, 1, 2, and muraymycin C1 had potent
IC50 values ranging from 4-22 pM against SaMraY and 68-350 pM against AaMraY, which is
significantly lower than IC50 values reported for synthetic analogues and naturally occurring
muraymycins D1 and D2 (D1, 11 nM against crude Mycobacterium tuberculosis;7 D2, 10 nM
against purified MraY from Bacillus subtilis,14 and 2.8 nM against SaMraY26). The comparable
IC50 values with or without the acid chain is consistent with prior conclusions that a long chain,
aliphatic component might not significantly contribute to MraY inhibition. 10 Contrastingly,
when compared with muraymycin C1, compound 3 showed reduced activity against both
enzymes. This result is consistent with a significant role of the intact aminoribosyl group for
MraY binding, which was postulated based upon analysis of the X-ray structure of muraymycin
D2 in complex with AaMraY.4 It has been found that a conformational rearrangement occurs
26

upon muraymycin D2 binding that generates a pocket for opportune interactions with the
aminoribose.4-5
We also examined the bacterial growth inhibition of 1-3 against S. aureus and two
strains of E. coli. Interestingly, the longer fatty acid side chains of 1 and 2 converted the B series
from inactive against S. aureus (MIC > 32 μg/mL for muraymycin B2 and B6)1, 3 to active
against S. aureus (MIC = 2-6 μg/mL for muraymycin B8 and B9). Furthermore, the lack of a
fatty acid side chain for 3 yielded an inactive compound. Taken together with the IC50 values
for MraY inhibition, this result suggests that the fatty acid unit indeed plays a role in cellular
uptake as suggested.40 In contrast to the MIC data against S. aureus, the addition of the fatty
acid side chain and increase in its length slightly reduced the activity against both effluxdeficient E. coli tolC (MIC for the B series range from 1-4 μg/mL) and efflux-competent E.
coli BL21(DE3) (MIC from 8-64 μg/mL). Similarly to the trends observed with the IC50 values,
however, acetylation of muraymycin C1 at the aminoribose significantly reduced the MIC
against all strains.
Self-resistance mechanisms to muraymycins remain undefined. The discovery and
assessment of muraymycin C6 suggests that acetylation might be such a mechanism, not unlike
acetyltransferases involved in aminoglycoside resistance. Interestingly, two potential resistance
genes that encode enzymes predicted to covalently modify muraymycins are found in the
biosynthetic gene cluster.22 However, neither would be expected to catalyze acetylation: mur28
is predicted to encode a TmrB-like ATP-dependent phosphotransferase and mur29 a putative
nucleotidyltransferase. Thus, the role of these two genes and relationship to resistance and/or
acetylation, if any, await further examination.
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Table 2.3 In vitro MraY assays and antimicrobial activities

compounds

S. aureus

A. aeolicus

S. aureus

E. coli ∆tolC

E. coli

MraY

MraY

growth

growth

BL21(DE3)

inhibition

inhibition

growth
inhibition

1

MIC (μg/mL)

MIC (μg/mL)

MIC (μg/mL)

(6.8±0.5)×101

2

4

64

2

6

2

32

IC50 (pM)

IC50 (pM)

4.0±0.7

2

22.1±3.2

(3.2±0.2)×10

3

93±8

(1.8±0.4)×103

>32

16

256

15.7±1.2

(3.5±0.4)×102

>32

1

8

muraymycin
C1
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2.4 Discussion
2.4.1 Synthesized Muraymycin B9 Analogue with Good Antibacterial Activity

Tanino et al.18 reported the synthesis and biological evaluation of muraymycin
analogues with different lipophilic side chain (Figure 2.3). Among these analogues, MRY1 with
similar lipophilic side chain as muraymycin B8 showed the best activity. Compared to MRY3,
which showed no activity to methicillin-resistant S. aureus and vancomycin-resistant E. faecalis
up to 64 µg/mL, the MIC of MRY1 to both strains were 2~4 µg/mL, which was 2~4 times lower
than MRY2, suggesting that long aliphatic side chain without aromatic ring is preferred for the
target inhibition.

Figure 2.3 Structures of synthesized muraymycin analogues.
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2.4.2 Resistant Modifications of Muraymycin

The isolation of muraymycin C6, the acetylated muraymycin C1, is proposed to be one
of the resistance modification of muraymycins. We sequenced the genome of Streptomyces sp.
NRRL30473. AntiSMASH analysis41-42 enabled us to identify the muraymycin biosynthetic
gene cluster, which spans ~31 kb on a single contig (~96 kb). However, a gene encoding an Nacetyltransferase was not found in the biosynthetic gene cluster. The N-acetylation modification
is possibly catalyzed by a N-acetyltransferase located outside the gene cluster. Genome
sequencing of Streptomyces sp. NRRL30473 also showed several N-acetyltransferases located
outside the gene cluster, one of which might be responsible for the modification.
Moreover, two muraymycin resistance genes were found in the biosynthetic gene
cluster of muraymycin from Streptomyces sp. NRRL 30473, one encoding a TmrB-like ATPdependent

muraymycin

phosphotransferase,

and

another encoding

a muraymycin

nucleotidyltransferase. As the disaccharide moiety of muraymycin is technically an
aminoglycoside, the three kinds of aminoglycoside resistance modification 43-44 are also
discovered in muraymycin. Functional assignment of muraymycin phosphotransferase and
muraymycin nucleotidyltransferase is presented in chapter 4.
2.5 Conclusion

With the goal of developing a muraymycin production platform and expanding upon
the known family of muraymycins, we examined the metabolic profile of Streptomyces sp.
strain NRRL 30473 and Streptomyces sp. strain NRRL 30477. Four muraymycins were
characterized by a suite of spectroscopic methods, including three new members of the
30

muraymycin family: B8, B9 and C6 (1−3). Muraymycin B8 and B9 showed promising
antibacterial activity and pM inhibition against SaMraY and AaMraY. Remarkably, the newly
discovered muraymycins B8 and B9 were the first congeners of the B series to display
antibacterial activity against S. aureus. In our hands muraymycin B8 and B9 have activity
against S. aureus that is comparable to or better than muraymycin A1,45 which was previously
noted as the most potent muraymycin,1-2 hence warranting a continued evaluation of these new
muraymycins as antistaphylococcal antibiotics. Contrastingly, muraymycin C6, the first Nacetylated version of muraymycin to be isolated, showed reduced activity in all screens
suggesting acetylation might be a mechanism of self-resistance.
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2.6 Supporting Information

Figure S2.1 (+)-HR-ESI-MS (positive mode) of muraymycin B8 (1).

Figure S2.2 1H NMR spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1).
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Figure S2.3 13C NMR spectrum (DMSO-d6, 100 MHz) of muraymycin B8 (1).

Figure S2.4 HSQC spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1).
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Figure S2.5 HMBC spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1).

Figure S2.6 1H-1H COSY spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1).
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Figure S2.7 TOCSY spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1).

Figure S2.8 NOESY spectrum (DMSO-d6, 400 MHz) of muraymycin B8 (1).
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Figure S2.9 (+)-HR-ESI-MS (positive mode) of muraymycin B9 (2).

Figure S2.10 1H NMR spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2).
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Figure S2.11 13C NMR spectrum (DMSO-d6, 150 MHz) of muraymycin B9 (2).

Figure S2.12 HSQC spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2).
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Figure S2.13 HMBC spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2).

Figure S2.14 1H-1H COSY spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2).
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Figure S2.15 NOESY spectrum (DMSO-d6, 600 MHz) of muraymycin B9 (2).

Figure S2.16 (+)-HR-ESI-MS (positive mode) of muraymycin C6 (3).
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Figure S2.17 1H NMR spectrum (D2O, 400 MHz) of muraymycin C6 (3).

Figure S2.18 13C NMR spectrum (D2O, 100 MHz) of muraymycin C6 (3).
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Figure S2.19 HSQC spectrum (D2O, 400 MHz) of muraymycin C6 (3).

Figure S2.20 HMBC spectrum (D2O, 400 MHz) of muraymycin C6 (3).
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Figure S2.21 1H-1H COSY spectrum (D2O, 400 MHz) of muraymycin C6 (3).

Figure S2.22 NOESY spectrum (D2O, 400 MHz) of muraymycin C6 (3).
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Figure S2.23 (+)-HR-ESI-MS (positive mode) of muraymycin C1 (4).

Figure S2.24 1H NMR spectrum (D2O, 400 MHz) of muraymycin C1 (4).
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Figure S2.25 13C NMR spectrum (D2O, 100 MHz) of muraymycin C1 (4).

Figure S2.26 HSQC spectrum (D2O, 400 MHz) of muraymycin C1 (4).
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Figure S2.27 HMBC spectrum (D2O, 400 MHz) of muraymycin C1 (4).

Figure S2.28 1H-1H COSY spectrum (D2O, 400 MHz) of muraymycin C1 (4).

45

Chapter 3 : Enzymatic Formation of Ribofuranosylated Glycyl-uridine Scaffold of
Antibiotic Muraymycin
3.1 Introduction
According to bioinformatics analysis of the muraymycin gene cluster, six enzymes,
Mur16 (encoding a putative dioxygenase), Mur17 (encoding a putative transaldolase), Mur20
(encoding a putative aminotransferase), Mur26 (encoding a putative phosphorylase), Mur18
(encoding

a

putative

nucleotidylyltransferase)

and

Mur19

(encoding

a

putative

glycosyltransferase) are proposed to be critical for the biosynthesis of the core structure,
ribofuranosylated glycyl-uridine, of muraymycin. Respective enzyme homologs from the
biosynthetic pathway of A-90289, a structurally related nucleoside antibiotic (Figure 3.1), have
been characterized (Figure 3.2).46-51 As muraymycin has similar disaccharide scaffold with A90289, we expect the muraymycin homologs to have a similar function. However, unlike A90289, the muraymycin nucleoside is not 2′-O-sulfated and the 2′′-OH of the aminoribose is
differentially modified, suggesting the possibility that the homologues have unique biochemical
properties. Moreover, the ribosyltransferase in the biosynthetic pathway of A-90289 was only
tested by utilizing its surrogate acceptor. In this chapter, the function of the six enzymes (Mur16,
17, 18, 19, 20 and 26) was identified and characterized. The ribosyltransferase Mur19 in
muraymycin biosynthetic pathway and LipN in A-90289 biosynthetic pathway were also tested,
for the first time, with its genuine aminoribose acceptor. A one-pot enzymatic reaction was
utilized to produce this disaccharide moiety and its 2"-deoxy analogue.
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Figure 3.1 Structure of muraymycin A1 and A-90289A containing similar ribofuranosylated
glycyl-uridine moiety.

Figure 3.2 Proposed biosynthetic pathway towards ribofuranosylated glycyl-uridine moiety.
Enzymes that were previously functionally characterized were labeled in black.
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3.2 Materials and Methods
3.2.1 Cloning, Overexpression and Purification of Proteins
The genes mur16, 17, 18, 19, 20 and 26 were amplified by PCR from genomic DNA
extracted from Streptomyces sp. NRRL30473 using Phusion Hot Start II DNA Polymerase from
Thermo Scientific with supplied HF buffer. Purified PCR products were ligated to pET30
Xa/LIC (Novagen) or pXY200 following the standard protocol and confirmed by DNA
sequencing (ACGT, INC).
Plasmids pET30-mur16, pET30-mur18, pET30-mur20 and pET30-mur26 were
introduced into E. coli BL21(DE3) cells, and the transformed strains were grown in LB
supplemented with 50 μg/mL kanamycin. Following inoculation of 500 mL of LB with 50
μg/mL kanamycin, the cultures were grown at 37 °C until the cell density reached an OD600 ~
0.5 when expression was induced with 0.1 mM IPTG. Cells were harvested after an overnight
incubation at 18 °C and lysed in Buffer A (100 mM KH2PO4, 300 mM NaCl, 10 mM imidazole,
pH 8.3) using a Qsonica sonicator (Qsonica LLC, Newtown, CT) for sonication for a total of 6
min at 40% amplitude with 30 s pulses separated by 30 s rest periods. Following centrifugation
the protein was purified using affinity chromatography with HisPurTM Ni-NTA agarose
(Thermo Scientific, Rockford, IL), and proteins were eluted with increasing concentrations of
imidazole in Buffer A. Purified proteins were concentrated and buffer exchanged into Buffer B
(25 mM KH2PO4, 100 mM NaCl, pH 8.3) using Amicon Ultra 10000 MWCO centrifugal filter
(Millipore) and stored as glycerol stocks (40%) at -20 °C. Protein purity was assessed as by 12%
acrylamide SDS-PAGE; His6-tagged proteins were utilized without further modifications.
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Protein concentration was determined using UV/Vis spectroscopy, and the extension
coefficients were calculated using the ProtParam tool available from ExPASY.
Plasmids pXY200-mur17 and pXY200-mur19 were transformed into S. lividans TK24
using PEG-mediated protoplast transformation and plated on R2YE supplemented with 50
μg/mL apramycin. After 6 days at 28 °C, positive transformants were confirmed by colony PCR
using InstaGene Matrix from Bio-Rad (Hercules, CA) and LA-Taq polymerase with GC buffer
I.

The recombinant strain was utilized to inoculate 50 mL R2YE containing 50
μg/mL apramycin, grown for 3 days at 28 °C at 250 rpm, and 2 mL transferred to fresh
100 mL containing 50 μg/mL apramycin. Following growth for 3 days at 28 °C at 250
rpm, protein expression was induced by addition of thiostrepton (5 μg/mL) and the
culture was incubated for another 24 h before harvesting. The cells from 400 mL of
culture were collected by centrifugation. The pellet was thoroughly resuspended in icecold Buffer A supplemented with 4 mg/mL of lysozyme was subsequently added to the
suspension. After incubation at 30 °C for 30 min, the cell suspension was mixed by
pipetting and lysed using a Qsonica sonicator (Qsonica LLC, Newtown, CT) for
sonication for a total of 10 min at 40% amplitude with 30 s pulses separated by 30 s
rest periods. The protein purification and storage was as described above.

3.2.2 Synthesis of 2'-Methoxy-UMP, 1c.
The synthesis of 1c followed a previously described procedure.52 Pyrophosphoryl
chloride (0.1 mL) was added to a cool solution (4 °C) of 2′-O-methyluridine (52 mg) in m49

cresol (2 mL). The mixture was stirred for 2 h at 4 °C and diluted with ice water (7 mL). The
product was extracted with diethyl ether (3 mL). The aqueous layer was adjusted to pH = 2 with
4 N sodium hydroxide. After freeze-drying, the product was purified by semipreparative HPLC
(Waters 600) with gradient shown in Table S3.7 to yield 30 mg.

Figure 3.3 13C NMR spectrum (D2O, 100 MHz) and 1H NMR spectrum (D2O, 400 MHz) of 2′methoxy-UMP.
3.2.3 Activity Assay of Mur16
Reactions consisted of 50 mM HEPES (pH 7.5), 2.5 mM α-KG, 2 mM ascorbic acid,
0.2 mM FeCl2, 1 mM UMP, dUMP or 2′-methoxy-UMP, and 100 nM Mur16 at 30 °C. Reactions
were terminated by ultrafiltration using Amicon® Ultra centrifugal filter units. Following
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centrifugation to remove protein, the reaction was analyzed by HPLC or LC-MS with the
gradient shown in Table S3.2.
3.2.4 Kinetics of Mur16
To determine the kinetic constants with respect to UMP and dUMP, reactions were
carried out in 50 mM Tris-HCl (pH 7.5), 2 mM α-KG, 2 mM ascorbic acid, 0.4 mM FeCl2 with
variable concentration of UMP (1 µM-500 µM), dUMP (1 µM-500 µM) or 2′-methoxy-UMP
and 40 nM Mur16 at 30 °C for 4 min and analyzed under initial velocity conditions using the
malachite green binding assay or at 30 °C for 1 h and analyzed by HPLC with gradient shown
in Table S3.2 at 260 nm. Each data point represents three replicate end point assays. Kinetic
constants were obtained by nonlinear regression analysis using GraphPad Prism 7 (GraphPad
Software, La Jolla, CA).
3.2.5 Activity Assay of Mur17
Reactions of Mur17 consisted of 50 mM HEPES (pH 7.5), 2 mM uridine-5′-aldehyde
2a, 5 mM L-threonine, 0.1 mM PLP and 1 μM Mur17 at 30 °C. Following removal of the
protein by ultrafiltration, the reaction was analyzed by LC-MS.
AQC, 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate, a derivatizing reagent for
amines, was used for the modification of 5′- and 6′-epimers of GlyU (synthesized by Christian
Ducho’s lab53). The reaction (20 μL) was mixed with 60 μL of 0.2 M sodium borate buffer
(pH8.8) and 20 μL of 3 mg/mL AQC acetonitrile solution. The mixtures were incubated at 55 °C
for 10 min and then allowed to cool to rt. The AQC-derivatized samples (50 μL) were applied
to LC-MS with the gradient shown in Table S3.3.
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3.2.6 Activity Assay of Mur20
Reactions of Mur20 consisted of 50 mM potassium phosphate (pH 7.5), 1 mM uridine
aldehyde with different 2′ modification (2a synthesized by previous lab members, 2b or 2c), 1
mM L-amino acid (methionine, alanine, arginine, etc.) and 1 μM Mur20 or LipO at 30 °C.
Following removal of the protein by ultrafiltration, the reaction was analyzed by LC-MS with
the gradient shown in Table S3.2.
To identify the production of α-keto-γ-methylthiol butyric acid, reaction mixtures or
the positive control (α-keto-γ-methylthiol butyric acid) were treated with reagent 3-methyl-2benzothiazolinone hydrazone hydrochloride (MBTH) according to the method described by
Tanaka.54 Following removal of the protein by ultrafiltration, 50 μL reaction mixtures were
mixed with 50 μL of 1 M sodium acetate (pH 5.0) and 50 μL of 8 mM MBTH aqueous solution.
The mixtures were then incubated at 50 °C for 30 min and then analyzed by LC-MS with the
gradient shown in Table S3.4 with detection at 350 nm.
3.2.7 Activity Assay of Mur26
Reactions of Mur26 consisted of 50 mM potassium phosphate (pH 7.5), 2 mM 5′amino-5′deoxy-uridine with different 2′ modification (4a, 4b, 4c) and 1 μM Mur26 or LipP at
30 °C. Following removal of the protein by ultrafiltration, reactions were analyzed by LC-MS
with the gradient shown in Table S3.2.
3.2.8 Activity Assay of Mur18
Reactions of Mur18 consisted of 50 mM potassium phosphate (pH 7.5), 2 mM 5′amino-5′-deoxy-uridine 4a or 5′-amino-2′, 5′dideoxy-uridine 4b (synthesized by previous lab
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members), 5 mM MgCl2, 2 mM UTP, 1 μM Mur26 or LipP and 1 μM Mur18. Following
removal of the protein by ultrafiltration, reactions were analyzed by HPLC with the gradient
shown in Table S3.5 or Table S3.6.
3.2.9 Activity Assay of Mur19
Reactions of Mur19 consisted of 50 mM potassium phosphate (pH 7.5), 2 mM 5′amino-5′-deoxy-uridine 4a or 5′-amino-2′, 5′-dideoxy-uridine 4b, 5 mM MgCl2, 2 mM UTP or
2′-F-dUTP, 1 mM GlyU 3, 1 μM Mur26 or LipP, 1 μM Mur18 or LipM and 1 μM Mur19 or
LipN. Following the removal of the protein by ultrafiltration, reactions were analyzed by HPLC
with the gradient shown in Table S3.5.

Large-scale production of 8b (30 mL reaction) was identical to reactions
described above using 3, 4b and UTP. The isolation of AQC-modified 8b was carried
out with semipreparative HPLC with the gradient shown in Table S3.8 with detection.
3.2.10 MIC assay of AQC modified 8b

The protocol used for the determination of the minimum inhibitory
concentration (MIC) was as described previously with minor modifications.29
Escherichia coli ∆tolC mutant JW5503 (E. coli genetic stock center) was used as model
strains for antimicrobial susceptibility assays. E. coli ∆tolC mutant were grown in 5
mL of LB medium with 50 μg/mL kanamycin for 16 h at 37 °C with shaking (250 rpm),
and then were diluted (ⅹ1000) into 4.5 mL of medium and incubated until OD600
reaching 0.4. An aliquot of the suspension was diluted (ⅹ1000) and 90 μL aliquots of
diluted culture were transferred into the individual well of a 96-well plate supplied with
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10 μL of the AQC modified 8b. Maximum final concentration of 32 μg/mL with serial
dilutions was added to obtain the antimicrobial activities and compared to the negative
control containing water alone. Resazurin solution (5 μL) was added to each well, and
the plates were shaken for 10 s and incubated at 37 °C for another 3 h to allow resazurin
to convert to resorufin by viable bacteria. The minimal concentration of the tested
compound that caused growth inhibition was recorded as the MIC.
3.2.11 One-Pot Enzymatic Reaction for the Biosynthesis of 8a
Reactions consisted of 50 mM Hepes buffer (pH 7.5), 2.5 mM α-KG, 2 mM ascorbic
acid, 0.2 mM FeCl2, 4 mM UMP, 2 mM L-threonine, 0.1 mM PLP, 2 mM L-methionine, 1 mM
MgCl2, 2 mM UTP, 1 μM Mur16, Mur17, LipO, LipP, Mur18 and Mur19 was added accordingly.
Following removal of the protein by ultrafiltration, reactions were analyzed by HPLC with the
gradient shown in Table S3.5.
3.2.12 One-Pot Enzymatic Reaction for the Biosynthesis of 8b
Reactions consisted of 50 mM HEPES buffer (pH 7.5), 2.5 mM α-KG, 2 mM ascorbic
acid, 0.2 mM FeCl2, 4 mM dUMP, 100 μM GlyU, 0.1 mM PLP, 2 mM L-methionine, 1 mM
MgCl2, 2 mM UTP. 1 μM Mur16, LipO, LipP, Mur18 and Mur19 was added accordingly.
Following removal of the protein by ultrafiltration, reactions were analyzed by HPLC with the
gradient shown in Table S3.5.
3.3 Results and Discussion
3.3.1 Functional Assignment of Mur16 as a Non-heme, Fe(II)-dependent α-Ketoglutarate: UMP
Dioxygenase
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Bioinformatic analysis revealed that Mur16 has a sequence similarity to dioxygenases
including LipL and Cpr19,55-56 which utilizes UMP, α-KG and FeCl2 to form uridine-5′aldehyde.25,36 The mur16 gene was cloned and expressed in E. coli BL21(DE3) to yield soluble
protein (Figure S3.1). Using HPLC for detection, the activity of Mur16 was tested with UMP
and a new peak corresponding to uridine-5′-aldehyde, 2a was formed in the presence of α-KG
and FeCl2 (Figure 3.4A, Figure S3.2A). Mur16 also catalyzed oxidative decarboxylation of αKG to form succinate from the LC-MS result (Figure S3.3A). The enzyme-coupled assay to
detect succinate production was also employed to confirm the production of succinate. Mur16
was previously proposed to utilize L-arginine as substrate,22 however, LC-MS analysis and the
enzyme-coupled assay to detect succinate revealed that L-arginine cannot be utilized by Mur16
(Figures S3.3B-C).
Different from LipL, which was unable to utilize deoxy-or 2′modified ribonucleoside
monophosphate, Mur16 can also utilize dUMP, 1b and 2′-methoxy-UMP, 1c as substrates to
form corresponding aldehyde 2b and 2c (Figures 3.4B-C, S3.2B-C). Mur16 was found to have
optimal activity at 2 mM ascorbate using 40 µM FeCl2 (Figure 3.5A). Steady-state kinetic
analysis with substrate UMP and dUMP was performed using the malachite green binding assay
to detect phosphate formation. Single-substrate kinetic experiments of Mur16 with UMP and
dUMP revealed typical Michaelis-Menten kinetics, yielding kinetic constants of Km = 20.81 ±
3.93 µM and kcat = 4.37 ± 0.23 s-1 with UMP and Km = 6.30 ± 2.13 µM and kcat = 2.3 ± 0.16 s-1
with dUMP (Figures 3.5B-C). However, kinetic experiments of Mur16 with 1c showed strong
substrate inhibition with the increased concentration of 1c (Figure 3.5D), which indicated that
the 2′-methyl group was added in a later step in the muraymycin biosynthetic pathway.
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Figure 3.4 Characterization of Mur16.
(A) Reaction catalyzed by Mur16. (B) HPLC analysis using UMP (1a) after I, 12 h reaction
w/ UMP, w/o Mur16; II, 12 h reaction w/ UMP, w/o Mur16; III, 12 h reaction w/ dUMP (1b),
w/o Mur16; IV, 12 h reaction w/dUMP, w/o Mur16; V, 12 h reaction w/ 2′-methoxy-UMP (1c),
w/o Mur16; VI, 12 h reaction w/ 2′-methoxy-UMP, w/ Mur16.
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Figure 3.5 Activity optimization and kinetic analysis of Mur16.
(A) Optimal activity of Mur16 with respect to varied ascorbate in reactions containing of 40
µM FeCl2 and 40 nM Mur16. (B) Single-substrate kinetic analysis using variable UMP (1 µM500 µM), near saturating α-KG and 40 nM Mur16. (C) Single-substrate kinetic analysis using
variable dUMP (1 µM-500 µM), near saturating α-KG and 40 nM Mur16. (D) Single-substrate
kinetic analysis using variable 2′-methoxy-UMP (1 µM-1000 µM), near saturating α-KG and
40 nM Mur16.
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3.3.2 Functional Assignment of Mur17 as an L-Threonine: Uridine-5′-aldehyde Transaldolase
Bioinformatic analysis of Mur17 revealed sequence similarity to LipK49, which was
previously assigned as a transaldolase that utilizes uridine-5’-aldehyde 2a and L-threonine to
generate GlyU, 3 (Figure 3.6A). Similar to LipK, the gene product of mur17 was only soluble
when expressed in S. lividans TK24 (Figure S3.1). Activity tests analysis using HPLC with
uridine-5’-aldehyde revealed a new peak (Figure 3.6B). LC-MS analysis of the purified new
peak revealed an (M+H) + ion at m/z = 318.1, consistent with the product of LipK (Figure S3.4).
However, Mur17 cannot utilize 2b or 2c as substrate, which potentially explains why all
discovered muraymycin congeners have the same GlyU core structure. 6-aminoquinolyl-Nhydroxysuccinimidyl

carbamate

(AQC)

modification,

which

generates

6-

quinolinylaminocarbonyl amines without alteration of the stereochemistry of the starting
material, of synthetically prepared 5′- and 6′-epimers of 3 all showed different elution time
(Figure S3.5). LC-MS analysis of AQC modified Mur17 reaction revealed enzymatic produced
3 showed same elution time with (5′S, 6′S)-3, which confirmed the stereo chemical assignment
of 3 (Figure S3.6).
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Figure 3.6 Characterization of Mur17.
(A) Reaction catalyzed by Mur17. (B) HPLC analysis using uridine aldehyde (2a) after I, 12 h
reaction without Mur17; II, 12 h reaction.
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3.3.3 Functional Assignment of Mur20 as an L-Methionine: 2-Aminotransferase.
Bioinformatic analysis revealed that Mur20 has a sequence similarity to LipO47, which
was previously assigned as a pyridoxal-phosphate (PLP)-dependent aminotransferase that
catalyzes amino transfer utilizing nucleoside 2 as the amine acceptor (Figure 3.7A). The mur20
gene was cloned and expressed in E. coli BL21(DE3) to yield soluble protein (Figure S3.1).
HPLC analysis of the activity test of Mur20 with 2a and L-methionine revealed a new peak
(Figure 3.7B) with (M+H) + ion at m/z = 244.0902 (Figure S3.7), corresponding to amino
uridine, 4a, which is consistent with the product of LipO. Reagent 3-methyl-2benzothiazolinone hydrazone hydrochloride (MBTH) was used to confirm the production αketo-γ-methylthiol butyric acid from L-methionine in the transamination reaction (Figure S3.8).
Further analysis revealed that 2′-deoxy-5′-uridine aldehyde 4b and 2′-methoxy-5′-uridine
aldehyde 4c were also amine acceptors of Mur20 (Figures 3.7C-D, S3.9A-B). Several other
potential amine donors like AdoMet, L-Arg or L-Ala can also be utilized as the amine donors
by Mur20. However, GlyU cannot serve as amine donor for the reaction, which possibly
indicated that GlyU was the acceptor of the glycosyltransferase in later steps.
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Figure 3.7 Characterization of Mur20.
(A) Reaction catalyzed by Mur20. (B) HPLC analysis using uridine aldehyde (2a) after I, 6 h
reaction without Mur20; II, 6 h reaction with Mur20; III, 6 h reaction with LipO. (C) LC-MS
analysis using 2′-deoxy uridine aldehyde (2b) after I, 6 h reaction without Mur20; II, 6 h
reaction with Mur20. (D) LC-MS analysis using 2′-methoxy uridine aldehyde (1c) after I, 6 h
reaction with Mur16; II, 6 h reaction with Mur16 and Mur20.
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3.3.4 Functional Assignment of Mur26 as a Low Specificity Uridine Nucleoside Phosphorylase
Bioinformatic analysis of Mur26 revealed a sequence similarity to LipP47, which
catalyzes the phosphorolysis of uridine or 5′-amino-5′-deoxy uridine to generate the respective
ribose-1-phosphate and uracil. The mur26 gene was cloned and expressed in E. coli to yield
soluble protein (Figure S3.1). Activity tests revealed that, identically to LipP, Mur26-catalyzed
reaction proceeded with uridine, 5′-amino-5′-deoxy-uridine 4a and 2′,5′-dideoxy-5′-aminouridine 4b (Figures 3.8, S3.10). Additional activity tests revealed that Mur26 didn’t utilize 2′methoxy-5′-amino-5′-deoxy-uridine 4c, which, combined with the kinetic experiment of Mur16
with 1c, supported the proposal that the 2′-methylation happened as a later step during
muraymycin biosynthesis.
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Figure 3.8 Characterization of Mur26.
(A) Reaction catalyzed by Mur26. (B) LC-MS analysis of reaction catalyzed by Mur26. I, 6 h
reaction w/ 5′-deoxy-5′-amino-uridine (4a) w/o Mur26; II, 6 h reaction w/ 4a w/ Mur26; III, 6
h reaction w/ 4a w/ LipP; IV, 6 h reaction w/ 2′, 5′-dideoxy-5′-amino-uridine (4b) w/o Mur26;
V, 6 h reaction w/ 4b w/ Mur26; VI, 6 h reaction w/ 4b w/ LipP.
3.3.5 Functional Assignment of Mur18 as a Primary Amine-requiring Nucleotidylyltransferase.
Bioinformatic analysis revealed that Mur18 has a sequence similarity to LipM47, 51,
which has already been demonstrated as nucleotidylyltransferase by utilizing 5′-amino-5′deoxy-α-D-ribose-1-phosphate 5a or 5′-amino-2′,5′-dideoxy-α-D-ribose-1-phosphate 5b and
UTP to generate the activated sugar. Different from LipM, which was only soluble when
expressed in S. lividans TK64, Mur18 is soluble when expressed in E. coli with either an Nterminal His6-tag or C terminal His6-tag, which makes it easier for the ongoing crystal structure
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study. Activity test revealed that Mur18 utilized 5b, which was generated in situ with LipP from
4b and UTP, to generate UDP-5-amino-2, 5-dideoxyribose 7b (Figures 3.9- S3.11).
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Figure 3.9 Characterization of Mur18.
(A) Reaction catalyzed by Mur26 (or LipP) and Mur18. (B) HPLC analysis of Mur18 reaction.
I, UTP; II, 2′, 5′-dideoxy-5′- amino-uridine (4b); III, 6 h reaction with LipP; IV, 6 h reaction
with LipP and Mur18.
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3.3.6 Functional Assignment of Mur19 as a GlyU: 5-Amino-5-Deoxyribosyltransferase
Bioinformatic analysis revealed that Mur19 has a sequence similarity to LipN47, which
has already been characterized as a ribosyltransferase that utilizes uridine as a surrogate
acceptor and the genuine sugar donor 7a (generated in situ with LipP and LipM) as substrates.
Both muraymycin and A-90289 have the GlyU moiety, which can be produced by Mur17 or
LipK, and thus, we propose that GlyU is the genuine sugar acceptor for both Mur19 and LipN.
Similar to LipN, soluble Mur19 was only obtained in S. lividans TK24 by heterologous
expression. HPLC analysis of Mur19 reactions using genuine acceptor 3 and in situ generated
sugar donor 7a revealed a new peak, which co-eluted with chemically synthesized standard 8a
(Figure 3.10).
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Figure 3.10 Characterization of Mur19.
(A) Reaction catalyzed by Mur26, Mur18 and Mur19. (B) HPLC analysis of Mur19 reaction. I,
chemically synthesized 8a; II, 6 h reaction with Mur26; III, 6 h reaction with Mur26 and Mur18;
IV, 6 h reaction with Mur26, Mur18 and Mur19.
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2′-Fluoro-2′-deoxyuridine-5′-triphosphate (2′-F-dUTP), was used to replace UTP in
order to form a more, stable activated sugar 7a′ and 7b′. Activity tests showed that 2′-F-dUTP
can be utilized by Mur18 to generate activated aminoribose, which was utilized by Mur19 to
generate 8a and 8b (Figure 3.11). The production of 8b was confirmed by HR-ESI-MS and 1H
NMR after large-scale purification of AQC derived reaction (Figures S3.12-S3.14). Activity of
LipN with genuine sugar acceptor GlyU was also tested for the first time. Surprisingly, different
from Mur19, LipN only accepted activated 5′-amino-5′-deoxy-amino ribose to generate 8a,
while 8b cannot be generated by LipN (Figure 3.12).
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Figure 3.11 Characterization of Mur19 with 2'-fluoro-2'-deoxyuridine-5'-triphosphate.
(A) HPLC analysis of Mur19 reaction with 4a. I, 6 h reaction without enzyme; II, 6 h reaction
with LipP; III, 6 h reaction with LipP and Mur18; IV, 6 h reaction with LipP, Mur18, and Mur19.
(B) HPLC analysis of Mur19 reaction with 4b. I, 6 h reaction without enzyme; II, 6 h reaction
with LipP; III, 6 h reaction with LipP and Mur18; IV, 6 h reaction with LipP, Mur18, and Mur19.
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Figure 3.12 Comparison of substrate promiscuity of Mur19 and LipN with 4a and 4b.
(A) Comparison of substrate promiscuity of Mur19 and LipN with 4a. I, 6 h reaction with LipP,
LipM and LipN; II, 6 h reaction with LipP, Mur18 and LipN; III, 6 h reaction with LipP, LipM
and Mur19; IV, 6 h reaction with LipP, Mur18 and Mur19. (B) Comparison of substrate
promiscuity of Mur19 and LipN with 4b. I, 6 h reaction with LipP, LipM and LipN; II, 6 h
reaction with LipP, Mur18 and LipN; III, 6 h reaction with LipP, LipM and Mur19; IV, 6 h
reaction with LipP, Mur18 and Mur19.
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3.3.7 One-Pot Six-enzyme Synthesis of Ribofuranosylated Uronic Acid Moiety of Muraymycin
Aminoribofuranosylated uronic acid 8a was generated in vitro by six proteins Mur16,
Mur17, LipO, LipP, Mur18 and Mur19 using UMP as the starting substrate (Figure 3.13). With
the addition of each enzyme, a new peak corresponding to respective product was revealed in
the HPLC traces except for the product of Mur18 7a, which was unstable and degraded into
UMP via intramolecular attack of the 2-hydroxy group of the aminoribosyl unit on the proximal
phosphate as our group has previously reported.47 The degradation product UMP was further
utilized by Mur16 followed by LipO and LipP, which resulted in the generation of twice the
amount of uracil. HPLC analysis of the six-enzyme one pot reaction revealed a small new peak
corresponding to the generation of 8a.
2″-Deoxy-aminoribofuranosylated uronic acid 8b was also generated using dUMP and
GlyU as starting substrates by five enzymes Mur16, LipO, LipP, Mur18 and Mur19. Mur17 was
omitted in this reaction with the supplementation of its product GlyU because Mur17 couldn’t
utilize 2′-deoxy-uridine aldehyde 2b, generated by Mur16 from dUMP, as a substrate. The
generation of UDP-5-amino-2,5-dideoxyribose 7b by Mur18 was observable in HPLC traces.
HPLC analysis of the five-enzyme one pot reaction revealed a small new peak corresponding
to the generation of 8b (Figure 3.14, Figures S3.11-S3.13).
Different from the one-pot enzymatic reaction I (reaction to produce 8a), the
equilibration of the reaction shows the similar amount of 3,4a and 8a, one pot enzymatic
reaction II (reaction to produce 8b) uses up all the synthetic 3 to produce 8b, and the excess of
dUMP was totally converted to 2b rather than 4b or uracil. It seems that, by only adding the
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UMP as start substrate, six enzymes added in one pot reaction I created a balance for the
production of 8a with similar amount of 3 and 4a.
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Figure 3.13 Characterization of one-pot enzymatic reaction with UMP and UTP as start
substrates.
(A) One pot enzymatic reaction catalyzed by Mur16, Mur17, LipO, LipP, Mur18 and Mur19.
(B) HPLC analysis of one pot enzymatic reaction. I, no enzyme control; II, 12 h reaction with
Mur16; III, 12 h reaction with Mur16 and Mur17; IV, 12 h reaction with Mur16, Mur17 and
LipO; V, 12 h reaction with Mur16, Mur17, LipO and LipP; VI, 12 h reaction with Mur16,
Mur17, LipO, LipP and Mur18; VII, 12 h reaction with Mur16, Mur17, LipO, LipP, Mur18 and
Mur19; VIII, 8a standard.
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Figure 3.14 Characterization of one-pot enzymatic reaction with GlyU, 2′-deoxy-UMP, UTP
as start substrates.
(A) One pot enzymatic reaction catalyzed by Mur16, Mur17, LipO, LipP, Mur18 and Mur19.
(B) HPLC analysis of one pot enzymatic reaction. I, no enzyme control; II, 12 h reaction with
Mur16; III, 12 h reaction with Mur16 and LipO; IV, 12 h reaction with Mur16, LipO and LipP;
V,12 h reaction with Mur16, LipO, LipP and Mur18; VI, 12 h reaction with Mur16, LipO, LipP,
Mur18 and Mur19.
72

3.4 Conclusion
In this chapter, six enzymes were functionally assigned and characterized: Mur16, a
non-heme, Fe(II)-dependent α-ketoglutarate: UMP dioxygenase; Mur17, an L-threonine:
uridine-5′-aldehyde transaldolase; Mur20, an L-methionine: 1-aminotransferase; Mur26, a low
specificity pyrimidine nucleoside phosphorylase; Mur18, a primary amine-requiring
nucleotidylyltransferase; Mur19, a 5-amino-5-deoxyribosyltransferase. Substrates promiscuity
for each enzyme was studied. Substrate promiscuity was preliminarily discussed. For the first
time a one pot enzyme reaction was utilized to produce two distinct disaccharide moieties, both
of which are potential biosynthetic intermediates that lead to the mature muraymycins (Figure
3.15).

Figure 3.15 Biosynthetic pathway and substrate promiscuity towards ribofuranosylated glycyluridne moiety of muraymycins.
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3.5 Supporting Information
Table S3.1 Primers used in this study.
Primer
Sequence
mur16_pET30F 5′- GGTATTGAGGGTCGCGTGGTCCGCGCTGAC -3′
mur16_pET30R 5′- AGAGGAGAGTTAGAGCC TCAGGGGCTCTCCAG-3′

Note
Used

for

mur16
expression

mur17_NdeI

5′- GATAGGCATATGACCTCTTCGGACGACTGC-3′

Used

for

mur17

mur17_BamHI

5′- CGAGTTGGATCCTCAGCCATGGAAGAGTCCGG-3′

expression
from

S.

lividans
TK24

mur18_pET30F

5′-GGTATTGAGGGTCGCATGGCTGACTTCGCCGAACC3′
mur18_pET30R 5′AGAGGAGAGTTAGAGCCTCATGACCAGCTCCCCGGA3′
mur19_NdeI
5′-AAAAAACATATGAGCCGCCCGACAAGAGT-3′

Used

for

mur18
expression

Used

for

mur19

mur19_BamHI

5′- AAAAAAGGATCCTCACAGGGTCGTAGTTCTCAG-3′

expression
from

S.

lividans
TK24

mur20_pET30F 5′- GGTATTGAGGGTCGC GTGAGCCCCCAGAGCG-3′
mur20_pET30R 5′- AGAGGAGAGTTAGAGCC TCAGGCCGTCGCCTCG-3′

Used

for

mur20
expression

Used
for
mur26_pET30F 5′- GGTATTGAGGGTCGC ATGAGCACCTCCCTCGCG-3′
mur26
mur26_pET30R 5′AGAGGAGAGTTAGAGCCTCACAGGACGGAGTGCACC- expression
3′
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Table S3.2 Gradient used for HPLC or LC-MS analysis of reactions with an analytical Apollo
C18 column (250 mm x 4.6 mm, 5 µm).
Solvent A = ddH2O with 0.1% formic acid; Solvent B = acetonitrile with 0.1% formic acid;
A260
Time (min)
0
16
28
37
38
41

% Solvent B
1
20
100
100
1
1

Flow Rate (mL/min)
0.5
0.5
0.5
0.5
0.5
0.5

Table S3.3 Gradient used for LC-MS analysis of AQC modified reactions with an analytical
AcclaimTM 120 C18 column (100 mm x 4.6 mm, 5 µm).
Solvent A = ddH2O with 0.1% formic acid; Solvent B = acetonitrile with 0.1% formic acid;
A260
Time (min)
0
40
41
44
45
47

% Solvent B
1
20
100
100
1
1

Flow Rate (mL/min)
0.4
0.4
0.4
0.4
0.4
0.4

Table S3.4 Gradient used for LC-MS analysis of MBTH modified reaction with an analytical
AcclaimTM 120 C18 column (100 mm x 4.6 mm, 5 µm).
Solvent A = ddH2O with 0.1% formic acid; Solvent B = acetonitrile with 0.1% formic acid;
A350.
Time (min)
0
10
20
27
28
30

% Solvent B
10
40
100
100
10
10

Flow Rate (mL/min)
0.4
0.4
0.4
0.4
0.4
0.4
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Table S3.5 Gradient used for HPLC analysis of reactions with an analytical Apollo C18 column
(250 mm x 4.6 mm, 5 µm).
Solvent A = 40 mM acetic acid-triethylamine pH 6.5; Solvent B = 40 mM acetic acidtriethylamine, 20% methanol, pH 6.5; A260
Time (min)
0
8
18
19

% Solvent B
0
100
60
60

Flow Rate (mL/min)
1.0
1.0
1.0
1.0

Table S3.6 Gradient used for HPLC analysis of reactions with an analytical ZIC®-HILIC
column (250 mm x 4.6 mm, 5 µm).
Solvent A = ddH2O with 0.1% formic acid; Solvent B = acetonitrile with 0.1% formic acid;
A260
Time (min)
0
12
26
27
35

% Solvent B
80
50
50
80
80

Flow Rate (mL/min)
0.4
0.4
0.4
0.4
0.4

Table S3.7 Gradient used for semipreparative HPLC analysis of reactions with an

analytical Apollo C18 column (250 mm x 10 mm, 5 µm).
Solvent A= ddH2O with 0.025% trifluoroacetic acid; Solvent B= acetonitrile with 0.025%
trifluoroacetic acid; A260
Time (min)
0
8
9
13
14
16

% Solvent B
3
10
100
100
3
3

Flow Rate (mL/min)
3.5
3.5
3.5
3.5
3.5
3.5
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Table S3.8 Gradient used for semipreparative HPLC analysis of reactions with an

analytical Apollo C18 column (250 mm x 10 mm, 5 µm).
Solvent A= ddH2O with 0.025% trifluoroacetic acid; Solvent B= acetonitrile with 0.025%
trifluoroacetic acid; A260
Time (min)
% Solvent B
Flow Rate (mL/min)
0
12
4
15
12
4
16
100
4
19
100
4
20
12
4
24
12
4

Figure S3.1 SDS-PAGE analysis of protein Mur16, Mur17, Mur18, Mur19, Mur20 and Mur26.
Mur 16 (expected MW of 33 kD), Mur18 (expected MW of 25 kD), Mur20 (expected MW of
46 kD) and Mur26 (expected MW of 48 kD) purified from E. coli BL21 (DE3) and Mur17
(expected MW of 47 kD), Mur19 (expected MW of 42 kD) purified from Streptomyces lividans
TK24. All proteins have N-terminal hexahistidine tag.
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Figure S3.2 LC-MS analysis of Mur16 catalyzed reactions.
(A) Mass spectrum for the ion peak eluting at time t = 10.274 min of Mur16 reaction with UMP
(uridine aldehyde expected (M+H)+ ion at m/z = 243.06, found: 243.1). (B) Mass spectrum for
the ion peak eluting at time t = 13.404 min of Mur16 reaction with dUMP (2′- deoxy-uridine
aldehyde expected (M+H)+ ion at m/z = 227.07, found: 227.1). (C) Mass spectrum for the ion
peak eluting at time t = 14.116 min of Mur16 reaction with 2′-methoxy-UMP (2′-methoxyuridine aldehyde expected (M+H)+ ion at m/z = 257.22, found: 257.1).
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Figure S3.3 Detection of succinate production using LC-MS and an enzyme coupled reaction.
(A) Mass spectrum for the peak at elution time t = 14.358 min corresponding to succinate
(succinate expected (M-H)- ion at m/z = 117.02, Found: 117.2). (B) Scheme of reactions
catalyzed by three additional enzymes that lead to oxidation of NADH for detection by UV/Vis
spectroscopy at 340 nm. (C) Mur16-catalyzed reaction with or without addition of UMP. In
presence of UMP, the production of succinate is faster.
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Figure S3.4 LC-MS analysis of Mur17 catalyzed reactions.
Mass spectrum for the ion peak eluting at time t = 7.111 min of Mur17 reaction with uridine
aldehyde (GlyU expected (M+H) + ion at m/z = 318.09, found: 318.1).
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Figure S3.5 Comparative analysis of enzymatic and synthetic 3 diastereomers.
(A) Primary amine of 3 reacts with AQC. (B) LC-MS analysis of AQC modified Mur17 reaction
and synthetic 3 diastereomers. I, Synthetic (5′S, 6′S)-3 modified by AQC; II, (5′S, 6′R)-3
modified by AQC; III, (5′R, 6′S)-3 modified by AQC; IV, AQC modified reaction using uridine
aldehyde w/o Mur17; V, AQC modified reaction using uridine aldehyde w/ Mur17.
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Figure S3.6 LC-MS analysis of AQC modified GlyU epimers and Mur17 catalyzed reactions.
(A) Mass spectrum for the ion peak eluting at time t = 16.169 min of AQC modified Mur17
reaction (aqc modified (5′S, 6′S)-3, expected (M+H) + ion at m/z = 488.14, found: 488.2). (B)
Mass spectrum for the ion peak eluting at time t = 16.169 min of AQC modified synthetic (5′S,
6′S)-3 (AQC modified synthetic (5′S, 6′S)-3, expected (M+H) + ion at m/z = 488.14, found:
488.0). (C) Mass spectrum for the ion peak eluting at time t = 19.484 min of AQC modified
synthetic (5′S, 6′R)-3 (AQC modified synthetic (5′S, 6′R)-3, expected (M+H) + ion at m/z =
488.14, found: 488.1). (D) Mass spectrum for the ion peak eluting at time t = 25.081 min of
AQC modified synthetic (5′R, 6′S)-3.
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Figure S3.7 (+)-HR-ESI-MS (positive mode) of purified Mur20 product amino uridine, 4a
(expected (M+H) + ion at m/z = 244.0934, found: 244.0902).
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Figure S3.8 LC-MS analysis of MBTH modified Mur20 catalyzed reactions.
(A) α-keto-γ-methylthiol butyric acid reacts with MBTH. (B) LC traces of MBTH modified
reaction. I, control reaction without Mur20; II, MBTH modified 6 h reaction with Mur20; III,
MBTH modified 6 h reaction with LipO; IV, MBTH modified α-keto-γ-methylthiol butyric acid.
(C) Mass spectrum for the ion peak eluting at time t = 15.485 min of MBTH modified Mur20
reaction (MBTH modified α-keto-γ-methylthiol butyric acid, expected (M+H)+ ion at m/z =
310.06, found: 311.0). (D) Mass spectrum for the ion peak eluting at time t = 16.427 min of
MBTH modified Mur20 reaction (Found: 311.1).
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Figure S3.9 LC-MS analysis of Mur20 catalyzed reactions.
(A) Mass spectrum for the ion peak eluting at time t = 7.824 min of Mur20 reaction with 2′deoxy uridine aldehyde, 2b (2′, 5′-dideoxy-5′-amino uridine,4b, expected (M+H) + ion at m/z =
228.10, found: 228.1). (B) Mass spectrum for the ion peak eluting at time t = 7.824 min of
Mur20 reaction with 2′-deoxy uridine aldehyde, 2c produced by Mur16 with 1c (2′-methoxy5′-deoxy-5′-amino uridine, 4c, expected (M+H)+ ion at m/z = 258.11, found: 258.1).
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Figure S3.10 LC-MS analysis of Mur26 catalyzed reactions.
(A) Mass spectrum for the ion peak eluting at time t = 8.289 min of Mur26 reaction with 4a
(4a, (M+H) + ion at m/z = 244.10, found: 243.9). (B) Mass spectrum for the ion peak eluting at
time t = 12.971 min of Mur26 reaction with 4b (4b, (M+H) + ion at m/z = 228.1, found: 227.9).
(C) Mass spectrum for the ion peak eluting at time t = 16.276 min of Mur26 reaction with 4a
(6, (M+H) + ion at m/z = 113.03, found: 113.0).
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Figure S3.11 LC-MS analysis of Mur26 and Mur18 catalyzed reactions with HILIC column.
(A) Extracted ion chromatograms showing the production of 7b. I, 6 h reaction w/o enzyme; II,
6 h reaction w/ Mur26; III, 6 h reaction w/ Mur26 and Mur18. (B) Mass spectrum for the ion
peak eluting at time t = 19.867 min of Mur26 and Mur18 reaction with 4a (7b, (M-H)- ion at
m/z = 518.06, found: 518.1).
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Figure S3.12 (+)-HR-ESI-MS (positive mode) of purified AQC modified 8b
(expected (M+H)+ ion at m/z = 773.2524, found: 773.2523).
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Figure S3.13 1H NMR spectrum (D2O, 400 MHz) of AQC modified 8b.

Figure S3.14 1H-1H COSY spectrum (D2O, 400 MHz) of AQC modified 8b.
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Chapter 4 : Self-Resistance During Muraymcyin Biosynthesis: A Complementary
Nucleotidyltransferase and Phosphotransferase with Identical Modification Sites and
Distinct Temporal Order
4.1 Introduction
Muraymycins, produced as a mixture of nearly 20 congeners by Streptomyces sp.
NRRL 30471 (also known as Streptomyces sp. LL-AA896), are peptidyl nucleoside antibiotics
that were discovered using a screen to identify inhibitors of the lipid cycle of peptidoglycan
cell wall biosynthesis.1-2 Detailed investigations into their mechanism of action has
subsequently revealed muraymycins to be potent and selective inhibitors of translocase 1
(MraY), which catalyzes the initiating step of the lipid cycle.7, 40 As a consequence of MraY
inhibition, many muraymycin congeners are endowed with antibacterial activity. Notably,
muraymycin A1, one of the more active of the congeners, displays a relatively broad
antibacterial spectrum with modest activity against Gram-positive bacteria including strains of
Staphylococcus aureus and Mycobacterium tuberculosis and Gram-negative bacteria including
strains of Escherichia coli and Pseudomonas aeruginosa.7-8, 25
Structurally, muraymycins belong to a larger family of peptidyl nucleoside MraY
inhibitors that share a common core consisting of a 5′-C-glycyluridine (GlyU) that is appended
with a 5′′-amino-5′′-deoxyribose (ADR) moiety via a standard O-glycosidic bond (ADR-GlyU
disaccharide, Figure 4.1). FR-900493 is structurally the simplest of this family known to be
endowed with antibacterial activity, and consists of the ADR-GlyU disaccharide core that is 6′N-alkylated with an aminopropyl group.57 A-90289s, caprazamycins, and liposidomycins
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(herein collectively termed A-90289-type),58-60 sphaerimicins,61 and muraymycins also contain
an aminopropyl group that is further modified leading to structural distinctions among these
three (Figure 4.1). Notably, muraymycins are the sole member of this family to have a linear
peptide attached to the aminopropyl linker, and variations within this peptide lead to the
different series of muraymycin congeners that were initially reported.1 The D series of
muraymycins contain L-Leu as part of the peptide, while the C series contain a β-hydroxylated
L-Leu that can be acylated with an aliphatic, branched chain fatty acid (B series) or an acyl
group containing a terminal-guanidium (A series). In addition to the standard 2′′-OH version of
the ADR moiety that is exemplified in muraymycin D2, congeners have also been isolated with
a 2′′-methoxy ADR (for example, muraymycin D1) or a 2′′-deoxy ADR (for example,
muraymycin D3). Although they tend to be the least potent, the D series muraymycins are
nonetheless strong inhibitors of MraY with IC50s near 10 nM depending upon the source of
MraY.7, 14 Hydroxylation and acylation that leads to the A-C series, however, significantly
improves the IC50 to the low picomolar range.45
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Figure 4.1 Structure of representative peptidyl nucleoside antibiotics consisting of an ADRGlyU disaccharide core.
Recently, a new muraymycin (C6) was isolated that was acetylated at the 5′′-amine of
the ADR moiety, yielding a compound with modestly reduced (≥ 6-fold) IC50 against MraY
from different strains (Chapter 2). In a separate report, a 3′′-O-phosphorylated caprazamycin
precursor called caprazol-3′′-phosphate was unexpectedly isolated following inactivation of
cpz23 encoding a putative SGNH hydrolase, although in this case the inhibitory or antibacterial
activity of the phosphorylated variant was not tested.62 Covalent modification of these types
(phosphorylation and acetylation), along with nucleotidylation, are often found as resistance
mechanisms to antibiotics, most notably for aminoglycosides.63-66 The same types of covalent
modifications appear to be utilized by aminoglycoside producing strains, as homologous genes
encoding for such resistance enzymes are often clustered with the biosynthetic genes. 67-69
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However, the reported muraymycin gene cluster lacked any candidate gene encoding for an
acetyltransferase.22 Instead, the gene cluster does encode for a pair of proteins—Mur29 and
Mur28—that potentially catalyze the remaining two types of covalent modifications that are
commonplaces for aminoglycoside resistance, namely nucleotidylation and phosphorylation,
respectively. Of the known biosynthetic gene clusters for peptidyl nucleoside MraY inhibitors,
Mur28 homologs are encoded in all of the biosynthetic gene clusters with two homologs
encoded within the gene cluster for A-90289-type MraY inhibitors46, 51, 70-71. The only exception
to this is the sphaerimicin gene cluster, which lacks a Mur28 homolog. Conversely, a Mur29
homolog is only encoded within the sphaerimicin gene cluster61.
As part of our goal to elucidate potential resistance mechanisms toward the peptidyl
nucleoside antibiotics, we now provide in vitro data to support the functional assignment of
Mur29 and Mur28 as a Mg·ATP-dependent nucleotidyltransferase and a Mg·ATP-dependent
phosphotransferase, respectively, that covalently modify the same site: the 3′′-OH of the ADR
component of muraymycins. Examination of the substrate specificity along with singlesubstrate kinetic analysis using muraymycins D1-D3 and a hypothetical biosynthetic
intermediate prepared through synthesis, however, suggests a distinct temporal order for Mur29
and Mur28 catalysis during biosynthesis. The antimicrobial and MraY inhibitory activity using
the adenylated or phosphorylated products compared with the respective unmodified versions
are reported, enabling us to propose a distinct and complementary role for Mur29 and Mur28
in the resistance and biosynthesis of muraymycin. Finally, a preliminary attempt to functionally
characterization TmrB from Bacillus subtilis is reported, and the unexpected results are
provided herein.
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4.2 Materials and Methods
4.2.1 Chemicals, reagents, and instrumentation

Nucleotides, buffers, salts, and media components were purchased from Sigma-Aldrich
(St. Louis, MO) or Alfa-Aesar (Ward Hill, MA, USA). Synthetic oligonucleotides were
purchased from Integrated DNA Technologies (Coralville, IA) and are listed in Table S4.2.
Genomic DNA from Streptomyces sp. NRRL30473 was extracted using UltraClean Microbial
DNA Isolation Kit (MoBio laboratories, Inc) following the manufacturer’s protocol. DNA
quality and concentration were confirmed using Nanodrop 2000c spectrophotometer (Thermo
Scientific) and gel electrophoresis. The tmrB gene from Bacillus subtilis (accession number
WP_042977443) was synthesized by Genscript to give pET28-tmrB.
Analytical HPLC was performed with Agilent 1200 series (Agilent Technologies, Santa
Clara, CA) or Dionex Ultimate 3000 HPLC system equipped with a diode array detector and
an analytical Apollo C18 column (250 x 4.6 mm, 5 µm) purchased from Grace (Deerfield, IL).
Semipreparative HPLC was performed with a Waters 600 controller and pump (Milford, MA)
equipped with a 996 diode array detector, 717 plus autosampler, and an Apollo C18 column
(250 × 10 mm, 5 µm). LC-MS was conducted with an Agilent 6120 Quadrupole MSD mass
spectrometer (Agilent Technologies, Santa Clara, CA) equipped with an Agilent 1200 Series
Quaternary LC system and an Eclipse XDB-C18 column (150 × 4.6 mm, 5 µm). HR-ESI-MS
spectra were acquired with an AB SCIEX Triple TOF 5600 System (AB Sciex, Framingham,
MA, USA). All solvents used were minimally of ACS grade and purchased from PharmcoAAPER (Brookfield, CT) or Fisher Scientific (Pittsburgh, PA). NMR data were recorded at 400
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MHz for 1H and 100 MHz for 13C with a Varian Inova NMR spectrometer (Agilent, Santa Clara,
CA).
4.2.2 Cloning Genes of mur28, mur29 and tmrB
The genes encoding Mur28 and Mur29 were amplified from genomic DNA extracted
from Streptomyces sp. NRRL 30473 by PCR using Phusion DNA polymerase. The gene
encoding TmrB was amplified from pET28a-tmrB. The gel-purified PCR product was inserted
into pET-30 Xa/LIC using ligation-independent cloning as described in the provided protocol
to yield pET30-mur28 and pET30-mur29 or digested with NdeI-BamHI and ligated to the
identical sites of pXY200 or pDB.His.MBP to yield pXY200-mur28, pDB.His.MBP-mur28,
pDB.His.MBP-mur29 and pDB.His.MBP-tmrB. The identity of the cloned genes was
confirmed by DNA sequencing. Plasmids pDB.His.MBP-mur28, pDB.His.MBP-mur29,
pET28-tmrB and pDB.His.MBP-tmrB were expressed in E. coli BL21(DE3) cells and plasmid
pXY200-mur28 was expressed in S. lividans TK24.
Plasmids were introduced into E. coli BL21(DE3) cells, and the transformed strains
were grown in LB supplemented with 50 μg/mL kanamycin. Following inoculation of 500 mL
of LB with 50 μg/mL kanamycin, the cultures were grown at 37 °C until the cell density reached
an OD600 ~ 0.5 when expression was induced with 0.1 mM IPTG. Cells were harvested after an
overnight incubation at 18 °C and lysed in Buffer A (100 mM KH2PO4, 300 mM NaCl, 10 mM
imidazole, pH 8.3) using a Qsonica sonicator (Qsonica LLC, Newtown, CT) for sonication for
a total of 6 min at 40% amplitude with 30 s pulses separated by 30 s rest periods. Following
centrifugation the protein was purified using affinity chromatography with HisPurTM Ni-NTA
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agarose (Thermo Scientific, Rockford, IL), and proteins were eluted with increasing
concentrations of imidazole in Buffer A. Purified proteins were concentrated and buffer
exchanged into Buffer B (25 mM KH2PO4, 100 mM NaCl, pH 8.3) using Amicon Ultra 10000
MWCO centrifugal filter (Millipore) and stored as glycerol stocks (40%) at -20 °C. Protein
purity was assessed by 12% acrylamide SDS-PAGE; His6-tagged proteins were utilized without
further modifications. Protein concentration was determined using UV/Vis spectroscopy, and
the extension coefficients were calculated using the ProtParam tool available from ExPASY.
Plasmids were transformed into Streptomyces lividans TK-24 using PEG-mediated
protoplast transformation and plated on R2YE supplemented with 50 μg/mL apramycin. After
6 days at 28 °C, positive transformants were confirmed by colony PCR using InstaGene Matrix
from Bio-Rad (Hercules, CA) and LA-Taq polymerase with GC buffer I. The recombinant
strain was utilized to inoculate 50 mL R2YE containing 50 μg/mL apramycin, grown for 3 days
at 28 °C at 250 rpm, and 2 mL transferred to fresh 100 mL containing 50 μg/mL apramycin.
Following growth for 3 days at 28 °C at 250 rpm, protein expression was induced by addition
of thiostrepton (5 μg/mL) and the culture was incubated for another 24 h before harvesting. The
cells from 400 mL of culture were collected by centrifugation. The pellet was thoroughly
resuspended in ice-cold Buffer A supplemented with 4 mg/mL of lysozyme. After incubation at
30 °C for 30 min, the cell suspension was mixed by pipetting and lysed using a Qsonica
sonicator (Qsonica LLC, Newtown, CT) for sonication for a total of 10 min at 40% amplitude
with 30 s pulses separated by 30 s rest periods. Protein purification and storage was described
above.
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4.2.3 Production of muraymycin D congeners
Streptomyces sp. NRRL 30475 was cultivated in 250 mL Erlenmeyer flasks containing
50 mL TSBG [Tryptic soy broth (Difco) supplemented with 20 g/L glucose] at 30 °C on a rotary
shaker (250 rpm) for 72 h. The seed culture was used to inoculate flasks (250 mL) containing
50 mL PM-1 medium. PM-1 was composed of glucose 2%, soluble starch 1%, pressed yeast
0.9%, peptone (Bacto) 0.5%, meat extract (Fluka) 0.5%, NaCl 0.5%, CaCO3 0.3% and CB-442
(NOF Co., Ltd.) 0.01% (pH 7.4, before sterilization). The fermentation was continued for 7
days at 23 °C on a rotary shaker (210 rpm).
All culture flasks were combined and centrifuged at 5000 rpm for 15 min to separate
the mycelium and water phase. The mycelial-cake portion was extracted with methanol by
sonication, and the organic phase was evaporated to obtain brown crude extract. Amberlite
XAD-16 (4%) resin was added to the water phase and stirred for 12 h. The resin was washed
with water until the effluent became colorless, and then eluted with methanol. The methanol
extract was concentrated under reduced pressure to obtain a crude extract. Components of the
mycelium crude extract and water phase crude extract were subjected to Sephadex LH-20 (25100 μm, GE Healthcare) column, and methanol was used to elute compounds at a flow rate at
2 mL/min. The major fraction was further purified by using semipreparative HPLC. A series of
linear gradients was developed from 0.025% trifluoroacetic acid in water (A) to 0.025%
trifluoroacetic acid in acetonitrile (B) in the following manner: 0 min, 10% B; 0-25 min, 22%
B; 25-26 min, 100% B; 26-31 min, 100% B; 31-32 min, 10% B; and 31-32 min, 10% B
(beginning time and ending time with linear increase to % B). The flow rate was kept constant
at 3.5 mL/min.
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4.2.4 Enzyme reactions
Reactions consisted of 50 mM Tris (pH 7.5), 10 mM MgCl2, 1 mM NTP (ATP, dATP,
dTTP, GTP, CTP or UTP) or dATP, 1 mM muraymycin D1, D2, D3 or 0.5 mM ADR-GlyU
disaccharide and 1 μM Mur29, Mur28, or TmrB at 30 °C. The reaction was terminated by
adding twice volume of methanol followed by centrifugation (14000 rpm, 30 min) to remove
the precipitated protein. Following centrifugation to remove protein, the reaction was analyzed
by HPLC or LC-MS using one of four gradient programs provided in the Supporting
Information.
4.2.5 Single-substrate kinetics
For Mur29 assays consisted of 50 mM Tris (pH 7.5), 10 mM MgCl 2, near saturating
ATP (1 mM) with variable muraymycin D1 (1 μM–1000 μM), muraymycin D2 (1 μM–1000
μM) or muraymycin D3 (5 μM–500 μM). Reactions were performed at 30 °C with 200 nM
Mur29 for 4 h with muraymycin D1, D2 or D3. For Mur28 assays consisted of 50 mM Tris (pH
7.5), 10 mM MgCl2, near saturating ATP (1 mM) with variable muraymycin D2 (1 μM–1000
μM), muraymycin D3 (5 μM–500 μM) or disaccharide (5 μM–500μM). Reactions were
performed at 30 °C with 200 nM Mur28 for 4 h with muraymycin D2 or D3 and for 15 min
with disaccharide. Product formation was determined using HPLC with GP2. All reactions were
analyzed under near initial velocity conditions (≤ 10% product). Each data point represents a
minimum of three replicate end point assays; kinetic constants were obtained by nonlinear
regression analysis using GraphPad Prism (GraphPad Software, La Jolla, CA) by fitting the
data to the following equations depending on the presence of substrate inhibition:
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𝑣=

𝑉𝑚𝑎𝑥 [𝑆]
𝐾𝑚 +[𝑆]

or

𝑣=

𝑉𝑚𝑎𝑥 [𝑆]
𝐾𝑚 +[𝑆]+[𝑆]2 ⁄𝐾𝑖

4.2.6 Antimicrobial Bioactivity
The protocol used for the determination of the minimum inhibitory concentration (MIC)
was as described previously with minor modifications29. The bacterial strains Mycobacterium
smegmatis ATCC 14468, E. coli DH5α/ΔtolC, and E. coli BL21(DE3) introduced with plasmids
pET30-mur28, pET30-mur29, pET28a-tmrB, or pET30-mur20 were used as model strains for
antimicrobial susceptibility assays. All strains were grown in appropriate liquid or on agar
plates using Middlebrook 7H9 with ADC enrichment for M. smegmatis or LB medium
supplemented with 50 μg/mL kanamycin for E. coli. Individual strains were grown in 5 mL of
medium for 16 h at 37 °C with shaking (250 rpm), and then were diluted ×1000 into 4.5 mL of
medium and incubated until OD600 reaching 0.4. An aliquot of the suspensions was diluted
×1000. Aliquots (90 μL) of each diluted culture and transferred into the individual well of a 96well plate supplied with 10 μL of the tested compound. Maximum final concentration of 256
μg/mL with serial dilutions was maintained to obtain the antimicrobial activities and compared
to the negative control (water). The culture plates were incubated at 37 °C for 16 h with shaking
(160 rpm) for E. coli and without shaking for M. smegmatis. The OD600 of each well measured
using BioTek™ Synergy™ 2 Multi-Mode Microplate Readers. The acquired OD600 values were
normalized to the negative control wells (100% viability). Resazurin solution (5 μL) was also
added to each well, and the plates were shaken for 10 s and incubated at 37 °C for another 3 h.
The minimal concentration of the tested compound that caused growth inhibition was recorded
as the MIC.
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4.2.7 MraY Inhibition
Inhibition against SaMraY was performed as previously reported (S. Koppermann, Z.
Cui, P. D. Fischer, X. Wang, J. Ludwig, J. S. Thorson, S. G. Van Lanen, and C. Ducho, submitted
for publication).
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4.3 Results
4.3.1 Functional insight through bioinformatic analysis
Mur29 consists of two conserved domains: an N-terminal nucleotidyltransferase
domain of DNA polymerase subunit beta and C-terminal DUF4111 superfamily/PRK13746
domain. PRK13746 domain-containing proteins are provisionally annotated as aminoglycoside
resistance proteins. Secondary structure-based prediction using HHPred suggested structural
similarity to Salmonella enteric aminoglycoside O-adenylyltransferase (annotated as AadA;
PDB 4CS6), which catalyzes a Mg·ATP-dependent adenylation of spectinomycin and
streptomycin72, and Staphylococcus aureus kanamycin nucleotidyltransferase (annotated as
ANT(4′); PDB 1KNY), which adenylates several distinct aminoglycosides at the 4′- or 4′′hydroxyl substituent depending upon the identity of the aminoglycoside73. Pairwise alignment,
however, revealed only 17% sequence identity to these proteins. Sequence alignment of Mur29
and the homologous gene product SphT encoded in the sphaerimicin gene cluster revealed a
48% sequence identity.
Bioinformatic analysis suggests Mur28 likely belongs to the conserved domain of Ploop-containing nucleoside triphosphate hydrolases that include several types of
nucleoside/nucleotide kinases. Proteins with the highest sequence identity (~47%)—notably
present in both Gram-positive and Gram-negative bacteria—are annotated as tunicamycin
resistance proteins, TmrB. Pairwise alignment of Mur28 with Bacillus subtilis TmrB
(BsTmrB)74-76, which consists of the same conserved domain and confers resistance to
tunicamycin upon heterologous expression of the gene, had a lower sequence identity, yet was
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nonetheless significant at 34% (Table S4.1). Sets of homologous genes encoding proteins with
similarity to Mur28 are located in each of the A-90289-type gene clusters, represented by LipX
(36% sequence identity) and LipI (23% sequence identity) for A-90289 (Table S4.1).
4.3.2 In vitro functional assignment and characterization of recombinant Mur29
The three known congeners of the muraymycin D series, which differ only at the 2′′
substituent of the ADR-GlyU disaccharide core (Figure 4.1), were isolated from Streptomyces
sp. NRRL 30475, a previously reported mutant strain of Streptomyces sp. NRRL 304712. MS
and NMR spectroscopic data were consistent with their identities as muraymycin D1 (Figures
S4.2-S4.7), muraymycin D2 (Figures S4.8-S4.12), and muraymycin D3 (Figures S4.13 and
S4.14). The ADR-GlyU disaccharide, the likely biosynthetic precursor of muraymycin D1 and
D2 as well as the other members of the peptidyl nucleoside MraY inhibitors (Figure 4.1), was
prepared using the synthetic methodology developed by Ichikawa with slight modifications 16.
MS and NMR spectroscopic data were comparable to the prior report and likewise consistent
with the identity of the disaccharide (Figures S4.15-S4.19).
Mur29 was produced in E. coli BL21(DE3) as a maltose-binding protein (MBP)-fusion
to obtain soluble protein for in vitro assays. Using HPLC analysis to monitor the reaction,
incubation of recombinant Mur29 with muraymycin D1 and ATP revealed a new peak eluting
with a later retention time relative to muraymycin D1 (Figure 4.2A). HR-MS analysis of the
purified product revealed an (M + H)+ ion at m/z = 1259.5045, consistent with the molecular
formula of C48H75N16O22P, corresponding to a monoadenylated muraymycin D1 (expected m/z
= 1259.5052) (Figure S4.20). 1H NMR spectroscopic data (Figures S4.21 and S4.22) were
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likewise consistent with adenylation of muraymycin D1 (Figure 4.2B), and comparison of the
substrate and product spectra revealed a clear downfield shift of the 3′′ proton (Figure 4.2C).
Thus, the results are consistent with Mur29 catalyzing a regioselective adenylation to yield the
product, 3′′-AMP-muraymycin D1 (D1-AMP).
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Figure 4.2 Functional assignment of Mur29
(A) HPLC analysis after (i) 12 h incubation without Mur29 and (ii) 12 h reaction. Data were
collected using gradient program 1 (GP1) described in the Supplemental Material. (▼) denotes
peak corresponding to D1-AMP; A260, absorbance units at 260 nm. (B) Structure of 3′′monoadenylated muramycin D1. (C) Comparison of the 1H-NMR spectrum for muraymycin
D1 and the Mur29 product.
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To provide insight into the specificity and timing of adenylation during muraymycin
biosynthesis, the activity of Mur29 was tested with the remaining two D series congeners and
ADR-GlyU disaccharide. In contrast to the disaccharide, which was not a substrate for Mur29,
both muraymycin D2 and muraymycin D3 yielded products with an (M + H)+ ion at m/z =
1246.2 and 1229.2, respectively, consistent with monoadenylated products (expected m/z =
1245.5 for D2-AMP and 1229.5 for D3-AMP) (Figures S4.23 and S4.24). The lack of activity
with ADR-GlyU disaccharide is consistent with the Mur29 reaction occurring after the addition
of the aminopropyl linker. Single-substrate kinetic analysis with variable muraymycins D1, D2,
and D3 revealed non-Michaelis Menten kinetics with modest substrate-inhibition for all three
substrates (Figures 4.3A-C). Comparison of the second order rate constants from the extracted
kinetic parameters did not reveal a clear substrate preference (Table 4.1).
Specificity toward the nucleoside triphosphate co-substrate was also examined using
muraymycin D1 as an acceptor. HPLC and LC-MS analysis revealed that the other canonical
ribonucleotide triphosphates could substitute for ATP to generate the corresponding
mononucleotide muraymycin D1 (Figures S4.25-S4.27). 2′-deoxy-ATP and 2′-deoxy-TTP were
also used by Mur29 as nucleotidyl donors (Figures S4.28 and S4.29). The highest specific
activity, however, was realized with ATP (Figure 4.3D). Finally, the addition of magnesium to
the reaction was essential for activity. The addition of 20 mM EDTA abolished the reaction.
Thus, the data are consistent with the functional assignment of Mur29 as a
Mg·ATP:muraymycin 3′′-adenylyltransferase.
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Figure 4.3 Biochemical characterization of Mur29.
Single-substrate kinetic analysis using near saturating ATP and variable (A) muraymycin D1,
(B) muraymycin D2, and (C) muraymycin D3. (D) Relative activity of Mur29 with muraymycin
D1 and different nucleotide donors.
4.3.3 In vitro functional assignment and characterization of Mur28
His6-Mur28 was initially produced in Streptomyces lividans TK24 to obtain soluble
protein for in vitro assays. In contrast to Mur29, incubation of recombinant Mur28 with
muraymycin D1 and ATP did not reveal any new peaks. However, HPLC analysis of an
overnight reaction of Mur28 with ATP and muraymycin D2, which is the likely direct
biosynthetic precursor of muraymycin D1, revealed the appearance of a new peak eluting after
muraymycin D2 (Figure 4.4A). The new peak was collected by semipreparative HPLC, and
HR-MS analysis of the purified product revealed an (M + H)+ ion at m/z = 996.4050, consistent
with the molecular formula of C37H62N11O19P, corresponding to a monophosphorylated
muraymycin D2 (expected m/z = 996.4034) (Figure S4.30). 1H NMR spectroscopic data
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(Figures S4.31 and S4.32) were likewise consistent with phosphorylation of muraymycin D2
(Figure 4.4B), and similarly to the Mur29-catalyzed adenylation of muraymycin D1,
comparison of the substrate and product spectra revealed a clear downfield shift of the 3′′ proton
(Figure 4.4C). To provide further evidence for a classical kinase activity, the Mur28-catalyzed
reaction was performed with [γ-P18O4]ATP. LC-MS analysis of the monophosphorylated
product revealed a shift of + 6.0 amu, consistent with the incorporation of the γ-phosphate of
ATP into muraymycin D2 (Figure S4.33). Finally, Mur28 was produced as a MBP-fusion
protein from E. coli BL21(DE3), and comparable results were obtained. Thus, the data are
consistent with Mur28 catalyzing a regioselective phosphorylation to yield the product, 3′′phospho-muraymycin D2 (D2-PHOS).
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Figure 4.4 Functional assignment of Mur28.
(A) HPLC analysis after (i) 12 h incubation without Mur28 and (ii) 12 h reaction. Data were
collected using GP1. (▼) denotes peak corresponding to D2-PHOS; (*) denotes unidentified
peak; A260, absorbance units at 260 nm. (B) Structure of 3′′-phospho-muramycin D2. (C)
Comparison of the 1H-NMR spectrum for muraymycin D2 and the Mur28 product.
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The specificity and timing of phosphorylation during muraymycin biosynthesis was
subsequently investigated. LC-MS analysis of Mur28 reactions with hypothetical substrates
muraymycin D3 or the ADR-GlyU disaccharide yielded new peaks with (M + H)+ ions at m/z
= 980.1 and 527.0, respectively, consistent with the formation of a monophosphorylated product
(expected m/z = 980.4 for D3-PHOS and 527.1 for ADR-GlyU-PHOS) (Figures S4.34 and
S4.35). Single-substrate kinetic analysis with variable muraymycin D2 and D3 revealed nonMichaelis-Menten kinetics with modest substrate-inhibition, while analysis with the ADRGlyU disaccharide revealed typical Michaelis-Menten kinetics (Figures 4.5A-C). Second order
rate constants from the extracted kinetic parameters revealed >60-fold higher catalytic
efficiency with ADR-GlyU relative to muraymycin D2, consistent with phosphorylation
occurring prior to the attachment of the aminopropyl-linked peptide.
LC-MS analysis of reactions using muraymycin D2 as the acceptor revealed Mur28
uses alternative phosphate donors, results that were similar to Mur29 (Figure S4.36). The
highest activity was achieved with ATP, although good conversion was realized with dATP,
dTTP, and the remaining ribonucleoside triphosphates (Figure 4.5D). Unexpectedly, ADP was
also utilized as a co-substrate, although D2-PHOS was only detected in trace amounts
suggesting that this activity is insignificant in vivo. Finally, similar to Mur29, the inclusion of
magnesium was essential for activity. In total the data are consistent with the functional
assignment of Mur28 as a Mg·ATP:ADR-GlyU 3′′-phosphotransferase.
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Figure 4.5 Biochemical characterization of Mur28.
Single-substrate kinetic analysis using near saturating ATP and variable (A) muraymycin D2,
(B) muraymycin D3, and (C) ADR-GlyU. (D) Relative activity of Mur28 with muraymycin
D2 and different nucleotide donors.
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Table 4.1 Kinetic parameters for Mur29 and Mur28
kcat/KM

Enzyme

Substrate

KM (μM)

Ki (μM)

kcat (min-1)

Mur29

Muraymycin D1

14 ±2

(4.6 ±1.4) x 103

1.4 ±0.1

1.7 x 103

41 ±8

(4.9 ±1.1) x 10

2

4.0 ±0.4

1.6 x 10

3

94

2

2.4 ±0.4

1.0 x 10

3

59

NA

NA

NA

NA

Muraymycin D2

Mur28

Muraymycin D3

39 ±10

(2.6 ±0.8) x 10

ADR-GlyU

NA

NA

Muraymycin D1

NA

Muraymycin D2

(1.7 ±0.4) x 10

Muraymycin D3

ND

ADR-GlyU

NA
2

38 ±4

(5.6 ±1.0) x 10
ND
NA

Abbreviations are NA, not applicable; ND, not determined.
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2

5.2 ±0.7

5.1 x 10

ND

ND

75 ±2

Relative (%)

(M-1·
s-1)

3.3 x 10

100

NA
NA
2

1.5
ND

4

100

4.3.4 Insight into the Function of Mur28-homologs BsTmrB
BsTmrB, which has never been functionally assigned in vitro except for its ability to
bind ATP74, 76 and tunicamycin75, was initially targeted to serve as a control due to its modest
sequence similarity to Mur28. Soluble His6-TmrB and MBP-TmrB fusion protein were
obtained using E. coli BL21(DE3) as an expression host. Using HPLC to monitor the reaction,
recombinant TmrB did not have any phosphotransferase activity when incubated with ATP and
commercial tunicamycin. Unexpectedly, however, LC-MS analysis revealed TmrB was able to
phosphorylate muraymycin D2 and ADR-GlyU using ATP as the phosphate donor (Figure
S4.37). The conversion of both was comparable to the Mur28-catalyzed reaction. Likewise, a
trace amount of D2-PHOS was detected with ADP as the phosphate donor. In contrast to Mur28,
however, no other nucleotide triphosphates were substrates for BsTmrB.
4.3.5 Potential role of Mur29 and Mur28 in self-resistance
The possibility that Mur29 and/or Mur28 play a role in self-resistance to muraymycins
was explored using three approaches. We first examined the antibacterial activity of
muraymycin D1 and D2 against E. coli BL21(DE3) harboring the mur29, mur28, or tmrB
expression plasmids (Table 4.2). E. coli BL21(DE3) harboring an expression plasmid for mur20,
encoding a putative aminotransferase likely involved in ADR biosynthesis, was used as control.
Both muraymycin D1 and D2 have low antibacterial activity against plasmid-free E. coli
BL21(DE3) or strains expressing mur20, with MICs determined in the range of 16-32 μg/mL.
A similar MIC for muraymycin D1 (32 μg/mL) was obtained against E. coli BL21(DE3)
expressing mur28 or tmrB. However, E. coli BL21(DE3) expressing mur29 was resistant to
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muraymycin D1 (MIC > 256 μg/mL). E. coli BL21(DE3) cells expressing mur29, mur28, or
tmrB were likewise all resistant to muraymycin D2 (MIC > 256 μg/mL). These results were
consistent with the substrate selectivity of each enzyme that was revealed through in vitro
assays.
The purified Mur29 and Mur28 products (D1-AMP and D2-PHOS) were next screened
against Mycobacterium smegmatis and E. coli DH5α/tolC (Table 2). Both strains are more
sensitive compared to E. coli BL21(DE3) with MIC = 4 μg/mL (muraymycin D1 or D2) and 1
μg/mL (muraymycin D1 or D2), respectively. In contrast to the unmodified muraymycins, D1AMP and D2-PHOS were inactive against M. smegmatis (MIC > 256 μg/mL) while both had
reduced activity against E. coli DH5α/tolC (MIC = 16 μg/mL).

The results are consistent

with the conferred resistance upon heterologous expression of mur29 and mur28 in E. coli
BL21(DE3).
The third and final approach to examine a potential role in self-resistance was to screen
D1-AMP and D2-PHOS for inhibitory activity against recombinant Staphylococcus aureus
MraY (SaMraY) in vitro. In contrast to muraymycin D1 and D2, which were determined to be
sub-nanomolar inhibitors of SaMraY with IC50 = 0.48 ± 0.13 and 0.39 ± 0.11 nM, respectively,
D1-AMP and D2-PHOS were significantly less potent with IC50 = 82 ± 32 nM and 20 ± 5 nM,
respectively. Therefore, the direct inhibition of the translocase I target is positively correlated
with the whole cell antibacterial activity.
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Table 4.2 Bacterial MraY assays and antimicrobial activities
E. coli
E. coli

inhibition

compound

BL21(DE3) BL21(DE3)

E. coli

E. coli
BL21(DE3)

∆tolC

E. coli

mur28

mur29

BL21(DE3)

M. smegmatis

mutant

BL21(DE3)

pET30

pET30

tmrB pET30 mur20pET30

growth

growth

growth

growth

growth

growth

growth

inhibition

inhibition

inhibition

inhibition

inhibition

inhibition

inhibition

MIC

MIC

MIC

MIC

MI

MIC

(μg/mL)

(μg/mL)

(μg/mL)

(μg/mL)

(μg/mL)

(μg/mL)

S. aureus
MraY

E. coli

IC50 (nM) MIC (μg/mL)

muraymycin
D1

0.48±0.13

4

1

32

32

>256

32

32

0.39±0.11

4

1

32

>256

>256

>256

16

82±32

>256

16

>256

na

na

na

na

20±5

>256

16

>256

na

na

na

na

muraymycin
D2
muraymycin
D1-AMP
muraymycin
D2-Phos

4.4 Discussion
4.4.1 Why We Choose Muraymycin D Series to Test the Activity

We have provided evidence to support the functional assignment of two enzymes that
covalently modify known muraymycins or a hypothetical biosynthetic precursor. Twenty-two
muraymycin congeners, categorized structurally into four series (A-D), were initially
discovered using an enzyme activity-based screen to identify inhibitors of MraY and/or MurG,
which catalyze sequential reactions to generate Lipid II intermediate in peptidoglycan cell wall
biosynthesis. The D series of congeners were targeted here as representative muraymycins in
part due to (i) the relatively decent titres in our hands, (ii) they are structurally the simplest of
the independent series, and (iii) this was the only series within which we could isolate the three
congeners with variations in the ADR (namely, D1, D2, and D3). Unfortunately, this series also
represents the weakest inhibitors of the four, but nevertheless remain potent inhibitors of the
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MraY-catalyzed reaction8, 77 and are modestly active against a few bacterial pathogens. In our
in vitro screen, muraymycin D1 and D2 were very potent inhibitors of recombinant
Staphylococcus aureus MraY with IC50 of 0.48 and 0.39 nM, respectively. The details of this
assay and the variability with respect to the literature is reported elsewhere. Given the moderate
sequence identity (~ 40%) and conservation of key motifs of SaMraY and MraY from different
Streptomyces including the muraymycin D2 binding site, we predict that the producing strain’s
MraY is equally inhibited.
4.4.2 Distinct Temporal Order for Mur29 and Mur28 Catalysis

The ADR-GlyU disaccharide core of muraymycin is technically an aminoglycoside,
and thus it seemed plausible that our results are consistent with the functional assignment of
Mur29 as an ATP-dependent muraymycin adenylyltransferase and Mur28 as an ATP-dependent
ADR-GlyU phosphotransferase. NMR spectroscopic analyses of each enzyme-catalyzed
product revealed a downfield shift with respect to the C-3″ proton, the magnitude of which is
consistent with other enzymes that adenylate or phosphorylate sugars such as the numerous
aminoglycoside resistance enzymes.78 Interestingly both Mur29 and Mur28 covalently modify
the ADR with the identical regioselectivity, yet Mur29 did not have any activity with ADRGlyU while Mur28 kinetically preferred this muraymycin precursor. The realization of the
substrate preferences suggests that ADR is phosphorylated at an earlier stage in the biosynthetic
pathway, and is potentially utilized as a transient resistance mechanism. The biochemical
data—along with consideration of MraY inhibition—lead us to conclude that ADR-GlyU is the
authentic in vivo substrate of Mur28, as the kinetic parameters are in line with other
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phosphotransferases and the attachment of the aminopropyl group leads to the first active
antibiotic scaffold, FR-900493. Thus, we propose that transient phosphorylation occurs inside
the cell and protects the producing strain from MraY self-inhibition during antibiotic maturation.
Following phosphorylation, muraymycin biosynthesis is completed by downstream, as-of-yet
uncharacterized enzymes, transported outside the cell, and dephosphorylated by an unknown
enzyme. In contrast to Mur28, the biochemical data support that Mur29 functions later in the
biosynthetic pathway. Therefore, as opposed to a preventive resistance mechanism that is
proposed via Mur28-catalyzed phosphorylation, we hypothesize that Mur29-catalyzed
adenylation provides a protective resistance mechanism in the case of intracellular
accumulation of muraymycin.
4.4.3 Predicted Phosphorylation Position of Tunicamycin by TmrB

Noda et al79 discovered that BsTmrB, responsible for tunicamycin resistance of B.
subtillis, confers resisitance to tunicamycin on E. coli. The same team also showed that TmrB
is an ATP-binding membrane protein74, and suggested that it could act to lower the intracellular
concentration of tunicamycin. Kapp reported the crtystal structure of TmrD (a homolog of
TmrB) and suggested that either of the three hydroxyls in ribose moiety of tunicamycin could
be the target by structural alignment and modelling with chloramphenicol phosphotransferase.76
In our experiment, although TmrB did not show any phosphotransferase activity with a
commercial mix of tunicamycin congeners, TmrB was able to phosphorylate muraymycin D2
and ADR-GlyU using ATP as the phosphate donor. Recently, MraY tunicamycin complex
structure was reported. 80 Based on the comparison of tunicamycin and muraymycin D2 binding
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with MraY, ADR-Gly moiety of muraymycin showed similar binding pattern of uridyl moiety
of tunicamycin to MraY. The 5′ hydroxyl group of tunicamycin located in the similar position
of aminoribose moiety of muraymycin D2, which lead us to propose that TmrB might transfer
phosphate from ATP to 5′ hydroxyl group in the ongoing studies.
4.5 Conclusion
In conclusion, we have provided evidence to support the functional assignment of
Mur29 as a Mg·ATP-dependent 3′′-O-muraymycin adenylyltransferase and Mur28 as a
Mg·ATP-dependent ADR-GlyU 3′′-phosphotransferase. The biochemical data—along with
consideration of MraY inhibition—lead us to conclude that ADR-GlyU is the authentic in vivo
substrate of Mur28, as the kinetic parameters are in line with other phosphotransferases and the
attachment of the aminopropyl group leads to the first active antibiotic scaffold, FR-900493.
Thus, we propose that transient phosphorylation occurs inside the cell and protects the
producing strain from MraY self-inhibition during antibiotic maturation. Following
phosphorylation, muraymycin biosynthesis is completed by downstream, as-of-yet
uncharacterized enzymes, transported outside the cell, and dephosphorylated by an unknown
enzyme. In contrast to Mur28, the biochemical data support that Mur29 functions later in the
biosynthetic pathway. Therefore, as opposed to a preventive resistance mechanism that is
proposed via Mur28-catalyzed phosphorylation, we hypothesize that Mur29-catalyzed
adenylation provides a protective resistance mechanism in the case of intracellular
accumulation of muraymycin.
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4.6 Supporting Information
Table S 4.1 Sequence identity for pairwise sequence alignment with Mur28.
Proteina,b

Identity (%)

Protein

Identity (%)

BsTmrB
LipX
Cpz27
LpmY
Mra06

34
36
38
38
38

LipI
Cpz12
LpmJ
Mra16

23
26
23
22

a

Accession numbers for proteins are as follows: BsTmrB, WP_042977443; LipX, BAJ05900; LipI,
BAJ05885; Cpz27, ACQ63635; Cpz12, ACQ63620; LpmY, ADC96673; LpmJ, ADC96658; Mra06,
BAM98967; Mra16, BAM98977
b
Protein annotations are Lip, A-90289 from Streptomyces sp. SANK 60405; Cpz, caprazamycin
from Streptomyces sp. MK730-62F2; Lpm, liposidomycin from Streptomyces sp. SN-1061M; and
Mra, muraminomicin from Streptosporangium amethystogenes.
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Table S 4.2 Primers used in this study.
3
Primer
mur28_NdeI
mur28_Bam
HI

Sequence
5’-GATAGGCATATG AGCAGGCACGCACACAC-3’
5’-CGAGTTGGATCC TCACCGCGCTCCGTCCG-3’

mur29_NdeI

5’-GATAGGCATATG AGCGTCGTCGACAACG-3’

mur29_Bam
HI

5’-CGAGTTGGATCCTCACGGCAGTAGTGACTCCAG3’

mur28_pET3
0F
mur28_pET3
0R
mur29_pET3
0F
mur29_pET3
0R
tmrB_ NdeI

5’-GGTATTGAGGGTCGCGTGATCATTTGGATC-3’
5’-AGAGGAGAGTTAGAGCCTCAAAACCTGGCGG-3’
5’-GGTATTGAGGGTCGCGTGCAAGCCATGAAC-3’

lipX_NdeI

5’-AGAGGAGAGTTAGAGCCTCAGCGGGTCACGTC3’
5’-AAAAAACAT ATGATCATTTGGATCAACGGTGCG3’
5’AAAAAAGGATCCTTATTTAATACGGATGTGGTTCAG
CTTAA-3’
5’GGTATTGAGGGTCGCGTGATCATCGTCATCACGGG
C-3’
5’AGAGGAGAGTTAGAGCCTCATGTGGCCGTCCCTGC
-3’
5’-AAAAAACATATGCTGGTGTGGATCAACGG-3’

lipX_BamHI

5’-AAAAAAGGATCCTCATGGACGCGAGTCCCTTC-

tmrB_
BamHI
lipI_pET30F

lipI_pET30R

3’
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Note
mur28
expression
with
pXY200 or
pDB.His.M
BP vector
mur29
expression
with
pDB.His.M
BP vector
Activity
assay with
E.
coli
BL21(DE3)
Activity
assay with
E.
coli
BL21(DE3)
tmrB
expression
with
pDB.His.M
BP
lipI
expression
with pET30
vector

lipX
expression
with
pDB.His.M
BP vector

Table S4.3 Gradient used for muraymycins separation.
Semipreparative HPLC separation of muraymycin D1, muraymycin D2, muraymycin D3,
muraymycin D1-AMP and muraymycin D2-Phosphate with an analytical Apollo C18 column
(250 × 10 mm, 5 µm).
Solvent A= ddH2O with 0.025% trifluroacetic acid; Solvent B= acetonitrile; A260
Time (min)
0
25
26
31
32
36

% Solvent B
10
22
100
100
10
10

Flow Rate (mL/min)
3.5
3.5
3.5
3.5
3.5
3.5

Table S4.4 Gradient program 1 (GP1) used for HPLC or LC-MS analysis of reactions with an
analytical Apollo C18 column (250 mm x 4.6 mm, 5 µm).
Solvent A= ddH2O with 0.1% formic acid; Solvent B= acetonitrile with 0.1% formic acid; A260
Time (min)
0
16
28
37
38
41

% Solvent B
1
20
100
100
1
1

Flow Rate (mL/min)
0.5
0.5
0.5
0.5
0.5
0.5

Table S4.5 Gradient program 2 (GP2) used for LC-MS analysis of AQC modified reactions
with an analytical Apollo C18 column (250 mm x 4.6 mm, 5 µm).
Solvent A= ddH2O with 0.1% formic acid; Solvent B= acetonitrile with 0.1% formic acid; A260
Time (min)
0
25
26
36
37
41

% Solvent B
10
60
100
100
10
10

Flow Rate (mL/min)
0.4
0.4
0.4
0.4
0.4
0.4
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Table S4.6 Gradient program 3 (GP3) used for HPLC analysis of reactions with an analytical
Apollo C18 column (250 mm x 4.6 mm, 5 µm).
Solvent A = 40 mM acetic acid-triethylamine pH 6.5; Solvent B = 40 mM acetic acidtriethylamine, 20% methanol, pH 6.5; A260
Time (min)
0
8
18
19
20
22

% Solvent B
0
100
60
60
0
0

Flow Rate (mL/min)
1.0
1.0
1.0
1.0
1.0
1.0

Table S4.7 Gradient program 4 (GP4) used for HPLC analysis of reactions with an analytical
Apollo C18 column (250 mm x 4.6 mm, 5 µm).
Solvent A = 40 mM acetic acid-triethylamine pH 6.5; Solvent B = 40 mM acetic acidtriethylamine, 20% methanol, pH 6.5; A260
Time (min)
0
16
20
21
24

% Solvent B
1
100
100
1
1

Flow Rate (mL/min)
0.5
0.5
0.5
0.5
0.5
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Figure S4.1 SDS-PAGE analysis of purified Mur28, Mur29, TmrB, LipI and LipX.
A, His6-Mur28; B, His6-MBP-Mur28; C, His6-MBP-Mur29; D, His6-TmrB; E, His6-MBPTmrB; F, His6-LipI; G, His6-MBP-LipX
A

B

C

D

E

kD
250
150
100
50
37

25

20

Protein

Size (aa)

Size (kD)

Mur28

184

20.8

Mur29

277

30.5

TmrB

197

22.7

LipI

189

21.2

LipX

188

21.3

MBP Tag

395

43.5
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F

G

Figure S4.2 (+)-HR-ESI-MS (positive mode) of muraymycin D1
(calcd for C38H63N11O16 expected (M+H)+ ion at m/z = 930.4527, found 930.4575).

Figure S4.3 1H NMR spectrum (D2O, 400 MHz) of muraymycin D1.
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Figure S4.4 13C NMR spectrum (D2O, 100 MHz) of muraymycin D1.

Figure S4.5 HSQC spectrum (D2O, 400 MHz) of muraymycin D1.
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Figure S4.6 1H−1H COSY spectrum (D2O, 400 MHz) of muraymycin D1.

Figure S4.7 HMBC spectrum (D2O, 400 MHz) of muraymycin D1.
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Figure S4.8 (+)-HR-ESI-MS (positive mode) of muraymycin D2
(calcd for C37H61N11O16, expected (M+H)+ ion at m/z = 916.4371, found: 916.4369).

Figure S4.9 1H NMR spectrum (D2O, 400 MHz) of muraymycin D2.
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Figure S4.10 13C NMR spectrum (D2O, 100 MHz) of muraymycin D2.

Figure S4.11 HSQC spectrum (D2O, 400 MHz) of muraymycin D2.
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Figure S4.12 1H-1H COSY spectrum (D2O, 400 MHz) of muraymycin D2.

Figure S4.13 (+)-HR-ESI-MS (positive mode) of muraymycin D3. (calcd for C37H61N11O15,
expected (M+H)+ ion at m/z = 900.4421, found 900.4307; expected (M+2H)2+ ion at m/z =
450.7247, found 450.7202).
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Figure S4.14 1H NMR spectrum (D2O, 400 MHz) of muraymycin D3.

Figure S4.15 (+)-HR-ESI-MS (positive mode) of compound ADR-GlyU
(calcd for C16H24N4O11, expected (M+H)+ ion at m/z = 449.1514, found: 449.1462).
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Figure S4.16 1H NMR spectrum (D2O, 100 MHz) of compound ADR-GlyU.

Figure S4.17 13C NMR spectrum (D2O, 100 MHz) of compound ADR-GlyU.
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Figure S4.18 HSQC spectrum (D2O, 400 MHz) of compound ADR-GlyU.

Figure S4.19 1H-1H COSY spectrum (D2O, 400 MHz) of compound ADR-GlyU.
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Figure S 4.20 (+)-HR-ESI-MS (positive mode) of compound D1-AMP.
(calcd for C48H75N16O22P, expected (M+H)+ ion at m/z =1259.5052, found: 1259.5045).

Figure S4.21 1H NMR spectrum (D2O, 400 MHz) of muramycin D1-AMP.
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Figure S4.22 1H-1H COSY spectrum (D2O, 400 MHz) of muramycin D1-AMP.
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Figure S4.23 Reaction catalyzed by Mur29 with muraymycin D2 and ATP.
(A) LC-MS analysis after (i) 12 h incubation without Mur29 and (ii) 12 h reaction. Data were
collected using GP1. (▼) denotes peak corresponding to D2-AMP; (*) denotes unidentified
peak; A260, absorbance units at 260 nm. (B) Mass spectrum for the peak eluting at t = 26.0 min
(D2-AMP, C47H73N16O22P, expected (M+H)+ ion at m/z = 1245.5, found: 1246.2).
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Figure S4.24 Reaction catalyzed by Mur29 with muraymycin D3 and ATP.
(A) LC-MS analysis after (i) 12 h incubation without Mur29 and (ii) 12 h reaction. Data were
collected using GP1. (▼) denotes peak corresponding to D3-AMP; A260, absorbance units at
260 nm. (B) Mass spectrum for the peak eluting at t = 25.9 min (D3-AMP, C47H73N16O21P,
expected (M+H)+ ion at m/z = 1229.5, found: 1229.2).
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Figure S4.25 Reaction catalyzed by Mur29 with muraymycin D1 and GTP.
A, LC-MS analysis using muraymycin D1 and GTP after (I) 12 h reaction without Mur29, (II)
12 h reaction. B, mass spectrum for the ion peak eluting at time t = 26.926 min of Mur29
reaction with muraymycin D1. (D1-GMP, C48H75N16O23P, , expected (M+2H)2+ ion at m/z
= 638.2, found: 638.2).
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Figure S4.26 Reaction catalyzed by Mur29 with muraymycin D1 and CTP.
A, LC-MS analysis using muraymycin D1 and CTP after (I) 12 h reaction without Mur29, (II)
12 h reaction. B, mass spectrum for the ion peak eluting at time t = 15.363 min of Mur29
reaction with muraymycin D1. (D1-CMP, C47H75N14O23P, expected (M+2H)2+ ion at m/z =
618.25, found: 618.2).
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Figure S4.27 Reaction catalyzed by Mur29 with muraymycin D1 and dATP.
A, LC-MS analysis using muraymycin D1 and dATP after (I) 12 h reaction without Mur29, (II)
12 h reaction. B, mass spectrum for the ion peak eluting at time t = 26.633 min of Mur29
reaction with muraymycin D1. (D1-dAMP, C48H75N16O21P, expected (M+2H)2+ ion at m/z =
622.25, found:622.6).

138

A

ii

A 260

D1

i

2

4

6

8

10

12

14

16

18

20

22

24

E lu tio n T im e ( m in )

B

Figure S4.28 Reaction catalyzed by Mur29 with muraymycin D1 and dTTP.
A, LC-MS analysis using muraymycin D1 and dTTP after (I) 12 h reaction without Mur29, (II)
12 h reaction. B, mass spectrum for the ion peak eluting at time t = 17.347 min of Mur29
reaction with muraymycin D1. (D1-dTMP, C48H76N13O23P, expected (M+H)+ ion at m/z =
1234.50, found: 1234.3).
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Figure S4.29 Reaction catalyzed by Mur29 with muraymycin D1 and UTP.
A, LC-MS analysis using muraymycin D1 and UTP after (I) 12 h reaction without Mur29, (II)
12 h reaction. B, mass spectrum for the ion peak eluting at time t = 26.986 min of Mur29
reaction with muraymycin D1. (D1-UMP, C47H74N13O24P, expected (M+H)+ ion at m/z =
618.74, found: 618.9).
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Figure S 4.30 (+)-HR-ESI-MS (positive mode) of compound D2-PHOS
(calcd for C37H62N11O19P, expected (M+H)+ ion at m/z = 996.4034, found: 996.4050).

Figure S4.31 1H NMR spectrum (D2O, 400 MHz) of muramycin D2-PHOS.
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Figure S4.32 1H-1H COSY spectrum (D2O, 400 MHz) of muramycin D2 -PHOS.
B
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Figure S4.33 Reaction catalyzed by Mur28 with D2 and [γ-P18O4]ATP.
A, mass spectrum for the ion peak eluting at time t = 27.167 min of Mur28 reaction with
muraymycin D2 and ATP. B, mass spectrum for the ion peak eluting at time t = 27.116 min of
Mur28 reaction with muraymycin D2 and [γ-P18O4]ATP (m/z increased by 6 amu).
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Figure S4.34 Reaction catalyzed by Mur28 with muraymycin D3 and ATP.
(A) LC-MS analysis using muraymycin D3 and ATP after (i) 12 h incubation without Mur29
and (ii) 12 h reaction. Data were collected using GP1. Adenosine was only observed when
reactions were performed with excess enzyme and prolonged incubation, suggesting the
formation is due to a contaminating phosphatase. (▼) denotes peak corresponding to D3PHOS; A260, absorbance units at 260 nm. (B) Mass spectrum of the D3-PHOS peak generated
with natural-isotope abundance ATP. (C) Mass spectrum of the D3-PHOS peak generated with
[γ-P18O4]ATP (m/z increased by 6.1 amu).
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Figure S4.35 Reaction catalyzed by Mur28 with ADR-GlyU and ATP
(A) LC-MS analysis using ADR-GlyU and ATP after (i) 12 h incubation without Mur29 and
(ii) 12 h reaction. Data were collected using GP3. (▼) denotes peak corresponding to ADRGlyU-PHOS; (*) denotes unidentified peak; A260, absorbance units at 260 nm. (B) (+)-HRESI-MS of compound ADR-GlyU-PHOS (calcd for C16H25N4O14P, expected (M+H)+ ion at
m/z = 529.1178, found: 529.1127).
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Figure S4.36 Reaction catalyzed by Mur28 with muraymycin D2 and different phosphate
donors.
LC-MS analysis after 12 h reactions including (i) all nucleotides and without Mur28, (ii) CTP,
(iii) GTP, (iv) TTP, (v) UTP, (vi) ATP, (vii) dATP. Data were collected using GP2. (▼) denotes
peak corresponding to D2-PHOS; (*) denotes unidentified peak; A260, absorbance units at 260
nm.
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Figure S4.37 Reaction catalyzed by TmrB.
(A) LC-MS analysis using muraymycin D2 and ATP after (i) 12 h incubation without enzyme;
(ii) 12 h reaction with Mur28; and (iii) 12 h reaction with TmrB. Data were collected using
GP1. (▼) denotes peak corresponding to D2 -PHOS; (*) denotes unidentified peak; A260,
absorbance units at 260 nm. (B) LC-MS analysis using ADR-GlyU and ATP with (i) ADRGlyU control and after (ii) 12 h incubation without enzyme, (iii) 12 h reaction with TmrB, and
(iv) 12 h reaction with Mur28. Data were collected using GP4. (▼) denotes peak
corresponding to ADR-GlyU-PHOS; A260, absorbance units at 260 nm. (C) LC-MS analysis
using muraymycin D2 and ADP after (i) 12 h incubation without enzyme, (ii) 12 h reaction
with TmrB, and (iii) 12 h reaction with Mur28. Data were collected using GP1. (▼) denotes
peak corresponding to D2 -PHOS; (*) denotes unidentified peak; A260, absorbance units at 260
nm. (D) Comparison of muraymycin D2-PHOS formation with different phosphate donors.
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Chapter 5 : A PLP and AdoMet Dependent Strategy for Aminopropyl Group
Incorporation in Nuceloside Antibiotics Biosynthesis

5.1 Introduction
Several nucleoside antibiotics represented by muraymycins from Streptomyces sp.
NRRL3047122, A-90289A from Streptomyces sp. SANK6040581, Spharimicins from
Sphaerisporangium sp. SANK6091161 and FR-900493 from Bacillus cereus No204582 are
structurally characterized with a high-carbon glycosylated aminopropyl uronic acid (Figure 5.1),
which undergoes different modifications to form the final nucleoside antibiotic. SAR studies
have shown that the 3-amino-3-carboxypropyl group is essential for the antibacterial activity
of muraymycins.21 Here we present the functional assignment of a butyric acid
ribofuranosylated 5′-C-glycyluridine synthase and a PLP-dependent butyric acid decarboxylase.
The results establish the first known PLP dependent enzymatic strategy for butyric acid
incorporation.
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Figure 5.1 Structure of representative nucleoside antibiotics containing an aminopropyl moiety
(highlighted in red).
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5.2 Materials and Methods
5.2.1 Synthesis
5.2.1.1 Materials and Methods
Hydrogen chloride solution (4.0 M in dioxane), Boc-L-vinylglycine and solvents were
purchased from Sigma-Aldrich (St. Louis, MO), and used without further purification.
Compound 7 was kindly provided by Prof. Christian Ducho (Department of Pharmacy, Saarland
University, Germany). All NMR data was recorded at 400 MHz for 1H and 100 MHz for 13C
with a Varian Inova NMR spectrometer (Agilent, Santa Clara, CA). LC-MS was conducted
with an Agilent 6120 Quadrupole MSD mass spectrometer (Agilent Technologies, Santa Clara,
CA) equipped with an Agilent 1200 Series Quaternary LC system and an Eclipse XDB-C18
column (150 × 4.6 mm, 5 µm). HR-ESI-MS spectra were acquired with an AB SCIEX Triple
TOF 5600 System (AB Sciex, Framingham, MA, USA). HPLC analysis was performed on an
Agilent 1200 system equipped with a photodiode array (PDA) detector and an analytical ZIC®HILIC column (250 mm x 4.6 mm, 5 µm).
5.2.1.2 Disaccharide Phosphate, 8

The reaction mixture consisted of 25 mM potassium phosphate (pH 8.5), 500 μM 7, 2
mM MgCl2, 2 mM ATP and 200 nM Mur28 was incubated at 30 °C. The reaction was terminated
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by ultrafiltration using a Microcon YM-3. 8 was purified by HPLC with HILIC column. The
separation gradient is shown in Table S5.2. The peak corresponding to the product 8 was
collected and freeze-dried as white solid prior to analysis.
5.2.1.3 L- Vinylglycine

An aliquot (500 μL) of hydrogen chloride solution (4.0 M in dioxane) was added to
Boc-L-vinylglycine (10 mg), and the mixture was stirred at room temperature for 30 min. Upon
completion of the reaction the volatiles were evaporated and the resulting mixture was
dissolved in DI water. The aqueous solution was freeze-dried twice from water as an off-white
solid prior to analysis.
5.2.2 Isotopic Enrichment
5.2.2.1 Fermentation, Extraction, Isolation, and Purification of Muraymycin D1
Streptomyces sp. NRRL30475 was cultivated in 250 mL Erlenmeyer flasks containing
50 mL TSBG (Tryptic soy broth (Difco) supplemented with 20 g/L glucose) at 30 °C on a rotary
shaker (250 rpm) for 72 h. The seed culture was used to inoculate flasks (250 mL) containing
50 mL PM-1 medium83. PM-1 was composed of glucose 2%, soluble starch 1%, pressed yeast
0.9%, peptone (Bacto) 0.5%, meat extract (Fluka) 0.5%, NaCl 0.5%, CaCO3 0.3% and CB-442
(NOF Co., Ltd.) 0.01% (pH 7.4, before sterilization). The fermentation was continued for 7
days at 23 °C on a rotary shaker (210 rpm).
All culture flasks were combined and centrifuged at 5000 rpm for 15 min to separate
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the mycelium and water phase. The mycelial-cake portion was extracted with MeOH by
sonication, and the organic phase was evaporated to obtain a brown crude extract.
Amberlite XAD-16 (4%) resin was added to the water phase and stirred for 12 h. The
resin was washed with water until the effluent became colorless, and then eluted with methanol.
The MeOH extract was concentrated under reduced pressure to obtain a crude extract.
Components of the mycelium crude extract and water phase crude extract were
subjected to Sephadex LH-20 (25-100 μm GE Healthcare) column, and MeOH was used to
elute compounds at a flow rate at 2 mL/min. The major fraction was further purified by using
semipreparative HPLC. The separation gradient used for semipreparative analysis is shown in
Table S5.3.
5.2.2.2 Isotopic Enrichment
Fermentation media and growth conditions for Streptomyces sp. NRRL30475 are
described above. A seed culture was incubated at 30 °C for 72 h, when 2 ml was used to
inoculate 50 mL fresh medium. After fermentation for 65 h, 25 mg of filter-sterilized L[13C5,15N]Met or L- [13C4,15N]Asp (Cambridge Isotope Laboratories, Inc) was added to each
flask (50 mL of liquid medium in a 250 mL flask). Fermentation was continued an additional
72 h. Muraymycin D1 were extracted and purified as described in section 5.2.2.1. Purified
muraymycin D1 was analyzed by NMR, and relative peak intensities were assigned based on
uronic acid C-1 from the natural abundance 13C NMR spectra.
5.2.3 Heterologous Protein Expression
5.2.3.1 Materials and Bacterial Strains
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Synthetic oligonucleotides were purchased from Integrated DNA Technologies
(Coralville, IA). Phusion DNA polymerase, restriction enzymes and T4 DNA ligase were
obtained from New England Biolabs Inc (Ipswich, MA) and used according to the
manufacturer’s instructions. LA-Taq polymerase were obtained from Takara Bio Inc. (Shiga,
Japan). Routine DNA sequencing was carried out at ACGT Inc. Competent E. coli NEB® 5alpha and BL21(DE3) from New England Biolabs (Ipswich, MA) and S. lividans TK24 were
used for routine cloning and protein expression.
5.2.3.2 Protein Expression Constructs
5.2.3.2.1 Cloning Genes of mur23, mur24 and lipJ
The gene for mur23 and mur24 was amplified from genomic DNA extracted from
Streptomyces sp. NRRL30473 by PCR using Phusion DNA polymerase (primers listed in Table
S5.1). Genomic DNA of Streptomyces sp. NRRL30473 was extracted using UltraClean
Microbial DNA Isolation Kit (MoBio laboratories, Inc) following manufacturer’s protocol.
DNA quality and concentration were confirmed using Nanodrop 2000c spectrophotometer
(Thermo Scientific) and gel electrophoresis. The gel-purified PCR product was digested with
NdeI-BamHI and ligated to the identical sites of pXY200 to yield pXY200-mur23 and
pXY200-mur24 following the standard protocol and confirmed by DNA sequencing.
5.2.3.2.2 Site-directed Mutagenesis
A K70A point mutation of Mur23, K234A of Mur24 and F201Y of Mur24 was
generated by PCR amplification with Q5 hot start high-fidelity DNA polymerase using pET30mur23 or pET30-mur24 as a template, respectively. The template, pET30-mur23 and pET30152

mur24, was obtained using ligation-independent cloning with pET-30 Xa/LIC vector following
the provided protocol. The template DNA after the PCR amplification was digested with 10
units of DpnI for 2 h at 37 °C and transformed into E. coli NEB5α competent cells. The
sequence of the entire gene with the introduction of the correct point mutation were confirmed
by DNA sequencing to yield pET30-mur23 (K70A), pET30-mur24 (K234A) and pET30-mur24
(F201Y), all of which were digested with NdeI-BamHI and the DNA fragment of the expected
size was purified and ligated to the identical sites of pXY200 to yield pXY200-mur23 (K70A),
pXY200-mur24 (K234A) and pXY200-mur24 (F201Y) were yielded following the same
procedure as described above.
5.2.3.3 Heterologous Protein Expression
Plasmids pXY200-mur23, pXY200-mur24, pXY200-mur23 (K70A), pXY200-mur24
(K234A) and pXY200-mur24 (F201Y) were transformed into S. lividans TK24 using PEGmediated protoplast transformation and plated on R2YE supplemented with 50 μg/mL
apramycin. After 6 days at 28 °C, positive transformants were confirmed by colony PCR using
InstaGene Matrix from Bio-Rad (Hercules, CA) and LA-Taq polymerase with GC buffer I.

The recombinant strain was utilized to inoculate 50 mL R2YE containing 50
μg/mL apramycin, grown for 3 days at 28 °C at 250 rpm, and 2 mL transferred to fresh
100 mL containing 50 μg/mL apramycin. Following growth for 3 days at 28 °C at 250
rpm, protein expression was induced by addition of thiostrepton (5 μg/mL) and the
culture was incubated for another 24 h before harvesting. The cells from 400 mL of
culture were collected by centrifugation. The pellet was thoroughly resuspended in ice153

cold Buffer A supplemented with 4 mg/mL of lysozyme was subsequently added to the
suspension. After incubation at 30 °C for 30 min, the cell suspension was mixed by
pipetting and lysed using a Qsonica sonicator (Qsonica LLC, Newtown, CT) for
sonication for a total of 10 min at 40% amplitude with 30 s pulses separated by 30 s
rest periods. Cells were harvested after an overnight incubation at 18 °C and lysed in Buffer
A (100 mM KH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.3) using a Qsonica sonicator
(Qsonica LLC, Newtown, CT) for sonication for a total of 6 min at 40% amplitude with 30 s
pulses separated by 30 s rest periods. Following centrifugation the protein was purified using
affinity chromatography with HisPurTM Ni-NTA agarose (Thermo Scientific, Rockford, IL),
and proteins were eluted with increasing concentrations of imidazole in Buffer A. Purified
proteins were concentrated and buffer exchanged into Buffer B (25 mM KH2PO4, 100 mM
NaCl, pH 8.3) using Amicon Ultra 10000 MWCO centrifugal filter (Millipore) and stored as
glycerol stocks (40%) at -20 °C. Protein purity was assessed as by 12% acrylamide SDS-PAGE;
His6-tagged proteins were utilized without further modifications. Protein concentration was
determined using UV/Vis spectroscopy, and the extension coefficients were calculated using
the ProtParam tool available from ExPASY (Mur23 ɛ280 = 44522 M-1cm-1; Mur24 ɛ280 = 53922
M-1cm-1.
5.2.4 Enzyme Assays
5.2.4.1 Materials and Methods
S-(5-Adenosyl)-L-methionine
aminocyclopropanecarboxylic

acid

chloride
(ACC),
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dihydrochloride

(AdoMet),

3-methyl-2-benzothiazolinone

1-

hydrazine

hydrochloride (MBTH), PLP and ATP were purchased from Sigma-Aldrich (St. Louis, MO),
[(3S)-3-amino-3-carboxypropyl] (dimethyl)-sulfonium iodide (SMM) was obtained from VWR
(Radnor, PA), 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) was purchased from
Apollo Scientific (Denton, Manchester) and used without further purification. All NMR data
were recorded at 400 MHz for 1H and 100 MHz for 13C with a Varian Inova NMR spectrometer
(Agilent, Santa Clara, CA). LC-MS was conducted with an Agilent 6120 Quadrupole MSD
mass spectrometer (Agilent Technologies, Santa Clara, CA) equipped with an Agilent 1200
Series Quaternary LC system. HR-ESI-MS spectra were acquired with an AB SCIEX Triple
TOF 5600 System (AB Sciex, Framingham, MA, USA). HPLC analysis was performed on an
Agilent 1200 system equipped with a photodiode array (PDA) detector and an analytical ZIC®HILIC column (250 mm x 4.6 mm, 5 µm) and an analytical Apollo C18 column (250 mm x 4.6
mm, 5 µm).
5.2.4.2 Tandem Enzymatic Reaction with Mur28, Mur24 and Mur23
The assay mixture for the reaction consisted of 25 mM potassium phosphate (pH 8.3),
500 μM 7, 500 μM AdoMet, 1 mM ATP, 1 mM MgCl2, 100 μM PLP, and 200 nM Mur28,
Mur24 and Mur23 at 30 °C, and the reaction was subsequently quenched by adding two
volumes of acetonitrile followed by centrifugation (14000 rpm, 30 min) to remove the
precipitated protein. The reaction components were analyzed by HPLC using C-18 reversephase column with gradient shown in Table S5.4 or monitored by HPLC using ZIC®-HILIC
column with the gradient shown in Table S5.2 with detection at 260 nm. 6-aminoquinolyl-Nhydroxysuccinimidyl carbamate (AQC), a derivatizing reagent for amines, was used for precolumn derivation. The reaction 20 μL was mixed with 60 μL of 0.2M sodium borate buffer
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(pH = 8.8) and 20 μL 3 mg/ mL AQC acetonitrile solution. The mixtures were incubated at
55 °C for 10 min and then allowed to cool to room temperature. The AQC-derivatized samples
(50 μL) were applied to LC-MS using C-18 reverse-phase column with detection at 260 nm
with gradient shown in Table S5.5.
5.2.4.3 Butyric Acid Incorporation Activity of Mur24
Reactions consisted of 25 mM potassium phosphate (pH 8.3), 500 μM 8, 500 μM
potential aminopropyl donor (AdoMet, SMM, L-VG or ACC), 100 μM PLP and 200 nM
enzyme (Mur24, Mur24 (K234A), Mur24 (F201Y) at 30 °C and the reaction was terminated by
adding two volumes of acetonitrile followed by centrifugation (14000 rpm, 30 min) to remove
the precipitated protein. The reaction was monitored by LC-MS using ZIC®-HILIC column
with gradient shown in Table S5.2 with detection at 260 nm. Large scale production of the
Mur24 product 9 was identical to the reactions described above and isolated by HPLC using
ZIC®-HILIC column.
5.2.4.4 Deaminase Activity of Mur24 or LipJ
Reactions for identification of α-ketobutyrate consisted of 50 mM potassium phosphate
(pH 8.3), 500 μM potential aminopropyl donor, 100 μM PLP and 400 nM or 4 μM enzyme at
30 °C and the reaction was terminated by ultrafiltration using a Microcon YM-3.

Reaction

mixtures were treated with MBTH as follows according to the method described by Tanaka 54.
50 μL reaction mixtures were mixed with 50 μL of 1 M sodium acetate (pH 5.0) and 50 μL of
8 mM MBTH aqueous solution. The mixtures were then incubated at 50 °C for 30 min and then
analyzed by LC-MS with the gradient shown in Table S5.6 with detection at 325 nm.
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5.2.4.5 Activity of Mur23
Reactions consisted of 25 mM potassium phosphate (pH 8.3), 500 μM 9, 100 μM PLP
and 200 nM Mur23 or Mur23 (K70A) at 30 °C and the reaction was terminated by adding two
volumes of acetonitrile followed by centrifugation (14000 rpm, 30 min) to remove the
precipitated protein. The reaction was monitored by LC-MS using ZIC®-HILIC column with
the gradient shown in Table S5.2 with detection at 260 nm. Large scale production of the Mur23
product 10 was identical to the reactions described above and was isolated by HPLC using
ZIC®-HILIC column.
5.2.4.6 Kinetics of Mur24
Assays consisted of 25 mM potassium phosphate (pH 8.3), 100 μM PLP, near saturating
AdoMet (2 mM) with variable 8 (5 μM–500 μM). The reaction was performed at 30 °C with
200 nM Mur24 for 3 h and analyzed under initial velocity conditions. Product formation was
determined using HPLC with gradient shown in Table S5.2. Each data point represents a
minimum of three replicate end point assays; kinetic constants were obtained by nonlinear
regression analysis using GraphPad Prism (GraphPad Software, La Jolla, CA).
5.2.4.7 Kinetics of Mur23
Assays consisted of 25 mM potassium phosphate (pH 8.3), 100 μM PLP with variable
8 (5 μM–1000 μM). The reaction was performed at 30 °C with 50 nM Mur23 for 1 h and
analyzed under initial velocity conditions. Product formation was determined using HPLC with
gradient shown in Table S5.2. Each data point represents a minimum of three replicate end point
assays; kinetic constants were obtained by nonlinear regression analysis using GraphPad Prism
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(GraphPad Software, La Jolla, CA).
5.3 Results and Discussion
5.3.1 Bioinformatic Analysis of Mur23 and Mur24
Blast analysis revealed that Mur24 belonged to pyridoxal-5’-phosphate (PLP)
dependent aspartate aminotransferase family (type I), members of which have a diverse set of
functions including transamination, racemization, decarboxylation, and various side-chain
reactions. However, sequence analysis of Mur24 didn’t show modest sequence identity (>30%)
to any characterized enzyme. Two clues shed light on our proposed function of Mur24,
especially after comparison of the biosynthetic gene clusters among other nucleoside antibiotics.
One is that Mur24 has 45% sequence identity (Cover 95%) to DNA binding transcription
regulator (SCL26195.1) that belongs to MocR family, the mechanism of which hasn’t been well
understood yet. This similarity, however, suggested that Mur24 potentially uses a nucleoside as
a substrate. Another is that Mur24 has 27% sequence identity (Cover 41%) to ACC synthaselike protein (XP0213717 68.1). Mur23 has modest sequence identity to several proteins
annotated as PLP dependent diaminopimelate decarboxylase.
Comparison among A-90289, caprazamycin and spharimicin biosynthetic gene cluster
revealed that Mur24 homolog is shared by the four gene clusters, while only sphaerimicin gene
cluster has Mur23 homolog. Structure comparison of the four nucleoside antibiotics revealed
that the four nucleoside antibiotics share the similar aminopropyl group (Figure 5.1 highlighted
in red), and both A-90289 and caprazamycin retain the carboxylate group (Figure 5.1
highlighted in blue) while both muraymycin and spharimicin do not. The bioinformatics
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analysis above led us to propose the pathway that Mur24 catalyzes the aminobutyric acid
incorporation, followed with decarboxylation reaction catalyzed by Mur23.
5.3.2 Feeding Experiments: the Source of the Aminopropyl Group
Two potential pathways for incorporation of aminopropyl group were proposed,
inspired by the characterized polyamine84 and staphylopine85 biosynthetic pathways. From
analysis of these two pathways, S-adenosylmethionine or aspartate β-semialdehyde serve as
aminopropyl group donors prior to further downstream modification by distinct enzymes.
In order to determine which precursor is the authentic donor of the aminopropyl group
in muraymycins, universal labeled L-methionine (L-Met) or L-aspartic acid (L-Asp) was fed to
the muraymycin D1 producer Streptomyces sp. NRRL30475 at the onset of production.
Analysis by 13C NMR spectroscopy revealed enriched resonances (average enrichment = 12%)
with fermentation fed with L-Met (Figure 5.2). The 13C-NMR resonances showed four carbon
resonances at δ25.0 (t), 35.8 (dd), 45.5 (d) and 57.9 (s) with increased abundance flanking the
other natural singlets, indicating that methionine is the origin of C1-C3 of aminopropane moiety
and 2′-O-methyl group of the aminoribose moiety of muraymycin. In contrast no significant
enrichment was observed with L-Asp. Mass analysis and extraction of the NMR coupling
constants were also consistent with retention of the N atom from L-Met in the final muraymycin.
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A

B

C

muraymycin D1

Figure 5.2 13C NMR spectrum of isotope labelled muraymycin D1.
(A) Chemical shift assignment for muraymycin D1. (B) 13C NMR spectra of muraymycin D1
fed with L-Methionine (13C5, 99%; 15N, 98%) and L-Aspartic acid (13C4, 99%; 15N, 99%),
respectively. (C) Zoom in part of signal of 13C NMR spectra of muraymycin D1 fed with Lmethionine.
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5.3.3 Six-enzyme Biosynthesis of Amino Disaccharide, compound 7: the Aminopropyl Group
Acceptor
Since muraymycin has a similar disaccharide moiety of A-90289, we compared the
biosynthetic gene cluster of muraymycin with that of A-90289. Six genes (mur16, mur17,
mur18, mur19, mur20, and mur26) have modest similarity to genes in A-90289 that are
responsible for the biosynthesis of the disaccharide moiety.47,

49,

55

However, the

glycosyltransferase (LipN) in A-90289 biosynthetic pathway was only confirmed to utilize
uridine as a surrogate aminoribose acceptor. The functions of the six enzymes were confirmed
individually upon in vitro characterization (Figure 5.3) (details shown in chapter 3), and Mur19
was shown to utilize GlyU as an acceptor to produce 7 with in situ generated activated amino
ribose 6. Notably, aminopropyl GlyU cannot be utilized by Mur19 to produce 7, which suggests
that aminopropyl group was added after the formation of 7.

Figure 5.3 Biosynthesis of the amino disaccharide moiety of muraymycins.
5.3.4 Function Assignment of Mur23 and Mur24
To interrogate the mechanism of aminopropane incorporation, Mur23 and Mur24 were
expressed in E. coli; however, the recombinant protein was completely insoluble under a variety
of expression conditions. In contrast, expression in S. lividans TK24 yielded soluble proteins
(Mur23, 5.8 mg/L, Mur24, 5.1 mg/L) (Figure S5.1A). Mur23 was yellowish and shown to co161

purify with PLP cofactor by UV/vis spectroscopy (Figure S5.1B), while Mur24 was purified
with bound PLP only when purification buffers were supplemented with PLP.
Based on the confirmed biosynthetic pathway of 7, we initially proposed 7 as the
aminopropyl group acceptor (Figure 5.4A), and incubated Mur24 and Mur23 with 7 and L-Met
derived aminopropyl group donors including L-Met, AdoMet and SMM, but observed no
reaction by both HPLC and LC-MS after pre-column primary amine derivation with 6aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC).
Since the initially proposed product 7 only lacks N-methylation compared to
nucleoside antibiotic FR-900493, we suspected that 7 might also have inhibitory effect to
bacteria and therefore a self-resistance modification of the acceptor might be required before
the incorporation of the aminopropyl group. Careful analysis of the gene cluster of muraymycin,
two ORFs (mur28 and mur29) have sequence similarity to proteins predicted to belong to
aminoglycoside resistance enzymes. In chapter 4, we reported the respective activity of Mur28
and Mur29. To our surprise, by single substrate kinetics we found that Mur28, which was a
kinase, preferred utilizing the precursor of muraymycin, 7, as its substrate; while a series of
muraymycin congeners showed inhibition to Mur28 at high concentration. However, Mur29, a
nucleotidyltransferase, can only catalyze muraymycins rather than its precursor (details shown
in chapter 4). This discovery led to another proposal that the incorporation of the aminopropyl
group might happen after the phosphorylation of 7 (Figure 5.4B).
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A

B

Figure 5.4 Two proposed biosynthetic pathway of the incorporation of aminopropyl moiety of
muraymycins.
LC-MS analysis of enzyme coupled reaction by incubating Mur28, Mur24 and Mur23
with 7 after pre-column derivation by AQC yielded an (M+2H)2+ ion at m/z = 463.7, consistent
with the molecular formula C39H46N9O16P of an AQC-modified 10 (10’), (expected m/z = 463.6)
(Figure S5.7). Since a C18 column did not give good separation for the reaction even under ion
pairing condition (Figure S5.4) due to the high polarity of the substrate and product, the tandem
reactions were analyzed with HILIC column without pre-column derivation (Figure 5.5).

In

situ generated disaccharide phosphate by Mur28 was clearly processed by Mur24 and a new
peak was formed, which was identified as butyric acid disaccharide 9 by HR-ESI-MS with
(M+H)+ ion at m/z =630.1643, consistent with the molecular formula C20H33N5O16P of 9
(expected (M + H)+ ion at m/z = 630.1654) (Figure S5.11). Decarboxylation of in situ generated
9 was also observed when incubating with Mur23. HR-ESI-MS of the purified new peak
yielded an (M + H)+ ion at m/z = 586.1735, consistent with the molecular formula C19H33N5O14P
for 10 (expected (M + H)+ ion at m/z = 586.1756) (Figure S5.16).
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Figure 5.5 HPLC analysis of tandem enzymatic reaction with Mur23, Mur24 and Mur28.
I, control reaction with ATP and 7; II, 6 h reaction with Mur28; III, 6 h reaction with ATP, 7,
AdoMet and Mur28; IV, 6 h reaction with Mur24 and Mur28; V, 6 h reaction with Mur23,
Mur24 and Mur28.
Purified 8 was used as substrate to directly test Mur24-catalyzed reaction with AdoMet
(Figure 5.6A) to confirm that 8 is the genuine aminopropyl group acceptor. The structure of the
product 9 was elucidated by NMR spectroscopy (Figure 5.7, S5.8-S5.10, S5.12-S5.15, S5.17S5.18). As expected, the connection between the butyric acid group and 8 in 9 was confirmed
by 1H-13C HMBC from the proton signal at δH 3.79 (H-10) to the carbon signal at δC 45.6 (C17) (Figure S5.15). Accordingly, purified 9 was used as substrate to test the activity of Mur23
(Figure 5.6B). NMR analysis of purified product 10 revealed the decarboxylation at C-19
position as expected.
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Figure 5.6 Characterization of Mur24 and Mur23.
(A) LC-MS analysis of Mur24 reaction using 8 as substrate. I, control reaction with AdoMet no
Mur24; II, 6 h reaction with AdoMet and Mur24; III, 6 h reaction with AdoMet and Mur24
(K234A); IV, 6 h reaction with L-Met and Mur24; V, 6 h reaction with SMM and Mur24. (B)
LC-MS analysis of Mur23 reaction using 9 as substrates. I, control reaction without Mur23; II,
6 h reaction with Mur23; III, 6 h reaction with Mur23 (K70A).
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Figure 5.7 Chemical shift assignment for compound 7, 8, 9 and 10.
5.3.5 Kinetic and Mutational Analysis of Mur24 and Mur23
Single-substrate kinetic analysis of Mur24 revealed typical Michaelis−Menten kinetics
with respect to varied 8, yielding kinetic constants of Km = 92.3 ± 7.3 μM and kcat = 2.67 ± 0.08
min−1 (Figure 5.8A). A Mur24 (K234A) mutant was generated by site-directed mutagenesis
with the expectation that the point mutation would make the enzyme unable to form an internal
aldimine with PLP which is a prerequisite for the catalytic activity, and as expected, incubation
of 8 with AdoMet and Mur24 (K234A) revealed no detectable conversion to 9 (Figure 5.6A).
Also, absence of adding PLP in the reaction with Mur24 greatly reduced the yield of the product
9 (Figure S5.21), which suggested that Mur24 catalyzed an unusual PLP-dependent reaction to
modify the high carbon nucleoside scaffold.

Kinetic analysis of Mur23 with respect to 9 also

revealed Michaelis-Menten kinetics yielding a Km = 701.8 ± 9.2 μM and kcat = 144.8 ± 1.1 min−1
(Figure 5.8B). Mur23 (K70A) mutant was still yellowish and had a similar UV/Vis profile to
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wild-type Mur23 (Figure S5.1). The activity of Mur23 (K70A) was significantly reduced when
incubating 9, suggesting an important—although not essential—role for this Lys residue in the
Mur23 reaction.
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Figure 5.8 Kinetic analysis of Mur24 and Mur23.
(A) Single-substrate kinetic analysis of Mur24 with 2 mM AdoMet and variable 8. (B) Singlesubstrate kinetic analysis of Mur23 with variable 9.
5.3.6 Mechanism Study of Mur24
Formation of 9 can involve in one of a few possible mechanisms (Figure 5.9). The
proposed ‘addition’ pathway involves an L-VG intermediate as an active vinyl ketamine.
Alternatively, in the ‘cyclization’ pathway, 1-aminocyclopropanecarboxylic acid (ACC)
involves as an intermediate to form the active aldimine. Moreover, the regular SN2 mechanism
for the aminopropane incorporation is also possible. To distinguish among the proposed
mechanisms, L-VG, ACC and SMM were tested as alternative aminopropane donor in the
reaction with 8 and Mur24. However, activity was only detected when incubating with SMM,
which, although suggested that the adenosyl group is not required for its activity, did not provide
further insight into the mechanism. However, Mur24 did have deaminase activity when 8 was
absent in the reaction, generating α-ketobutyrate (α-KB) (identified by treating with reagent 3methyl-2-benzothiazolinone hydrazone hydrochloride (MBTH)) from either AdoMet and SMM.
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Surprisingly, the formation of α-KB was also observed when incubating L-VG with 10 times
more Mur24, but was not observed in reaction with ACC. Mur24 (K234A) revealed no
detectable conversion to α-KB with AdoMet and SMM (Figure 5.10, S5.22). The inhibition
effect of L-VG to Mur24 was observed when testing its deaminase activity. Although neither
L-VG nor ACC can be aminopropyl donor of Mur24, the deaminase activity of Mur24 with LVG rather than with ACC possibly supported the proposed ‘addition’ mechanism with L-VG
as intermediate for the aminopropyl moiety incorporation reaction. However, since L-VG
cannot act as aminopropane donor in this reaction, the regular SN2 mechanism is still possible
for the reaction.

Figure 5.9 Mechanistic proposal for Mur24 catalyzed aminopropyl incorporation reaction.
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Figure 5.10 LC-MS analysis of MBTH modified Mur24 catalyzed reactions.
(A) α-keto-butyrate reacts with MBTH. (B) LC traces of MBTH modified Mur24 reaction with
AdoMet. I, control reaction without enzyme; II, MBTH modified 6 h reaction with Mur24
(K234A); III, MBTH modified 6 h reaction with Mur24. (C) LC traces of MBTH modified
Mur24 reaction with SMM. I, control reaction without enzyme; II, MBTH modified 6 h reaction
with Mur24 (K234A); III, MBTH modified 6 h reaction with Mur24. (D) LC traces of MBTH
modified Mur24 reaction with L-VG. I, control reaction without enzyme; II, MBTH modified
6 h reaction with Mur24 (K234A); III, MBTH modified 6 h reaction with Mur24.
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5.4 Discussion
5.4.1 Similarity between ACC Synthase and Mur24

ACC synthase is a PLP dependent enzyme that catalyzes the formation of ACC from
AdoMet (Figure 5.11).86 ACC synthases have only been found in higher plants and fungus. It
catalyzes α, γ-elimination from SAM to produce ACC and MTA; it also catalyzes β, γelimination to yield L-VG in 1 of 30,000 catalytic cycle.87 Like Mur24, ACC belongs to α
family of PLP-dependent enzymes. It can also transaminate L-VG and SMM to α-ketobutyrate
and ammonia.88-89 Although the aminotransferase activity of ACC synthase is similar to Mur24,
ACC synthase can only catalyze AdoMet to form ACC, and SMM cannot be utilized to form
ACC. However, Mur24 can utilize both AdoMet and SMM for the butyric acid encorporation.

Figure 5.11 The biosynthesis of ethylene.
5.4.2 Relationship of Mur24 and MocR Transcription Regulator
Mur24 has modest sequence identity to PLP dependent MocR/GabR DNA binding
transcription regulator, the molecular mechanism of which remains to be elucidated.
MocR/GabR DNA binding transcription regulators also have PLP dependent Class I
aminotransferase domain but lack the aminotransferase acitivity. Okuda etal90 reported the
spectroscopic studies of the aminotransferase domain of GabR, a PLP dependent transcriptional
regulator and revealed that GABA forms an external aldimine with the PLP in the
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aminotransferase domain of GabR. It’s possible to speculate that Mur24 may also regulate the
transcription of its downstream genes.
5.4.3 Phosphorylation Modification is Also Required in Caprazamycin Biosynthetic Pathway

LipJ, from biosynthetic gene cluster of caprazamycin A-90289 (Figure 5.1), shared 35%
sequence identity to Mur24. Activity tests revealed that, like Mur24, LipJ catalyzes the
incorporation of butyric acid to phosphorylated disaccharide, and also showed deaminase
activity with AdoMet. Recently, Shiraishi etal62 reported the identification of caprazol-3″phosphate (Figure 5.12) in cpz23(acyltransferase)-deleted caprazamycin producing strain
mutants. This discovery indicated that the phosphorylation at the 3″ position will also exist in
the following biosynthetic steps.

Figure 5.12 Structures of caprazol-3’’-phosphate.
5.5 Conclusion
In this chapter, Mur23 and Mur24 were assigned as two enzymes that modify the
cryptic phosphorylated intermediate by attachment of an aminopropyl group. Structures of the
products were elucidated by the cumulative analysis of NMR spectroscopy and HR-ESI-MS.
Three possible catalytic mechanism was proposed. Mur24 catalyzes an unusual β, γ elimination
of AdoMet to form a vinylglycine-bound intermediate that serves as the Michael-type acceptor
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of the phosphorylated-disaccharide, or the phosphorylated-disaccharide attacks γ carbon of
AdoMet-bound PLP aldimine via SN2 to incorporate the butyric acid. Following the butyric
acid incorporation, Mur23 catalyzes a PLP-dependent decarboxylation.
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5.6 Supporting Information
Table S5.1 Primers used in this study.
Primer
Sequence
mur23_NdeI
5′-GATAGGCATATG AGCAGGCACGCACACAC-3′
mur23_BamHI
5′-CGAGTTGGATCC TCACCGCGCTCCGTCCG-3′
mur24_NdeI
5′-GATAGGCATATG AGCGTCGTCGACAACG-3′
mur24_BamHI
5′-CGAGTTGGATCCTCACGGCAGTAGTGACTCCAG3′
mur23_pET30F
5′-GGTATTGAGGGTCGCATGAGCAGGCACGC-3′
mur23_pET30R
5′-AGAGGAGAGTTAGAGCCTCACCGCGCTCCGTC-3′
mur23-K70A_F
5′CGCCTGTTGTTCAGCGTCGCGGCCAACCGGAGCCG
GGCCG-3′
mur23_K70A_R
5′CGGCCCGGCTCCGGTTGGCCGCGACGCTGAACAAC
AGGCG-3′
mur24_pET30F
5′-GGTATTGAGGGTCGCGTGAGCGTCGTCGAC-3′
mur24_pET30R
5′-AGAGGAGAGTTAGAGCCTCACGGCAGTAGTG-3′
mur24_K234A_F 5′CTGGCGATGACCCCGTCCGCGGACCTGTCCCTTCC
CG-3′
mur24_K234A_R 5′CGGGAAGGGACAGGTCCGCGGACGGGGTCATCGC
CAG-3′
pTipA
5′-GAG AAG GGA GCG GAC ATA C-3′

Note
mur23
expression
mur24
expression

mur23

Site-

directed
mutagenesis

mur24

Site-

directed
mutagenesis

pXY200
sequencing
primer

* the engineered Ala or Tyr codon is underlined
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Table S5.2 Gradient used for HPLC or LC-MS analysis of Mur28, Mur24, or Mur23 product
with an analytical ZIC®-HILIC column (250 mm x 4.6 mm, 5 µm).
Solvent A= ddH2O with 0.1% formic acid; Solvent B= acetonitrile with 0.1% formic acid; A260
Time (min)
0
12
26
27
35

% Solvent B
80
50
50
80
80

Flow Rate (mL/min)
0.4
0.4
0.4
0.4
0.4

Table S5.3 Gradient used for semipreparative HPLC isolation of muraymycin D1 with an
Apollo C-18 column (250 mm x 10 mm, 5 μm).
Solvent A= ddH2O with 0.025% trifluoroacetic acid; Solvent B= acetonitrile; A260
Time (min)
0
25
26
31
32
36

% Solvent B
10
22
100
100
10
10

Flow Rate (mL/min)
3.5
3.5
3.5
3.5
3.5
3.5

Table S5.4 Gradient used for HPLC analysis of Mur28, Mur24 and Mur23 tandem reactions
with an analytical Apollo C18 column (250 mm x 4.6 mm, 5 µm).
Solvent A= 40 mM acetic acid-triethylamine pH 6.5; Solvent B= 40 mM acetic acidtriethylamine, 20% methanol, pH 6.5; A260
Time (min)
0
16
20
21
24

% Solvent B
1
100
100
1
1

Flow Rate (mL/min)
0.5
0.5
0.5
0.5
0.5
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Table S5.5 Gradient used for LC-MS analysis of AQC modified Mur28, Mur24 and Mur23
tandem reactions with an analytical AcclaimTM 120 C18 column (100 mm x 4.6 mm, 5 µm)
Solvent A= ddH2O with 0.1% formic acid; Solvent B= acetonitrile with 0.1% formic acid; A260
Time
(min)
0
40
41
44
45
47

% Solvent B

Flow Rate (mL/min)

1
20
100
100
1
1

0.4
0.4
0.4
0.4
0.4
0.4

Table S5.6 Gradient used for LC-MS analysis of MBTH modified α-KB production by Mur24
or LipJ with an analytical AcclaimTM 120 C18 column (100 mm x 4.6 mm, 5 µm)
Solvent A= ddH2O with 0.1% formic acid; Solvent B= acetonitrile with 0.1% formic acid; A325
Time (min) % Solvent B Flow Rate (mL/min)
0
10
0.4
10
40
0.4
20
100
0.4
27
100
0.4
28
10
0.4
30
10
0.4
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Table S5.7 1H NMR (400 MHz) data for 7-10 in D2O (δ in ppm, mult, J in Hz).

No.

7

8

9

10

1

7.60, d (7.7)

7.55, d (8.0)

7.57, d (7.8)

7.53, d (8.2)

2

5.71, d (7.7)

5.78, d (8.0)

5.80, d (7.8)

5.75, d (8.1)

5

5.66, br s

5.65, br s

5.66, br s

5.62, br s

6

4.18, m

4.16, m

4.29, m

4.22, m

7

4.07, m

4.11, m

4.17, m

4.11, m

8

4.06, m

4.05, m

4.14, m

4.14, m

9

4.35, br s

4.44, br s

4.42, br s

4.55, brs

10

3.73, br s

3.86, br s

3.79, br s

3.56, br s

12

5.02, br s

5.02, br s

5.07, br s

5.04, br s

13

3.98, m

4.10, m

4.13, m

4.07, m

14

3.99, m

4.24, m

4.30, m

4.25, m

15

3.96, m

4.03, m

4.09, m

4.00, m

16a

2.95,
12.2)

(9.9, 3.03, m

3.11, m

3.08, m

16b

3.15, d (11.4)

3.23, m

3.17, m

17

3.17, m

2.90, t (7.4)

18

2.09, m

1.83, m

19

3.73, t (6.3)

2.90, t (7.4)

t

3.20, m
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A

B

M u r2 3 w / 9

0 .3

M u r2 3
A b s o rb a n c e

M u r2 3 1 m in w / 9
M u r2 3 (K 7 0 A )

0 .2

M u r2 3 (K 7 0 A ) 1 m in w / 9

0 .1

0 .0
300

350

400

450

500

550

600

650

W a v e le n g t h ( n m )

Protein

Size (aa)

Size(kD)

Mur23

388

42

Mur24

433

48

Figure S5.1 SDS-PAGE analysis of purified protein and UV/Vis spectrum of Mur23.
(A) SDS-PAGE analysis of purified His6-Mur23 (lane 1), His6-Mur23 (K70A) (lane 2), His6Mur24 (lane 3), His6-Mur24 (234A) (lane 4), His6-Mur24 (F201Y) (lane 5). (B) UV/Vis
spectrum of Mur23 and Mur23 (K70A) with or without 9.
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Figure S5.2 (+)-HR-ESI-MS (positive mode) of L-[13C5,15N] Met enriched muraymycin D1.

muraymycin D1

Figure S5.3 1H NMR spectrum (D2O, 100 MHz) of isotope enriched (L-[13C5, 15N] Met or L13
C4, 15N] Asp) muraymycin D1.
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Figure S5.4 Analysis of tandem enzymatic reaction with Mur23, Mur24 and Mur28
(A) HPLC analysis of tandem enzymatic reaction with Mur23, Mur24 and Mur28 using ion
pairing condition with C18 column. I, 6 h reaction with 7 and Mur28; II, 6 h reaction with 7,
Mur24 and Mur28; III, 6 h reaction with 7, Mur23, Mur24 and Mur28. (B) LC-MS analysis of
AQC modified tandem enzymatic reaction with Mur23, Mur24 and Mur28. I, 6 h reaction with
7 and Mur28; II, 6 h reaction with 7, Mur24 and Mur28; III, 6 h reaction with 7, Mur23, Mur24
and Mur28.
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869.1

Figure S5.5 ESI-MS spectrum of 7’ eluted at 23.325 min
(calcd for C36H37N8O16P, expected (M+H) + ion at m/z = 869.21, found 869.1).

Figure S5.6 ESI-MS of 10’ eluted at 24.157min
(calcd for C39H45N9O16P, expected (M+2H)2+: ion at m/z = 463.64, found 463.7).
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Figure S5.7 (+)-HR-ESI-MS (positive mode) of compound 8
(calcd for C16H25N4O14P, expected (M+H)+ ion at m/z = 529.1178, found: 529.1127).

Figure S5.8 1H NMR spectrum (D2O, 100 MHz) of compound 8.
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Figure S5.9 HSQC spectrum (D2O, 400 MHz) of compound 8.

Figure S5.10 1H-1H COSY spectrum (D2O, 400 MHz) of compound 8.
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Figure S5.11 (+)-HR-ESI-MS (positive mode) of compound 9
(calcd for C20H32N5O16P, expected (M+H)+ ion at m/z = 630.1654, found: 630.1643).

Figure S5.12 1H NMR spectrum (D2O, 400 MHz) of compound 9.
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Figure S5.13 HSQC spectrum (D2O, 400 MHz) of compound 9.

Figure S5.14 1H-1H COSY spectrum (D2O, 400 MHz) of compound 9.
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Figure S5.15 HMBC spectrum (D2O, 400 MHz) of compound 9.
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Figure S5.16 (+)-HR-ESI-MS (positive mode) of compound 10
(calcd for C19H32N5O14P, expected (M+H)+ ion at m/z = 586.1756, found: 586.1735).

Figure S5.17 1H NMR spectrum (D2O, 400 MHz) of compound 10.
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Figure S5.18 1H-1H COSY spectrum (D2O, 400 MHz) of compound 10.

Figure S5.19 (+)-HR-ESI-MS (positive mode) of 5’-deoxy-5’-(methylthio) adenosine
(calcd for C11H15N5O3S, expected (M+H)+ ion at m/z = 298.0968, found: 298.0966).
187

Figure S5.20 1H NMR spectrum (D2O, 400 MHz) of L-VG.
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Figure S5.21 HPLC analysis of Mur24 reaction with or without PLP using 8 as substrates.
I, 6 h reaction without PLP; II, 6 h reaction with PLP.
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B

A
264.1

264.1

Figure S5.22 LC-MS analysis of MBTH modified Mur24 catalyzed reactions.
(A) Mass spectrum for the ion peak eluting at time t = 21.210 min of MBTH modified Mur24
reaction (MBTH modified α-keto-butyrate expected (M+H)+ ion at m/z = 264.08, found: 264.1).
(B) Mass spectrum for the ion peak eluting at time t = 22.413 min of MBTH modified Mur24
reaction (MBTH modified α-keto-butyrate expected (M+H)+ ion at m/z =264.08, found: 264.1).
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Chapter 6 : Characterization of Mur15 as a Non-heme Fe(II), α-Ketoglutarate:
Muraymycin Dioxygenase

6.1 Introduction
The cupin superfamily, which was named on the basis of a conserved β barrel fold of
the proteins, is one of the most functionally diverse protein superfamily. The largest subset of
this family is the non-heme Fe(II), α-ketoglutarate dependent dioxygenases. In this chapter in
vitro data are provided to support the functional assignment of Mur15, an enzyme that belongs
to cupin superfamily, from the muraymycin gene cluster, as a non-heme, Fe(II)-dependent αKG: muraymycin dioxygenase that catalyzes the β-hydroxylation of leucine moiety in
muraymycin D1 to form muraymycin C1. It can also hydroxylate the γ-position of leucine
moiety to muraymycins with fatty acid chain in β-position. To our knowledge, this is the first
discovered natural enzyme that catalyzes the γ-hydroxylation of leucine moiety in peptidyl
compound.
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6.2 Materials and Methods
6.2.1 Cloning, Overexpression and Purification of Proteins
The gene for mur15 was amplified from genomic DNA extracted from Streptomyces
sp. NRRL30473 by PCR using Phusion DNA polymerase with primer pairs:
mur15 (forward) 5′-GGTATTGAGGGTCGCGTGAGGAGCCCTCC-3′/
(reverse) 5′-AGAGGAGAGTTAGAGCCTCAGCCGTCCGCGC-3′.
Genomic DNA of Streptomyces sp. NRRL30473 was extracted using UltraClean
Microbial DNA Isolation Kit (MoBio laboratories, Inc) following manufacturer’s protocol.
DNA quality and concentration were confirmed using Nanodrop 2000c spectrophotometer
(Thermo Scientific) and gel electrophoresis. The gel-purified PCR product of mur15 was
inserted into pET30 Xa/LIC using ligation-independent cloning as described in the provided
protocol to yield pET30-mur15 and confirmed by DNA sequencing. The procedure of protein
overexpression and purification from E. coli BL21 (DE3) was stated in section 3.2.1.
6.2.2 Fermentation, Extraction, Isolation, and Purification of Muraymycins
Muraymycin producer strains Streptomyces sp. NRRL30473, 30475 and 30477 were
cultured for the production of muraymycin A1, B2, B6, C1, D1and D2 following the method
stated in section 4.2.3.
6.2.3 Activity Assay of Mur15
Reactions consisted of 50 mM HEPES (pH 7.5), 2.5 mM α-KG, 500 μM ascorbic acid,
500 μM FeCl2, 1 mM muraymycin congeners, L-Arg, L-Leu or dipeptide and 1 μM Mur15 at
191

30 °C. The reaction was terminated by adding twice volume of methanol followed by
centrifugation (14000 rpm, 30 min) to remove the precipitated protein. Following
centrifugation to remove protein, the reaction was analyzed by HPLC or LC-MS with gradient
shown in Table S4.3 or Table S4.4 with detection at 260 nm.
6.2.4 Activity Optimization
Optimal ascorbic acid concentration for activity was determined with assays containing
50 mM HEPES (pH 7.5), 2.5 mM α-KG, 0.25 mM muraymycin D1, 200 μM FeCl2 and 0-2000
μM ascorbic acid and 200 nM Mur15. After identifying the optimal ascorbic acid concentration,
the optimal iron concentration was determined with reactions containing 50 mM HEPES (pH
7.5), 2.5 mM α-KG, 0.25 mM muraymycin D1, 500 μM ascorbic acid and 0-1000 μM FeCl2
and 200 nM Mur15. All reactions were carried out at 30 °C, and product formation was analyzed
by HPLC with gradient shown in Table S4.3 or Table S4.4 under initial velocity conditions.
6.2.5 Kinetics of Mur15
Assays consisted of 50 mM Hepes (pH 7.5), 500 μM ascorbic acid, 500 μM FeCl2, near
saturating muraymycin D1 (0.25 mM) with variable α-KG (5 μM–200μM), or near saturating
α-KG (2.5 mM) with variable muraymycin D1 (5 μM–1000μM), or near saturating α-KG (2.5
mM) with variable muraymycin B2 (5 μM–1000 μM). The reaction was performed at 30 °C
with 200 nM Mur15 for 2 h and analyzed under initial velocity conditions. Product formation
was determined using HPLC with gradient shown in Table S4.3. Each data point represents a
minimum of three replicate end point assays; kinetic constants were obtained by nonlinear
regression analysis using GraphPad Prism (GraphPad Software, La Jolla, CA).
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6.2.6 Antimicrobial Bioactivities
The protocol used for the determination of the minimum inhibitory concentration (MIC)
was as described in section 4.2.8.
6.2.7 MraY Inhibition
The assay was carried out by Prof. Christian Ducho’s lab in Department of Pharmacy,
Pharmaceutical and Medicinal Chemistry, Saarland University. Details are described in section
2.2.5.
6.3 Results and Discussion
6.3.1 Bioinformatic Analysis of Mur15
BLASTP analysis showed that Mur15 belongs to cupin superfamily but has no
significant sequence homology to any characterized protein. Proteins in cupin superfamily,
which is named after the conserved barrel domain, has diverse functions.91 Therefore, structural
homology search using HHpred was carried out.92 Mur15 showed structural homology to αketoglutarate dependent ribosomal oxygenases YcfD in E. coli and nucleolar protein 66 (NO66)
in human. YcfD catalyzes arginine hydroxylation in ribosomal protein L16 while NO66
catalyzes histidine hydroxylation in ribosomal protein RPL8.93 Thus, we proposed that Mur15
may similarly function as an Fe(II) and α-KG dependent dioxygenase to catalyze the
hydroxylation of the peptide moiety of muraymycin.
6.3.2 Functional Assignment and Activity Test
Mur15 was cloned as an N-terminal His6-tagged protein using the genome of
193

Streptomyces sp. NRRL30473 as template, expressed and purified from E. coli BL21(DE3)
with a yield of 6.3 mg/L (Figure S6.1). As no hydroxylation of free L-leucine catalyzed by
Mur15 could be detected by LC-MS, five muraymycin congeners, muraymycin D1, D2 (from
Streptomyces sp. NRRL30475), muraymycin A1, B2, B6, C1 (from Streptomyces sp.
NRRL30473) were isolated from culture medium of Streptomyces sp. for activity tests. When
Mur15 was incubated with muraymycin D1 and α-KG, HPLC analysis revealed a new peak
with concomitant loss of the peak corresponding to D1 (Figure 6.1B). The new peak was
confirmed as muraymycin C1 by LC-MS, coinjections with authentic muraymycin C1 and
proton NMR comparison (Figure S6.2). No activity was observed when α-KG was omitted in
the reaction. Activity of Mur15 was also observed when it was incubated with muraymycin D2
to generate muraymycin C2 (Figure 6.1C). Therefore, Mur15 is preliminarily assigned as an αKG dependent muraymycin D1 leucine moiety β hydroxylase.
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Figure 6.1 Characterization of Mur15 with muraymycin D1 (1).
(A) Reaction catalyzed by Mur15 with 1 or 3. (B) LC-MS analysis using 1 (Ο) after 6 h without
Mur15 (I), 6 h reaction (II). (C) LC-MS analysis using 3 (Ο) after 6 h without Mur15 (I), 6 h
reaction (II).
No activity was detected by HPLC when Mur15 was incubated with C1 and α-KG.
However, to our surprise, when Mur15 incubated with muraymycin congeners with fatty acid
chain (muraymycin A1, B2 and B6) in β-position, HPLC and LC-MS traces revealed a new
peak with 16 amu greater than the substrate (Figure 6.2), indicating that Mur15 also catalyzed
the hydroxylation reaction of muraymycins with fatty acid chain. Following large scale
purification of the hydroxyl B2 generated by Mur15, 1HNMR revealed absent signal of proton
on C4 and downfield shifts of protons on C5 and C6 of leucine moiety, indicating that the
hydroxylation occurred at the γ position of leucine moiety (Figure 6.3). To our knowledge, this
is the first discovered natural enzyme that catalyzes the γ-hydroxylation of leucine.94 However,
the mass of hydroxyl muraymycin A or B congeners were not found in the reported metabolites
of the producer strain.2
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Figure 6.2 Characterization of Mur15 with muraymycin B2 (5), B6 (7) and A1 (9).
(A) Reaction catalyzed by Mur15 with 5 or 7 or 9. (B) LC-MS analysis using 5 (Ο) after 6-hr
without Mur15 (I), 6 h reaction (II). (C) LC-MS analysis using 7 (Ο) after 6 h without Mur15
(I), 6 h reaction (II). (D) LC-MS analysis using 9 (Ο) after 6 h without Mur15 (I), 6 h reaction
(II).
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Figure 6.3 Comparison of 1H NMR (DMSO-d6, 400 MHz) between muraymycin B2, 5 and
Mur15 product hydroxyl muraymycin B2, 6.
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Discovery of the activity promiscuity of Mur15 led us to test the activity of Mur15 with
L-Arg and L-Arg-Leu dipepetide as we proposed that hydroxyl arginine possibly is the
precursor for the biosynthesis of L-epicapreomycidine moiety of muraymycin. No
hydroxylation activity was detected by LC-MS with free L-Arg. However, Mur15 showed
hydrolase activity when incubated with Arg-Leu dipeptide and generated free arginine and
leucine (Figure 6.4). The result didn’t exclude the possibility that Mur15 can catalyze the
hydroxylation of nonribosomal peptide synthetase (NRPS) tethered arginine, which is still in
the ongoing NRPS activity study.
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Figure 6.4 Characterization of Mur15 with L-Arg-Leu dipeptide, 11.
(A) Reaction catalyzed by Mur15 with 11. (B) LC-MS analysis using 11 (Ο) after 6 h without
Mur15 (I); 6 h reaction (II). Extracted ion chromatograms showing the production of leucine.
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6.3.3 Activity Optimization and Kinetics Analysis
α-KG and O2 was found to be necessary for the activity of Mur15 while ascorbate or
Fe (II) was not essential for the reaction. Optimal activity of Mur15 was achieved in the range
of 10-1000 μM FeCl2. With 500 μM FeCl2, Mur15 was found to have optimal activity in the
range of 10-1000 μM ascorbate (Figures 6.5 A-B).
Kinetics analysis of Mur15 with muraymycin D1 revealed Michaelis-Menten kinetics
yielding a Km = 11±1μM and kcat = 2±0.1 min-1 with respect to α-KG and Km= 0.6±0.1 mM and
kcat = 10±1 min-1 with respect to muraymycin D1. Kinetics analysis of Mur15 with muraymycin
B2 revealed Michaelis-Menten kinetics yielding a Km = 0.6±0.2 mM and kcat = 6 ± 0.2 min-1
with respect to muraymycin B2 (Figures 6.5 C-E). The catalytic efficiency kcat/Km with respect
to muraymycin D1 is 2.4 times more than that of muraymycin B2, which to some extent
predicted that the amount of hydroxyl muraymycin A or B congeners should be relatively low
in the metabolites of the producer strain.
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Figure 6.5 Activity optimization and kinetic analysis of Mur15.
(A) Optimal activity of Mur15 with respect to varied ascorbic acid in reactions containing 200
μM FeCl2 and 200 nM Mur15. (B) Optimal activity of Mur15 with respect to varied FeCl2 in
reactions containing of 500 μM ascorbic acid and 200 nM Mur15. (C) Single-substrate kinetic
analysis using variable α-KG (5 μ-200 μM), near saturating muraymycin D1(250 μM) and 200
nM Mur15. (D) Single-substrate kinetic analysis using variable muraymycin D1 (5 μ-1000 μM),
near saturating α-KG (2.5 mM) and 200 nM Mur15. (E) Single-substrate kinetic analysis using
variable muraymycin B2 (5 μ-1000 μM), near saturating α-KG (2.5 mM) and 200 nM Mur15.
Data represent the average of minimally three independent replicates under initial velocity
conditions.
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6.3.4 Bioactivity of the Mur15 Products
The isolated Mur15 products, muraymcyin C1 and muraymycin B2-OH were tested for
enzyme inhibitory activity against MraY from S. aureus, and antimicrobial activity against
Gram-positive as well as Gram-negative strains (Table 6.1). To our surprise, muraymycin C1
showed 32 times decrease in IC50 against muraymycin D1, suggesting that hydroxylation at β
position of muraymycin D1 greatly increased the inhibitory activity against MraY. Enzyme
inhibitory activity against MraY S. aureus showed comparable IC50 of B2 and B2-OH,
indicating that the hydroxylation at γ position didn’t interfere with its binding to the target
protein MraY. Muraymcyin C1 showed comparable antimicrobial activity to muraymycin D1
against M. smegmatis and E. coli, which indicates that the β hydroxylation didn’t affect its
antibacterial activity. Considering that muraymycin C1 showed 32 times increased efficacy
against the target, hydroxylation at β position of muraymycin D1 possibly interfere its cellular
penetration. Importantly, B2-OH didn’t show growth inhibitory against M. smegmatis ATCC
14468 and E. coli BL21(DE3). However, B2-OH showed similar antibacterial activity to B2
against E. coli ∆tolC mutant, which further indicated that the hydroxylation possibly interfered
with the cellular uptake.
Table 6.1 Bacterial MraY assays and antimicrobial activities of the substrate and product of
Mur15.
S. aureus MraY

M. smegmatis E. coli ∆tolC mutant E. coli BL21(DE3)
growth

inhibition

inhibition

growth inhibition

growth inhibition

compound

IC50 (pM)

MIC (μg/mL)

MIC (μg/mL)

MIC (μg/mL)

muraymycin B2

10±2

8

1

32

>256

1

>256

4

1

16

4

1

8

muraymycin B2OH

16±3

muraymycin D1

(4.8 ±1.3)×10

muraymycin C1

16±2

2
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6.4 Discussion
6.4.1 Timing of Hydroxylation in Muraymycin Biosynthetic Pathway

The discovery of muraymycin D and muraymycin C congeners indicates that the
hydroxylation reaction occurred in the biosynthetic pathway. There are three possibilities of
when the hydroxylation of the leucine moiety occurs in the biosynthetic pathway of
muraymycin. I, hydroxylation of free leucine before the peptide assembles. Hydroxylation of
free amino acid is well known in many biosynthetic pathways of nature products.95-98 L-leucine
was tested with Mur15 at first. However, Mur15 not reacting with free L-leucine exclude this
possibility. II, late stage modification of muraymycin D congeners. The discovery of
muraymycin D and C congeners also suggests that the hydroxylation may happen after the
formation of muraymycin D. Activity assay and kinetic study of Mur15 with muraymycin D
congeners both supported this hypothesis. Actually, late stage hydroxylation is also observed in
many biosynthetic pathways.99-100 III, hydroxylation of nonribosomal peptide synthetases
(NRPS) tethered leucine moiety. Hydroxylation of NRPS peptidyl carrier protein (PCP)-bound
amino acid is also found in many biosynthetic pathways.101-103 There are several NRPSs in the
biosynthetic assembly line of muraymycin, which are proposed to be responsible for the
biosynthesis of peptide side chain of muraymycin. Whether or not Mur15 can catalyze the
hydroxylation of NRPS tethered amino acid will be explored in the ongoing NRPS activity
assays.
6.4.2 Repeated Hydroxylation by Multifunctional Enzyme
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Dioxygenase Mur15 showed unusual substrate promiscuity. It catalyzed the
hydroxylation of muraymycin D congeners, which are further utilized by acyltransferase to
produce different fatty acid chain appended muraymycins (muraymycin A or B congeners).
Different lipo-muraymycins can be further oxidized by the same enzyme Mur15 (Figure 6.6).
Although oxygenase usually has strong substrate specificity, recently an emerging group of
multifunctional dioxygenase have been studied. These enzymes usually catalyze two or more
reactions in a very ordered behavior and goes through conformational change to catalyze
different reactions.104 Structure study of Mur15 bound with different muraymycin congeners
will offer more information for further study of this unusual repeated hydroxylation reaction.

Figure 6.6 Repeated hydroxylation catalyzed by Mur15.
6.5 Conclusion
Enzyme Mur15, which belongs to cupin family and involves in muraymycin late stage
modification, is functionally assigned as a non-heme, Fe (II)-dependent α-ketoglutarate
dioxygenase that catalyzes the β hydroxylation of leucine moiety in muraymycin D1 to form
muraymycin C1. Mur15 can also hydroxylate the γ position of leucine moiety to muraymycins
with fatty acid chain in β position. Moreover, Mur15 showed lyase activity to hydrolyze
arginine-leucine dipeptide but could not catalyze the single amino acid to its hydroxylated form.
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6.6 Supporting Information

250 kD
100 kD

50 kD

37 kD

Figure S6.1 SDS-PAGE analysis of purified His6-Mur15
(expected MW of 39 kD).
A

B

930.4

946.4

Figure S6.2 Identification of the Mur15 product with 1.
(A) Mass spectrum for the peak at elution time t = 21.893 min corresponding to 1. (B) Mass
spectrum for the peak at elution time t = 20.248 min corresponding to Mur15 product 2.
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A

B

932.3

916.4

Figure S6.3 Identification of the Mur15 product with 3.
(A) Mass spectrum for the peak at elution time t = 22.410 min corresponding to 3. (B) Mass
spectrum for the peak at elution time t = 19.866 min corresponding to Mur15 product 4.
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Figure S6.4 Identification of the Mur15 product with 1.
(A) HPLC analysis using 1 (Ο) after 6 h without Mur15 (I), 6 h reaction (II), 6 h reaction coinjected with 2 (●) (III). (B) Comparison of 1HNMR between 2 and Mur15 product hydroxyl
muraymycin D1.
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B

A

1100.4

1100.5833

D

C

1116.3

1116.5807

Figure S6.5 Identification of the Mur15 product with 5.
(A) Mass spectrum for the peak at elution time t = 25.786 min corresponding to 5. (B) (+)-HRESI-MS (positive mode) of 5 (expected (M+H)+ ion at m/z = 1100.5834, found: 1100.5833). (C)
Mass spectrum for the peak at elution time t = 25.081 min corresponding to Mur15 product 6.
(D) (+)-HR-ESI-MS (positive mode) of 6. (expected (M+H)+ ion at m/z = 1116.5783, found:
1116.5807).
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Figure S6.6 1H NMR spectrum (DMSO-d6, 400 MHz) of muraymycin B2 (5).

Figure S6.7 13C NMR spectrum (DMSO-d6, 100 MHz) of muraymycin B2 (5).
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Figure S6.8 HSQC spectrum (DMSO-d6, 400 MHz) of muraymycin B2 (5).

Figure S6.9 HMBC spectrum (DMSO-d6, 400 MHz) of muraymycin B2 (5).
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Figure S6.10 1H-1H COSY spectrum ((DMSO-d6, 400 MHz) of muraymycin B2 (5).

210

B

A

1072.3
1072.5553

D
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1088.5390

1088.3

Figure S6.11 Identification of the Mur15 product with 7.
(A) Mass spectrum for the peak at elution time t = 24.039 min corresponding to 7. (B) (+)-HRESI-MS (positive mode) of 7(expected (M+H)+ ion at m/z = 1072.5521, found: 1072.5553). (C)
Mass spectrum for the peak at elution time t = 22.283 min corresponding to Mur15 product 8.
(D) (+)-HR-ESI-MS (positive mode) of 8(expected (M+H)+ ion at m/z = 1088.5470, found:
1088.5407).
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Figure S6.12 1H NMR spectrum (DMSO-d6, 400 MHz) of muraymycin B6 (7).

Figure S6.13 13C NMR spectrum (DMSO-d6, 100 MHz) of muraymycin B6 (7).
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Figure S6.14 HSQC spectrum (DMSO-d6, 400 MHz) of muraymycin B6 (7).

Figure S6.15 HMBC spectrum (DMSO-d6, 400 MHz) of muraymycin B6 (7).
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Figure S6.16 1H-1H COSY spectrum ((DMSO-d6, 400 MHz) of muraymycin B6 (7).
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608.6
616.3

Figure S6.17 Identification of the Mur15 product with 9.
(A) Mass spectrum for the peak at elution time t = 17.466 min corresponding to 9 (expected
(M+H)+ ion at m/z = 608.33, found: 608.6). (B) Mass spectrum for the peak at elution time t =
19.222 min corresponding to Mur15 product 10 (expected (M+H)+ ion at m/z = 616.33, found:
616.3).
B

A

132.2

288.2

Figure S6.18 Identification of the Mur15 product with 11.
(A) Mass spectrum for the peak at elution time t = 17.466 min corresponding to 11(Calc: 288.20,
found: 288.2). (B) Mass spectrum for the peak at elution time t = 19.222 min corresponding to
Mur15 product L-leucine (expected (M+H)+ ion at m/z = 132.10, found: 132.2).
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Chapter 7 : Ongoing Studies and Future Directions
7.1 Biosynthetic Mechanism of the NRPS Assembly Line
We have presented the delineation of the biosynthetic pathway for the alkyl
aminoribosyl-glycyluridine moiety upon in vitro characterization of nine enzymes (Mur16-20,
Mur23, 24,26) (Figure 7.1). Next we are going to study the assembly line of the peptidyl moiety
of muraymycin, which contains basic amino acid-epicapreomycidine-urea-valine moiety with
interesting amino acid-urea-amino acid motif effectively inverting the direction of the peptide
chain. Seven enzymes that are proposed to be involved in the NRPS assembly line have been
expressed. Isotopic enrichment experiment feeding with leucine, arginine, valine and sodium
bicarbonate is carried out. ATP-PPi exchange assay will be performed to test adenylation
domains activity. Covalent loading of the amino acid will be characterized by SDS-gel and
HRMS. The condensation of the assembled peptide with the alkyl aminoribosyl-glycyluridine
will also be studied.

Figure 7.1 Biosynthetic pathway towards alkyl aminoribosyl-glycyluridine moiety of
muraymycin.
7.2 Biosynthetic Mechanism of the Formation of the N-methyldiazepanone Moiety of
216

Caparazamycin Like A-90289
LipJ, from biosynthetic gene cluster of caprazamycin A-90289 (Figure 5.1), shared 35%
sequence identity to Mur24. Activity tests revealed that, like Mur24, LipJ catalyzes the
incorporation of butyric acid to phosphorylated disaccharide. Proposed biosynthetic pathway
of the formation of N-methyldiazepanone moiety of A-90289 by BLAST analysis is shown in
Figure 7.2. LipG, LipH, LipI and LipQ were expressed in E. coli BL21(DE3). Activity tests
will be performed accordingly.

Figure 7.2 Proposed biosynthetic pathway towards N-methyldiazepanone moiety of A-90289.
7.3 Acyltransferase for the Fatty Acid Chain Appendage of Muraymycin
All of muraymycins have a common peptide appended aminoribosyl uronic acid core
structure. Members of this family are mainly different in the fatty acid chain. Muraymycin A1,
the one with the longest charged fatty acid chain, is the most active one. In chapter 2, we also
presented that the structure of the fatty acid chain has great impact on activity of muraymycin.
As in chapter 6 we characterized the function of dioxygenase Mur15, which catalyzes the β
hydroxylation of muraymycin D1 to form muraymycin C1 (Figure 6.6), we proposed that
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acyltransferase will be required to form muraymycins with different fatty acid chain. Therefore,
the acyltransferase that is responsible for the fatty acid chain appendage of muraymycin will be
characterized. Muraymycins with different fatty acid chains will be made with the
acyltransferase in order to obtain more active muraymycin congeners.
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Y6-Y9 and Zp from Streptomyces sp. Strain Gö-GS12, J Nat Prod, 2016, 79(10), 2731-2739.
• Liu, X., Jin, Y., Cui, Z., Nonaka, K., Baba, S., Funabashi, M., Yang, Z., Van Lanen, S.G.,*
The Role of a Nonribosomal Peptide Synthetase in l-Lysine Lactamization During
Capuramycin Biosynthesis, ChemBioChem, 2016(17), 804-810.
• Khisamutdinov, E.F., Bui, M.N., Jasinski, D., Zhao, Z., Cui, Z., Guo, P.,* Simple Method for
Constructing RNA Triangle, Square, Pentagon by Tuning Interior RNA 3WJ Angle from 60° to
90° or 108°, Methods Mol Biol, 2015(1316), 181-193.
• Li, H., Rychahou, P.G., Cui, Z., Pi, F., Evers, B.M, Shu, D., Guo, P.,* Luo, W.,* RNA
Nanoparticles Derived from Three-Way Junction of Phi29 Motor pRNA Are Resistant to I-125
and Cs-131 Radiation, Nucleic Acid Ther, 2015(25), 188-197.
226

• He, S., Cui, Z., Wang, X., Zhang, H., Dai, W., Zhang, Q.,* Cremophor-free Intravenous SelfMicroemulsions for Teniposide: Safety, Antitumor Activity in vitro and in vivo, Int J Pharm,
2015(495), 144-153.
• Gao, W., Lin, Z., Chen, M., Yang, X., Cui, Z., Zhang, X., Yuan, L., Zhang, Q.,* The codelivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes
against breast cancer with low P-glycoprotein expression, Int J Nanomedicine, 2014(9), 34253437.
• Zhang, X., Cui, Z., Zhang, X., He, B., Wang, X., Zhang, H., Zhong, Z., Zhang, Q.,*
Characteristics, cellular uptake and transepithelial transport of coumarin6 loaded PEO-(hbPG)-g-PCL miktoarm copolymer micelles, J. Chin. Pharm. Sci., 2013, 22(3), 251-258.
• He, S., Cui, Z., Mei, D., Zhang, H., Wang, X., Dai, W., Zhang, Q.,* A Cremophor-Free SelfMicroemulsified Delivery System for Intravenous Injection of Teniposide: Evaluation in vitro
and in vivo, AAPS PharmSciTech., 2012, 13(3), 846-852.
• Zhang, J., He, B., Qu, W., Cui, Z., Wang, Y., Zhang, H., Wang, J., Zhang, Q., * Preparation
of the Albumin Nanoparticle System Loaded with Both Paclitaxel and Sorafenib and Its
Evaluation in Vitro and in Vivo, J Microencapsul., 2011, 28(6), 528-536.
• Zhuang, J., Ping, Q.,* Song, Y., Qi, J., Cui, Z., Effects of Chitosan Coating on Physical
Properties and Pharmacokinetic Behavior of Mitoxantrone Liposomes, Int J Nanomedicine.,
2010, 5, 407-416.
• Zhuang, J., Shi, Y., Ping, Q.,* Su, Z., Cui, Z., Song, Y., 壳聚糖包覆米托蒽醌脂质体在荷
瘤小鼠体内的组织分布及药效学 (Tissue Distribution and Pharmacodynamics of Chitosan
Coated Mitoxantrone Liposomes in the Tumor Bearing Mice), Journal of China Pharmaceutical
University, 2010, 41(4), 353-359.
• Gao, Z., Cui, Z., Kou, J.,* 组胺 H1 受体功能及调节机制研究进展 (Advances on
Research of Function and Regulatory Mechanism of Histamine H1 Receptor), Progress in
Modern Biomedicine, 2009, 9(19), 3768-3771.
• Cui, Z., Zheng, X., Gao, Z., Cao, F., Ping, Q.,* β-环糊精包合川芎挥发油的制备工艺研究
(Study on Inclusion Technique of Ligusticum Chuanxiong Hort Volatile Oil-β-Cyclodextrin
Complex by Orthogonal Test), Journal of Chinese Medicinal Materials, 2008, 31(12), 19031906.

Zheng Cui

227

